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Abstract 
Abstract 
A previously unknown protein produced by an mRNA mutation has recently been 
identified in Alzheimer's patients. The protein, designated UbN, is composed of the 
first 75 residues of ubiquitin followed by an unrelated sequence of 20 residues. The 
synthesis of this 1 0.7kDa entity was carried out, as well as its purification which was 
based on a novel affinity support in conjunction with the tetrabenzofluoroene moiety. 
In vitro testing established how the protein could compromise the ubiquitin-
dependent proteolytic system, hence exerting a toxic effect in Alzheimer's patients. 
The synthesis of an analogue of ubiquitin (76 residues, 8.5kDa), which contained the 
unnatural amino acid 2S,4S-5-fluoroleucine in place of leucine at the 50 and 67 
positions, has been carried out. A short purification and folding protocol was 
developed, and comparison of the analogue with the native structure was undertaken. 
A possible application of the analogue in the study of protein folding using 19F nmr 
has been examined. 
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Chapter 1 
Chapter 1: Introduction 
Since the pioneering work of both Paul Berg' and Stanley Cohen 2 and the advent of 
the Polymerase Chain Reaction 3 , the production of proteins has witnessed an 
explosive growth. Today, the biochemical techniques involved in moving from DNA 
to proteins and vice versa are now well established. Several genomes have now been 
completely sequenced  and the data generated reveals many more proteins with as yet 
unknown function. Despite the obvious power that these techniques offer, they are 
subject to some limitations in that only natural amino acids are incorporated by the 
ribosome into a protein. The techniques of chemical synthesis, however, offer a 
viable alternative to the production of proteins containing non-natural amino acids, as 
evidenced by Kent's synthesis of HIV-1 protease 5 , which contained only D-amino 
acids. The methods of preparing such species are discussed in the following sections. 
1.1 	Peptide synthesis 
From the turn of the century, organic chemists have had the ability to make peptides, 
following Fischer's synthesis of glycylglycine 6 . In the contemporary synthesis of a 
peptide there exist two main considerations, namely protecting group design and 
activation of the carboxyl functional group. Protecting groups at the N-terminus of 
one component as well as side chain protection are necessary to ensure that amide 
bond formation occurs at one site only. To this end, Bergman and Zervas 7 introduced 
the benzyloxycarbonyl (Z) protecting group (Figure 1.1) which could be removed by 
hydrogenolysis. 
Q 0 NCO2H 
Figure 1.1: The Zprotecting group. 
This heralded a new dawn in peptide synthesis, since for the first time, two amino 
acid fragments could be unambiguously coupled. Protecting group design, in unison 
with advances in the activation of the carboxyl group 8, allowed the synthesis of some 
1 
Chapter 1 
complicated peptides, many of which had an interesting biological function, 
including oxytocin9 and tyrocidine A' ° (Figure 1.2) 
L-Va----L-Orn--L-Leu--D-Phe-- L-Pro 
L-TyF---L-GIu—L-Asp —D-Phe---L-Phe 




Figure 1.2: Amino acid composition of lyrocidine A (left) and oxytocin fright). 
However, notwithstanding the impressive feats of synthesis demanded for the 
preparation of these molecules, it became apparent that if chemists were to synthesise 
much larger entities, a radical change in the existing methodology would be required. 
In 1956, R.B.Woodward" alluded to this fact, when he suggested that if chemists 
were to synthesise enzymes, then we should "get our reactions out of solution where 
the molecules take advantage of their freedom and do not efficiently enough hew the 
line we wish them to follow". At a cursory level, this remark is almost counter-
intuitive. However, almost as these words were being written, both Merrifield 2 and 
Letsinger' 3  were actively putting them into practice. Merrifield's new approach to 
peptide synthesis involved the use of an insoluble functionalised polymeric resin 
acting as a C-terminal protecting group, and in this way synthesised a tetrapeptide 
(Figure 1.3). 
o-O :: 	o-O-- ZNaOH 0-0-02C--NHZ DW 
O0 02CVaI-GIY-,1a-Leu -NHZ 
1.30% HBr/AcO'>\\ 
2. 1M NaOH 




3  = co-polymer of styrene 1% divinylbenzene 
Figure 1.3: MerrIeld's synthesis of a tetrapeptide on the solid phase. 
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The polymer selected was a co-polymer of styrene and divinylbenzene with 1% 
cross-linking, which gave good swelling and hence excellent penetration of the resin 
by the reagents. The polymer was also robust enough to allow filtration meaning that 
removal of excess reagents and isolation of the product was straightforward. In this 
initial synthesis, Merrifield elected to use the Z-group to protect the N-terminus of 
the peptide and cleaved it under acidolytic conditions, while retaining the linkage to 
the resin. The carboxyl group was activated using DCC' 4, and the subsequent amino 
acids were introduced in a stepwise manner, following the same protocols. Upon 
removal of the N-terminal Z-group, the free peptide was isolated by saponification. 
Merrifield soon revised the procedure 15,  and used the tert-butoxycarbonyl (Boc)' 6 
group for protection of the N-terminus. In all subsequent syntheses, the free peptide 
was obtained by cleavage under acidolytic conditions, which allowed concomitant 
removal of any side chain protecting groups (Figure 1.4) 







SPIRS NHC0' NHB0c 
Coupling 
NH2 —PEPTIDE—CO2 H 
P = side chain protecting group. 
Figure 1.4: Synthesis ofpeptides using the Boc protecting group. 
The approach of Letsinger' 3 contrasts with that of Merrifield, as it is based upon 
synthesis from the N-terminus to the C-terminus. Again, a co-polymer of styrene and 
divinylbenzene was used, with 0.5% cross-linking in this case. Functionalisation of 
the resin was achieved as illustrated in Figure 1.5. 
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MeNO,AICl 0—
kNPh2 2.  LiAIH4rTHF O—C~~OH 
phosgenelPhH 
H2 N-Leu-OMe/DMF 
I 	 *31MNaOH 
1. 
CO2Bz 	
:::0::e 0-0----O'~- N?CO2H H 	 2. 
Figure 1.5: Letsinger 's solid phase synthesis of a dipeptide. 
However, the Letsinger approach was largely abandoned in favour of the Merrifield 
strategy. The main concern with synthesis in the N to C direction is that there exists 
a significant potential for racemisation from the second residue onwards, due to 
oxazolone formation (Figure 1.6). 
0--C~~O N 
H 




Figure 1.6: Oxazalone formation during N to C peptide synthesis. 
The advantages of the solid phase approach are numerous; firstly, the method 
obviates the need to isolate any intermediates, hence reducing the overall time 
required for synthesis. Given that separation of the polymer from any unreacted 
reagents can be smoothly achieved, the use of excess reagents to drive coupling 
reactions to completion is possible. Merrifield also demonstrated that the cyclic 
nature of peptide synthesis allows the process to be automate& 7 , facilitating the rapid 
construction of relatively large proteins. 
4 
Chapter 1 
Merrifield's synthesis of a tetrapeptide highlights several factors which are crucial to 
the success of a peptide/protein synthesis on the solid phase and these will be 
discussed in subsequent sections. 
1.1.1 Activation techniques 
Generally in peptide synthesis the carboxyl group of the incoming amino acid must 









NHP NHP 	0 
R2 
1 	 2 
P, P = protecting groups 
Figure 1.7: Activation of the carboxyl system. 
The earliest methods of activation  employed either acid chlorides  8 or acyl 
azides 8  with the former approach still widely practised to this day. Following this 
initial work, several other methods of activation were introduced, including the use 
of mixed carboxylic acid anhydrides' 8  and aminolysis ofp-nitrophenol esters 19 . 
1.1.1.1 In situ activation techniques 
Sheehan and Hess introduced the concept of in situ activation using 
dicyclohexylcarbodiimid& 4, subsequently used by Merrifield on the solid phase 
(Figure 1.8). 
0 	 N (H ~ C 	 (0 NH 
R 1 0  
11 R 1 O 
N 
a R2 á 
3 
0 
.  R 1 N R2 + a N ANIO
H 	 H H 
4 
Figure 1.8: Activation using the DCC reagent. 
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An O-acyl urea (3) is formed from the diimide and the carboxyl moiety, which 
condenses with the free amine component to yield the desired peptide bond. In the 
absence of any amine containing moiety the O-acyl urea will condense with a second 
carboxylic acid group, furnishing a symmetric anhydride. The dicyclohexylurea (4) 
generated as a by-product can be conveniently removed by filtration owing to its low 
solubility in organic media. However, a serious side reaction associated with the use 
of DCC involves rearrangement of the O-acyl urea to an N-acyl species (5, Figure 
1.9). 





Figure 1.9: Rearrangement to an N-acyl urea. 
The issue of N-acyl urea formation, together with the potential for racemisation, 
directed some effort into moderating the activity of the O-acyl urea. Several 
additives, including p-nitrophenol 20 and N-hydroxysuccinamide 21 , were examined 
before Konig & Geiger introduced the heterocyclic reagent 1 -hydroxybenzotriazole 
(HOBt, 6). This additive and its variants (Figure 1.10), are widely used in amide 
bond formation in both solution and on the solid phase. 
0 
N 	-_- N 
II 	I 'N "N 	
N OH EtO\ 
N NQN 
OH 	OH 	 OH 
HOW 22 (6) 	HOAt23 	HOOBt24 	HOCt25 
Figure 1.10: Some additives used in carbodiimide mediated coupling reactions. 
Recently, Dendrinos et a126 described the synthesis and use of a polymer supported 
HOBt reagent. The reagent exhibited high reactivity and compatibility with a range 
of solvents, including water. In addition, the reagent could also be easily recycled, 
minimising waste. 
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1.1.1.2 Phosphonium and uronium salts 
Phosphonamide salts (7, Figure 1.11) were first introduced by Kenner 
27  as peptide 
coupling reagents. 
R2N..® 
I.IPX Y I2I'4 	I 
NR2 
7 
Figure 1.11: Kenner 's phosphonium based coupling reagents. 
When employed in peptide synthesis, these systems (X=Y= tosylate, R= methyl) 
were found to give efficient couplings and minimal racemisation, with 
straightforward isolation of products. Shortly after Kenner's work, Castro 28 
developed the benzotriazolyl-N-oxytrisdimethylamino phosphonium (BOP) salts 
(XOBt, YPF6, Rmethyl). The BOP system and its related analogues are 
commercially available, and are extensively used in peptide synthesis. 
By analogy with the phosphonium systems above, Gross 29  and Knorr3° introduced the 
uronium based coupling reagents (8). 
ci N I 	X=CH0rN 
0 N- 
 8 
Figure 1.12: Uronium based agents for amide bond formation. 
Again, these compounds and their derivatives are commercially available from a 
number of sources, and are widely employed in peptide synthesis. 
7 
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1.1.2 Protecting group strategies for SPPS 
1.1.2.1 N'-protecting groups 
As discussed above, the original work of Merrifield used the Z protecting group of 
Bergmann and Zervas 7, however, the Boc' 6 group was soon adopted owing to the 
mild conditions used in its deprotection. In this mode, any side-chain protecting 
groups and the attachment to the resin are cleaved under strongly acidic conditions 
using HE 
The Boc approach was used almost exclusively in solid phase peptide synthesis until 
Sheppard 3 ' applied the 9-fluorenylmethoxycarbonyl (Fmoc) 32 protected amino acids 
(9) for use on the solid phase (Figure 1.13). 
H 
0 	P 
cTI- 0'  NH CoNH---Q 
H 
NOfl 





Figure 1.13: Deprotection of the Fmoc group in SPPS. 
Deprotection is achieved by treatment of the system with solutions of secondary 
amines such as piperidine, and occurs via an E1b  mechanism. The fulvene-
piperidine adduct which arises may be exploited to monitor the assembly of a 
peptide, which can assist in the identification of "difficult" parts of a sequence (see 
Section1.1.4)33  The adduct adsorbs in the UV with an isobestic point at 302nm, 
and by passing an aliquot of the deprotection solution through a detector set at that 
wavelength, it is possible to relate the absorbance of the deprotection solution to the 
efficiency of coupling of the previous amino acid. 
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With the Fmoc strategy, cleavage from the solid support is achieved together with 
concomitant side chain deprotection using mildly acidic conditions (95:5 TFA: 
water). In this way, the protecting group strategy is completely orthogonal in 
comparison to the Boc approach where the different acid labilities of JyQ  and side 
chain groups are exploited. The main advantage the Fmoc system is that it avoids 
repeated exposure of the peptide to acid, which could have a deleterious effect, 
particularly in the synthesis of large fragments. Additionally, the use of HF, which 
requires specialised handling, for global deprotection and cleavage is no longer 
necessary. 
More recently, Samukov 34 introduced the 2-(4-nitrophenyl)sulfonylethoxycarbonyl 
(Nsc) protected amino acids (10) asjan alternative to the Fmoc group (Figure 1.14) 
02N SO29JCH2 CONH-PEPTIDE 	 H2NCONH-PEPTIDE 
10 — 	 + 02N—'--SO2CH2CH2 	 H 	
ON_KTSO 
Figure 1.14: The Nsc protecting group applied in SPPS. 
The Nsc group has been effectively applied in automated SPPS and is compatible for 
use in Fmoc cycles, as illustrated by Ramage in the synthesis of Big Endothelin 35 . 
The deprotections may be monitored in an analogous fashion to Fmoc chemistry, 
using an isobestic point of 380nm. In addition, the Nsc-based amino acids have 
shown to possess superior stability in DMF solutions compared to their Fmoc 
counterparts, with less than 2% decomposition after 3 weeks 35 . 
1.1.2.2 Side chain protecting groups 
The peptide and protein synthesis on the solid phase described in this work rely 
exclusively on the use of the Fmoc protection strategy. In this mode, the side chain 
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protecting groups are as detailed in Table 1.1. As discussed above, these protecting 
groups may be cleaved under mildly acidic conditions, being removed with 
concomitant cleavage from the solid support. 
It should be noted, however, that when deprotecting a peptide, the inclusion of 
scavengers into the reaction mixture is mandatory. These agents, which include 
ethaneditiol (EDT), triisopropylsilane (TIS), phenol and thioanisole are necessary in 
order to trap reactive species such as the tert-butyl cation which are capable of 
alkylating the aromatic side chains of tryptophan and tyrosine. 
Amino Acid 	 Protecting Group 	 Name 
Ser, Thr, Tyr 	
-'-. 	
tert-butyl ether 36 
Asp, Glu 	 0 	 tert-butyl ester 41 
I - 
Cys, Gln, Asn, His 	 trity1 37 '38'39  
Trp, Lys 	 0 	 Boc40'4' 






Table 1.1: Side chain protecting groups used in Fmoc SPPS. 
D] 
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1.1.3 Solid support and choice of linker 
The original formulation of Merrifield is still extensively employed in both peptide 
and general organic synthesis on the solid phase. However, there have been a number 
of other supports developed specifically for peptide synthesis, the main examples of 
which are discussed below. 
1.1.3.1 Polyethylene glycol based resins 
Resins based on a polyethylene glycol (PEG) construct have found widespread 
popularity, owing to their swelling properties being complimentary to those of 
polystyrene (Table In addition, the PEG portion of the resin is believed to 
confer a more "solution like" environment to the system. 
Solvent PS/1%DVB PS/PEG (Tentagel) 
NMP 6.4 4.4 
THF 6.0 4.0 
CHC13 5.6 5.6 
Dioxane 5.6 4.2 
DCM 5.4 5.6 
DMF 5.2 4.4 
THF/1-120(1:1) 2.8 5.2 
CH3CN/H200:1) 2.0 4.0 
CH3NO2 2.0 4.0 
TFA 2.0 6.4 
H20 1.6 3.6 
EtOAc 4.2 2.0 
Table 1.2: Swelling properties of PS and PS/PEG resins in various solvents 
(volume in mL/g) 
11 
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Bayer first introduced PEG as a support in 197 145  in a solution phase synthesis, 
separating the PEG labelled product from unreacted starting materials by 
ultrafiltration. However, the filtration process was slow, so attention was turned 
towards alternatives, including grafting PEG onto a polystyrene support (Figure 
1.15). The most obvious method of achieving this would be to employ a Williamson 
ether synthesis between cholromethylated polystyrene and PEG chains. 
'- CH2O —(C2H40)— H 
Figure 1.15: PEG grafted polystyrene/divinylbenzene 
Warshawsky and co-workers 46  demonstrated that yields were generally unsatisfactory 
when chains of greater than 800Da were employed. This was due to crown ether 
formation, through both hydroxyls of the PEG reacting with chioromethyl groups. 
In order to overcome the problem of low loading, the ethylene glycol portion was 
introduced by means of anionic polymerisation 47,48 (Figure 1.16). 
%OCH20-(C2H4O) 	dioxane 	 O—CH20-C2H40H 
Figure! .16: Anionic polymerisation producing PEG grafted PS/i %D VB. 
The ideal length of PEG chain for a composite polymer of this type has been found 
to be approximately 3000Da, with corresponding functionalities of the order 0.1-
0.4mmo1/g. The properties of these systems are controlled considerably by the PEG 
containing moiety. 
1.1.3.2 Polyacrylamide based resins 
The hydrophobic nature of polystyrene based resins can make them unattractive for 
use in the synthesis of hydrophilic peptides. This prompted Sheppard to investigate 
12 
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the use of a polymer support derived from polyacrylamide 49 . The swelling properties 
of the polymer were markedly different to that of polystyrene, with greater swelling 
in DMF than in DCM. The resin was successfully used in the synthesis of acyl 
carrier protein (65-74) which had previously proved difficult to synthesise on 
polystyrene50 . The support ostensibly has a polarity which is more compatible with 
that of a peptide chain, having an adequate balance of hydrophobic and hydrophilic 
properties. However, Stewart 5 ' has suggested that the polarity of the peptide on resin 
is much different to that of the free peptide, owing to the presence of hydrophobic 
protecting groups. This has led to the suggestion that in many cases polystyrene can 
be just as effective a support for peptide synthesis as polyamide. 
1.1.3.3 Other supports for peptide synthesis 
A number of semi-synthetic supports have been examined for use in solid phase 
peptide synthesis. Proteins themselves have been employed, for example Hansen et 




N 	 Peptide 4 
0 
deprotection 
Figure 1.17: Solid phase peptide synthesis using BSA as a support. 
The method exploits the insolubility of proteins in certain organic solvents, allowing 
isolation of the peptide-protein conjugate by filtration. The acidic side chains of 
aspartic acid and glutamic acid are first blocked as their diethyl amides, before the 
peptide was synthesised directly onto the lysine side chains of the protein. In this 
way, the peptide-BSA conjugate can be used directly for the production of antibodies. 
Frank 53  illustrated that cellulose paper could be used as a support in multiple peptide 
synthesis. The cellulose disc was functionalised as shown (Figure 1.17), by 




Figure 1.17: Functionalised cellulose as a support for SPPS. 
However, the lack of mechanical stability and the sensitivity of the discs to acid 
rendered them unsuitable for Boc chemistry. 
Eichler, together with Lebl 54 , used cotton, the purest form of cellulose as a support 
and found it to have superior mechanical stability. The first amino acid is covalently 
attached to the support by direct esterification, with loadings in the region of 0.04 to 
0.12mmol/g. Following synthesis, the peptide can be removed from the cotton 
carrier by saponification. This technique has also been applied in the production of 
antibodies in rabbits, by directly implanting the antigen supported on cotton in the 
animal. 
Geyson55 has used a functionalised polyethylene surface in the synthesis of multiple 
peptide antigens. The surface was functionalised by irradiation of the polymer in an 
aqueous solution of acrylic acid (Figure 1.18), giving loadings of 0.15-0.2nmol/mm 2 . 
Peptides were then synthesised using Boc protocols, with the peptide linked to the 




o OH 	 OMe 
0 	 _1t1 





Figurel.1 8: Peptide synthesis using functionalised polyethylene. 
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1.1.3.4 Linkers to the solid support 
The choice of linker can dictate both the type of chemistry that can be performed on a 
resin and the C-terminal functionality that results following cleavage. Table 1.3 
shows some linkers used in the synthesis of peptides, and the conditions employed 
during cleavage. 
Linker Cleavage C-terminal 
Conditions functionality 
11 	3—CH20--—CH20H 50% TFA acid 
12 	O_CH2NH) Br Pd(0)/NMO acid 
0 	SIMe3 
13 TBAF acid 
OH 
14 CI 




AcOH/DCM (1:9) acid (XOH) 
TFA/DCM (1:1) 	amide (X=NH2) 




CH20 	MeO 	OMe 
\ 
17 





Table 1.3: Examples of linkers used in SPPS. 
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The most commonly used linker in Fmoc SPPS in the p-alkoxybenzyl alcohol system 
(11), developed by Wang56. Cleavage of a peptide from a support functionalised 
with this linker can be achieved without recourse to strong acids such as HE 
Several linkers have been developed that offer mild, non-acidic cleavage conditions, 
facilitating the preparation of fully protected peptide fragments. The HYCRAM 
system (12), devised by Kunz 57  yields an allylic ester when loaded. The system can 
then be readily cleaved using catalytic Pd(0) in the presence of a suitable scavenger. 
Ramage 58  developed a silicon based system (13) which is cleaved when exposed to 
TBAF. However, it was not found to possess sufficient acid resistance, making it 
unsuitable for Boc chemistry, but could be successfully applied when using the Fmoc 
strategy. 
The 2-chlorotrityl system 59  (14), devised by Barbs, is highly acid labile, making it a 
valuable system for producing peptide fragments with protecting groups intact, 
including the t-butyl moiety. Cleavage can also be achieved using AcOH/TFE/DCM 
(1:1:8) and it is noted that the use of TFE can lead to an acceleration in rate of 
cleavage from the support. 
A highly versatile linker system based on a benzosuberyl scaffold (15) has been 
developed by Ramage60 . A range of C-terminal functionalities are available, 
including amide and the hydrazide which is important for further elaboration of the 
fragment by ligation approaches. 
Rink 6 ' has developed an acid labile linker based on a trialkoxy-diphenylmethyl amide 
core (16). Liberation of protected peptide amides can be achieved using weak acids. 
However, the Rink system can suffer significant loss of peptide from resin during 
synthesis using the weakly acidic HOBt as the coupling reagent. Rink advises that 
coupling reactions involving HOBt should be buffered with DIEA to minimise this 
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loss 6 '. The Rink system has more recently been deployed in the synthesis of C-
terminal sulphonamides 62 . 
Another example of a highly acid sensitive linker is the SASRIN (Super Acid 
Sensitive ResiN, 17) system introduced by Mergier et a!63 . A complication with this 
system is that racemisation occurs when histidine or cysteine are loaded owing to the 
length of time required (overnight using DCC/DMAP). 
The hydroxylamine system (18) facilitates the preparation of peptide aldehydes upon 
cleavage from the solid phase 64 . Loading of the first amino acid results in a Weinreb 
amide linkage65 , and conventional Boc chemistry is performed to construct the 
desired peptide. Cleavage is carried out in a two stage protocol, involving HF 
deprotection of side chain protecting groups, followed by treatment with LiA1H 4 to 
produce the aldehyde. A series di and tripeptide aldehydes were synthesised, which 
appeared to racemise during chromatography. 
An interesting method of cleaving a peptide from the solid support would be to make 
use of enzyme-scissile linkers. Such systems are particularly attractive owing to the 
mild conditions and specificity offered by enzymes. One obvious limitation is that 
many enzymes do not function in organic media, resulting in little or no reaction. 
This necessitates the use of mixed solvent systems, which are not always compatible 
with the substrates used. The first system examined for cleavage of peptides used a 
phosphatase 66 (Figure 1.19). 
0 	 0 	- 	0-PEPTIDE 
Figure 1.19: A phosphatase labile linker system. 
Treatment of the resin bound system (19) with calf spleen phosphatase gave a p-
hydroxymethylbenzyl ester. A shortcoming of this method is that to obtain the free 
peptide, the ester must then be treated with 33% HBr which effectively negates any 
advantages of using enzymes. 
17 
Chapter 1 
Since this initial report, relatively few other enzyme labile systems have been 
examined. However, a recent report from the group of Waldmann 67 described a 
robust enzyme-scissile system (20, Figure 1.20). 
0 OAc 	 0 
N 	- 	 lipase 	O---.. 	
0) 
H I 
50mM MES buffer! 	 + ROK 
20 	
OR 	 (.pR 	
N 
TENTAGEL 
Figure 1.20: Waldmann 's enzyme-scissile linker system. 
Acids were directly attached to the linker while alcohols and amines were 
incorporated using carbonates and urethanes, respectively. The cleavage reaction 
was found to proceed smoothly, and in acceptable yield when the commercially 
available lipase RBOO1-05 was utilised. 
1.1.4 Difficult sequences in SPPS 
So called "difficult sequences" are exemplified by reproducible segments in a 
particular peptide/protein synthesis where coupling reactions do not reach 
completion. Kent 68  has suggested that this phenomenon is the most serious problem 
associated with linear SPPS. 
1.1.4.1 Causes of difficult sequences 
A number of workers have been active in attempting to define the cause of these 
problematic regions. The majority of evidence obtained thus far indicates that 
inefficient coupling reactions are generally accompanied by formation of structure in 
the resin bound peptide. Milton et a!69 studied the synthesis of gondatropin hormone 
A number of other less serious residue specific side reactions are possible and these are discussed at 
length by Fields and Noble [Reference 31(b)] 
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(14-36), a known difficult sequence. Using Fourier transform infra red (FT-IR) 
spectroscopy, they showed that a n-sheet structure was present. 
Further evidence for secondary structure formation leading to coupling difficulties 
has been provided more recently by Lippens and co-workers 70. This work used 
magic angle spinning NMR (MAS-NMR) to study the synthesis of a 10 residue 
peptide. At each stage of the synthesis, a portion of the resin was withdrawn and 
examined by MAS-NMR. By qualitative analysis of nOe data, an extended structure 
was shown to exist throughout the chains. Addition of DMSO, which competes for 
hydrogen bonds, produced enhanced mobility of the chains as witnessed by line-
narrowing in the MAS-NMR spectrum. Also, following addition of DMSO, an 
increase in coupling efficiency was observed, as well as an enhancement in resin 
swelling. This observation supports the idea that disruption of secondary structure 
leading to higher mobility of the peptide chains, is an important consideration in 
ensuring successful acylation reactions. 
1.1.4.2 Overcoming difficult sequences 
The majority of the strategies developed to subjugate the problem of difficult 
sequences rely on disrupting secondary structure. The use of chaotropes, such as 
NaC104 51 and LiBr71 have been shown to lead to an increase in swelling of the resin, 
and hence improved efficiency of coupling. Trifluoroethanol 72 has also been 
employed to the same end. Yu et a173 have used a domestic microwave oven in the 
formation of a series of dipeptides, giving a significant improvement in coupling 
efficiencies following irradiation. 
Another approach is modification of amino acids at difficult segments in order to 
disrupt secondary structure. To this end, both Sheppard and Mutter have been active. 
The approach taken by Mutter 74 was based on earlier work, showing that the 
inclusion of a proline residue into a sequence which could form secondary structure 
minimised the possibility of both a-helix and n-sheet formation 75 . This idea was 
extended into a temporary protection system, giving structural similarity to a proline 
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residue. These pseudo-prolines (Figure 1.21) were shown to be useful in disrupting 
secondary structure by inserting a kink into the conformation of the peptide 
backbone. 
o NH- 




x =0, S 
Figure 1.21: Incorporation ofpseudo-proline residues in SPPS. 
The pseudo-proline motif can be derived from serine, threonine or cysteine, with the 
native functionality being unmasked by acidolysis. By modification of the alkyl 
groups at the C2 position in the oxazolidine/thiazolidine ring, the acid lability of the 
system may be tuned, allowing the possibility for protection to remain in place 
following cleavage from the solid support 76 . 
Sheppard's approach 77  involves protection of the amide bond, using NO-bis Fmoc 






Figure 1.22: Sheppard's backbone protection using HMB amino acids. 
These amino acid derivatives may be smoothly incorporated without extension of the 
chain being inhibited, with the next amino acid coupled through an internally 
catalysed O-acylation reaction followed by intramolecular acyl transfer. Despite the 
obvious utility of both these systems, their application is hampered by long coupling 
times. These are often in excess of 24 hours, which limits their compatibility with 
automated synthesis protocols. 
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One other approach to handling difficult sequences is to predict their occurrence. 
Several groups 78,79  have examined this possibility through statistical analysis of 
several hundred coupling reactions. Preliminary results indicate that potentially 
difficult sequences may be predicted. 
1.1.5 Monitoring of synthesis 
As discussed above, methods for the qualitative or quantitative evaluation of the 
success of a peptide or protein synthesis are essential, and can offer vital information 
on optimising a particular synthesis. Several methods based on established 
techniques have been developed, including automated resin sampling for ninhydrin 
analysis 80  and quantitative Edman degradation of the resin bound 
product 81  In the case of Fmoc chemistry, real time analysis of coupling is possible 
by measuring the UV absorbance of the fulvene containing deprotection solution, 
(Section 1.1.2.1). Some more recent methods, many of which rely on new 
instrumentation, have also been documented and these are highlighted below. 
Kent et a182 have used MALDI-TOF-MS in conjunction with a photocleavable linker 
to analyse fully protected peptide fragments directly from the solid support (Figure 
1.23). The method is rapid and requires negligible amounts of resin, making it 
compatible with real time monitoring. 
	
P P 	
0 Chemically cleaved 
BocHN ' 
linker 	
Ph tolabile linker 
TAG_ij2 0 
02 N 
Figure 1.23: Kent's on-resin analysis using MALDI-TOF-MS. 
FT-IR spectroscopy can also be used to study the assembly of peptides. Bayer 
83  used 
both UV and FT-IR methods to follow the synthesis of HIV- 1 protease (80-99). The 
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FT-IR approach was found to be more predictive, indicating the presence of 
secondary structure up to three residues before any appreciable drop in the synthesis 
could be detected by UV monitoring. 
1.1.6 Chemical ligation approaches 
Until recently, the approach taken in the synthesis of proteins of any significant size 
relied on linear, stepwise synthesis, often resulting in very low yields of target 
compound. However, exciting results from the laboratories of Kent 84  and Tam 85 
have pioneered a convergent strategy, using a technique called native chemical 
ligation (Figure 1.24). Using this method, the union of two unprotected peptide 
fragments in a chemoselective fashion is possible in aqueous solution. The initial 
product, a thioester (22), undergoes spontaneous rearrangement to furnish a native 
peptide bond (23). Kent has successfully applied the technique to the synthesis of 
more than 60 different proteins and protein analogues 86 . 
Another strategy is fragment condensation in solution, using fully protected peptide 
fragments. Side chain deprotection is carried out following assembly of the chain. 
Such an approach was taken by Sakakibara 87 in his impressive synthesis of the 238 
residue green fluorescent protein. 
0 
H2N-PEPTIDE A—U\( 	H3N 	
PTIDE B-COO 
SR 
¶ Chemoselective reaction 
FH 9 2N 0 PEPTIDE B_COp] 22 





H 2 N-PEPTIDE A. NPEPTDE  B-COO° 23 
H 
0 
Figure 1.24: Native chemical ligation. 
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1.2 The ubiquitin system 
Ubiquitin (MW 856513a) is a small, globular protein which was first isolated almost a 
quarter of a century ago by Goldstein 88 , as part of the characterisation of the peptide 
hormones of the calf thymus. As its name suggests, the protein is present in almost 
all living cells88 . Ubiquitin exhibits a most remarkable conservation throughout 
species, being identical in man 89  and in insects90 . The ubiquitin gene indicates that 
the molecule is synthesised as a polyprotein 91 , with different numbers of repeats 
according to species. 
The protein has been extensively characterised by both x-ray crystallography 92 
(Figure 1.25) and nmr studies 93,  which reveal that the protein has four n-sheets 
across one a-helix, with no disulphide linkages. The C-terminal gly-gly region 
protrudes, and has considerable freedom of motion, a property which is important in 
considering its biological role. The size of the protein, together with its interesting 
structure and biology, made it an attractive candidate for total synthesis, achieved 7 
94 years ago; 
Figure 1.25: Crystal structure of ubiquiiiii at iSA. 
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1.2.1 Biological role of ubiquitin 
Two main purposes for ubiquitin in biology have been identified. The first of these 
is modification of the histones, where the C-terminal glycine is covalently bound the 
an E-amino group on an internal lysine of the histone 996. The other principal 
function of ubiquitin is related to intracellular proteolysis. and this is discussed in 
some detail below. 
1.2.1.1 Ubiq uitin and proteolysis. 
The role of ubiquitin in proteolysis has been extensively investigated. Hershko 97 
isolated ubiquitin as a heat stable polypeptide component of an ATP dependent 
proteolytic system in reticuolytes. This discovery gave the first indication that 
ubiquitin was implicated in a proteolytic system. Cienhanover 98 then showed that 
ubiquitin was covalently attached to proteins in this proteolytic cycle, indicating that 
ubiquitin behaves as a marker. Shortly after the discovery of the tagging role of 
ubiquitin, it was shown that the protein forms a multiple conjugate with lysozyme, a 
good substrate for ATP dependent proteolysis 99 . It was later shown that the links in 
the polyubiquitin chain are constructed from isopeptide bonds from g1y76 to 1ys48, 











Figure 1.26: Multiple ubiquitination of lysozyme 
24 
Chapter 1 
According to Hershko' °° , the requirement of ATP for the proteolytic event stems 
from a sequence of reactions which conjugate ubiquitin to a target protein. The 
enzymes involved in ubiquitin conjugation have been delineated (Figure 1.27), 
although precise details of the mechanism involved remains unclear. 
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Figure 1.27: The ubiquitin conjugating pathway. 




The ubiquitin activating enzyme (El) binds both ubiquitin and ATP, resulting in a 
tightly held ubiquitin-adenylate intermediate (24)101.  A cysteine on El then reacts 
with the adenylate to yield a covalently bound Ub moiety (25)102.  The first step is 
then repeated to give a ternary complex of non-covalently bound ubiquitin-adenylate 
and ubiquitin-thioester (26). Transfer of the thioester to a ubiquitin carrier protein 
(E2)' °3 , which acts as a shuttle between the El protein and the ubiquitin-protein 
isopeptide ligase (E3), results in ubiquitination of the target protein. However, it 
should be noted that not every E2 enzyme that has been isolated has been shown to 
work with a particular E3 system 104 . 
1.2.1.2 The N-end rule 
While the mechanism relating to the precise targeting of proteins by ubiquitin 
remains unclear, what is known is that the rate of proteolysis of a protein is affected 
by the nature of the N-terminal residue. Hershko showed that both conjugation of 
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ubiquitin and, subsequent degradation of a protein, could be affected by acetylation 
of its N-terminus. This led to the suggestion that the presence of a free amino 
terminus was a pre-requisite for degradation and the possibility that the nature of the 
N-terminus could accelerate the formation of ubiquitin conjugates. Varshavsky' °5 
demonstrated that the half life of a protein was related to the identity of the N-
terminal residue, with half lives of a few second to a few days' °6 (Table 1.4). 
N-terminal Residue 	 Half-Life of X-gal 
Arg, Lys, Phe, Leu, Trp, Tyr 2 minutes 
His, lie, Asp, Glu, Asn, Gln, Cys, Ala, 	 >10 hours 
Ser, Thr, Gly, Val, Met 
Pro 	 not determined 
Table 1.4: Half lives of various Ji-galactosidase proteins in E.coli at 36°C. 
1.2.1.3 The 26S proteasome 
The 26S proteaseome is the organelle responsible for the intracellular degradation of 
proteins in the ubiquitin pathway. It was first identified by Hough et all 07  as an ATP 
dependent protease in rabbit reticulocyte lysates, which was capable of degrading 
ubiquitin-lysozyme conjugates. Analysis of the complex by electrophoresis showed 
it to be multi-component, and sedimentation analysis revealed it had a molecular 
weight of in excess of l000kDa 108 . Some clues regarding its structure were provided 
by Peters and co-workers' 09  who studied the complex by electron diffraction (Figure 
1.28). For the first time the 20S core could be seen, together with two subunits at 
either end, giving the system overall C2-symmetry. 
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Figure 1.28: Electron d[fraction structure of the 26Sproteasome. 
The capping domains at either end were subsequently identified as 19S subunits, by 
isolation of both the 20S core and the 19S caps" ° . This work also showed that the 
19S subunits themselves are composed of a set of polypeptides in the molecular 
weight range 22-35kDa. 
The structure of the 20S core has been studied further by x-ray crystallography at 3.4 
and 2.4A 1112 which was an important step in elucidating the mechanism of the 
proteasome function. The structure obtained (Figure 1.29) revealed that the complex 
was composed of 14 copies of two subunits, cx and P , with overall structural 
similarity to the molecular chaperone groEL. 
Figure 1.29: Crystal structure of the 20Sproteaseome in Saccharomyces cerevisiae. 
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The structure revealed that there are no large openings in the walls of the cylinder, 
with only a narrow channel of less than 13A leading to the catalytic site. This 
suggests that the substrates must be unfolded in order to be processed' 3 The core 
also contains hydrophobic residues which could stabilise unfolded proteins. 
By consideration of both the electron diffraction model and the crystal structure, it is 
apparent that the 19S caps lead to the core of the 20S chamber. Given that the 19S 
caps contain multiple ATPases' 14,  it has been suggested that the unfolding of a 
substrate takes place here. Another possibility is that the process of ubiquitination 
serves to unfold proteins 115 although only scant experimental evidence currently 
exists to support this. The 19S caps also recognise the polyubiquitin chains that 
mark target proteins. Pickart and co-workers 116  using mutagenesis techniques, 
showed that three repeating hydrophobic residues (Leu8, 1le44, Va170) were essential 
for binding of polyubiquitin chains to the 19S caps. 
1.2.2 Protein deubiquitination 
Deubiquitinating enzymes (DUBs) are a class of proteins responsible for the 
processing of ubiquitin adducts. They are involved with the hydrolysis of linearly 
extended ubiquitin fusion proteins 117  including the product of the ubiquitin gene, 
which is a polyprotein91 , and the UbCEP52 fusion system 118  Hydrolysis of C-
terminal esters' 9 and amides of ubiquitin is facilitated by ubiquitin carboxyl-
hydrolyases, which are one class of DUBs. 
Isopeptidase T, a ubiquitin C-terminal isopeptidase, has been shown to operate on 
polyubiquitin chains 120, suggesting that the role of this enzyme is to facilitate 
recycling of ubiquitin following proteolysis. Isopeptidase T is also known to operate 
on unanchored ubiquitin chains. Removal of these chains is essential to sustain 
proteolysis, as polyubiquitin chains are known inhibitors of the 26S proteaseom& 21 . 
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In general, the role of deubiquitinating enzymes seems to be as negative regulators of 
the ubiquitin proteolytic cycle. In addition to post-proteolytic recycling of ubiquitin, 
DUBs are able to remove ubiquitin from incorrectly tagged systems, including 
moieties containing highly reactive sulfhydryl groups' 19,  which otherwise could 
consume the reserves of free ubiquitin in a cell. 
1.2.3 Summary 
The ubiquitin system has been shown to be a highly complex regulatory pathway, 
operating in all eukaryotic cells. Information regarding its function has been gleaned 
from biochemical approaches. However, with the advent of more powerful structural 
elucidation techniques together with genetic approaches, a deeper insight into the 
function of the system has been obtained. Despite this, many aspects of ubiquitin-
dependent proteolytic system, including targeting of substrates and proteolytic 
function, still remain somewhat obscure, underlining the need for on-going research 
in this area. 
1.3 Protein folding 
The rapid folding of a polypeptide into a well-defined three dimensional array is 
essential for the correct function of the protein. It is now well established that a 
random search for a native conformation is not feasible, as for even a small protein 
(ca. 100 residues) there exist around 10 49  different conformations, which would 
require around 1029  years to explore them all ' 22 . The so-called "Levinthal Paradox" 
has led to the belief that there exist defined pathways for protein folding. Around the 
same time, pioneering work by Anfinsen' 23 demonstrated that the information 
required for protein folding is contained within the primary amino acid sequence of 
most proteins. Today, many researchers are active in the study of protein folding, an 
understanding of which could facilitate the prediction of tertiary structure from 
sequence, which would be an extremely powerful tool in the post-genomic era. 
Knowledge of how proteins fold would also offer a valuable insight into how 
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proteins rnisfold, for example, in neurological conditions such as Creutzfelt-Jacob 
Disease' 24 . A crude, generalised pathway for protein folding is illustrated in Figure 
1.30 
if 
Unfolded 	 Molten globule 	Folded 
Figure 1.30: Generalised protein folding pathway. 
As long ago as 1931, Wu 125  proposed that the denatured state involved a transition 
from an ordered structure to a highly flexible random coil state. A widely accepted 
set of intermediates on the protein folding pathway are the molten globule states 126 . 
They are characterised by their relative compactness, with elements of secondary 
structure in place. It is believed that such intermediates lead to the folded form of the 
protein. The molten globule state may not apply to the whole structure, as there 
exists some evidence that folding of one domain in a protein may be essentially 
complete, whereas another domain can remain in the molten globule state. Kim 127 
has shown that for a-lactalbumin, the molten globule state is restricted to the J3-sheet 
domain. 
1.3.1 Experimental studies on protein folding 
A variety of experimental techniques are now being employed in attempting to 
observe intermediates in the folding pathway of proteins. Some of these techniques 
are outlined below. 
Circular Dichroism offers a sensitive probe with which protein folding can be 
monitored ' 27 " 28 . Following the far UV signal as a function of time allows the 
appearance of a-helicity to be studied. By use of the near UV signal, one can 
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Figure 1.31: Following protein folding using near andfar CD techniques. 
Nuclear magnetic resonance has been applied to study protein folding for around ten 
years 129.  Using hydrogen-deuterium exchange to label amide regions on the protein 
which are not protected by hydrogen-bonding after various time points, Roder 129  was 
able to follow the folding of cytochrome c. The protein was denatured in guanidine 
hydrochloride/D 2 0 before being refolded by rapid dilution into an acetate buffer. 
Labelling of the protein is achieved by changing the pH to 9.3 for SOms and then 
switching back to pH 5.3 before the nmr spectrum is recorded. By use of 2-
dimensional nmr techniques, specific protons in the protein structure may be 
followed, which can offer information on the structure of intermediates. Dobson 130 
has use such an approach to examine a lysozyme molten globule. 
The accuracy of electrospray mass spectrometry has been shown to compliment the 
information offered by hydrogen-deuterium exchange experiments' 31 . Although nmr 
can provide information on specific sites in a protein, it cannot indicate the 
population of different intermediates on the folding pathway. For example, a system 
where 50% of all the protein molecules are labelled with deuterium and the 
remaining 50% are unlabelled would appear identical to a system which has all of the 
molecules labelled with deuterium to the extent of 50% by nmr, as it reports an 
average. However, the use of electrospray mass spectrometry would clearly show the 




On 	 7 	 7, 
- c6s,naJ 91,11 
Chapter 1 
If the folding of a protein is relatively slow, then examination of individual 
resonances in time resolved nmr spectroscopy is possible ' 32 . Dobson has recorded 
the nmr spectrum of x-lactalbumin at 2 second intervals and in this way, could 
follow refolding and structural changes with the sample inside the nmr magnet 
(Figure 1.32). 
Figure 1.32: Time resolved nrnr spectroscopy during refolding of a-lactalbumin. 
Small angle x-ray scattering has also been applied to the study of protein folding. 
Using this method, the radius of gyration (R g) of a protein can be monitored on the 
millisecond to second timescale. In this way, Jennings' 33  showed that for the 
unfolded state of apomyoglobin the R g was around 34A and I OOms after refolding 
the apparent R g is 23A, only IA larger than the fully folded state. 
1.3.2 Molecular chaperones 
The 60kDa protein groEL was initially identified as being essential for the correct 
assembly of bacteriophages' 34" 35 . More recently, Ellis 136 suggested that this 
molecule and its homologues are part of a wider class of compounds known as 
"molecular chaperones". Akin to their human counterparts, the molecular 







preventing aggregation. GroEL and its co-chaperonin groES (1 OkDa) have been 
shown to refold a number of enzymes, in the presence of ATP, including 
dihydrofolate reductase and rhodanase' 37 . The existence of such molecules tends to 
negate the Anfinsen experiments which showed that the information needed for 
protein folding is contained within the polypeptide itself. 
Many groups have been active in attempting to ascertain how the triad of groEL, 
groES and ATP induce refolding of protein systems. Again structural studies, 
combined with the techniques of mutagenesis, have considerably enhanced our 
knowledge of the process. 
Horowich 138 , from consideration of the crystal structure of groEL 139, constructed a 
set of mutants which established the residues requires for polypeptide binding. It was 
suggested that a protein binds through hydrophobic interaction to key residues in the 
core 
The crystal structure of the groEL-groES-AMP complex 140 (Figure 1.33) shows back 
to back groEL rings forming a cavity in the centre of the rings, with groES capping 
the structure. 
Figure 1.33: Crystal Structure ofgroES 7-groEL 14  complex at 3. OA with top view (left) and 
side view (right) taken from reference 141. 
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The complex also shows significant differences in geometry from the structure of 
groEL alone. The apical regions were observed to move up by almost 600  and 
twisting around by 90°. Rye et al 141  using mutagenesis, demonstrated that ATP 
binding to the cis ring of groEL was essential in promoting this highly allosteric 
conformational change. 
Consideration of the crystal structure and the mutagenesis experiments described 
above have led to the pictorial representation of chaperone-mediated protein folding 
shown in Figure 1.34, below 142 . The substrate protein is bound to the hydrophobic 
sites of the cavity (a). On binding of ATP the apical regions of the complex twist by 
90°, effectively unfolding the protein by stretching (b). The substrate then resides in 
the centre of the cavity which is now lined with hydrophilic residues, and folding 









Protein folding is a highly complex event, involving several factors, some of which 
remain to be elucidated. The work described above illustrates the importance of 
structural studies on folding intermediates and indeed misfolded forms of proteins. 
The involvement of other agencies in the folding pathway is an important area which 
is receiving increasing attention. Considerable effort in both these areas is required if 
the folding problem is to be understood. 
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Chapter 2 
Chapter 2: Synthesis and Function of an Alzheimer's Protein 
2.1 Research overview 
Alzheimer's disease is a progressive neurodegenerative disorder of the brain, and is 
the most common form of dementia. The seriousness of the condition is underlined 
by the fact that approximately one in ten people are believed to have Alzheimer's, 
and at least $100 billion a year is spent on care for Alzheimer's patients in the United 
States alone'. 
The principal pathological changes associated with the condition are the development 
protein deposits known as plaques, which contain the J3-amyloid protein, and 
neurofibrillaiy tangles which contain an insoluble form of the tau protein. The tau 
protein, normally present as part of intracellular structure in the brain was shown to 
be monoubiquitinated in when inside these tangles 2 . This fact lends credibility to the 
notion that the ubiquitin system is somehow implicated in the development of 
Alzheimer's disease. For around ten years it has been recognised that impairment of 
ubiquitination may cause neuronal death 3 . In addition, early work by Perry et a14 
indicated the presence of ubiquitin in neurofibrillary tangles. Further evidence for 
the involvement of ubiquitin in Alzheimer's was presented more recently when van 
Leeuwen et a15 detected a frameshift mutant of ubiquitin in the brains of demented 
patients (Figure 2.1). 
Met-Gln-Ile-Phe-Val-Lys-Thr-Leu-Thr-Gly-Lys-Thr-Ile-Thr-
Leu-Glu-Val-Glu-Pro-Ser--Asp-Thr-Ile-Glu-Asn-val-Lys_Ala_ 
Lys- I le-Gln-Asp-Lys-Glu- I le-Pro-Pro-Asp-Gln-Gln-Arg-Leu-
I le - Phe -Ala-Gly-Lys -Gln-Leu-Asp-Gly-Arg-Thr-Leu-ser-Asp_ 
Tyr -Asn-G1n -Lys -G1u - Ser-His-Leu-va1-LeuArgLeu_Arg_G1y_ 
Tyr-A1a-Asp-Leu-Arg-G1u-Asp-Pro-Asp-Arg_G1n_Asp_fljs_Hj_ 
Pro-Gly-Ser-Gly-Ala-Gin 
Figure 2.1: Amino acid sequence of the mutant protein. 
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This protein, which is a C-terminally extended ubiquitin analogue, without glycine at 
the 76 position, was found to be absent from the brains of young, non-demented 
control patients. Van Leeuwen has suggested that the information contained in the 
mRNA coding for the polyubiquitin precursor is not stable, but instead can be edited 
by some as yet unknown process. The mutant mRNA produced contains a 
dinucleotide deletion, resulting in the production of the extended ubiquitin analogue, 
ubiquitin-nonsense (UbN). Figure 2.2 contains a schematic depiction of the editing 
process. 
i 	
Human ubiquitin-B DNA 
Human ubiquitin-B mRNA 
mutant mRNA 	deletion Al- 
DUB 
1 	 76 	 76 
751 	20 	 ub 	 I ub 
28 
27 
Figure 2.2: mRNA editing resulting in the production of UbN. 
A similar editing process is believed to exist for the vasopressin gene in Brattleboro 
rats, where a single nucleotide is deleted. New-born rats do not have any functional 
vasopressin but the amount of functional protein that the animals produce increases 
with age owing to mRNA editing allowing translation of the active protein 6 . 
The ubiquitin polyprotein (28), which is the usual product of the translation process 
is converted into mature ubiquitin by the action of deubiquitinating enzymes (Section 
1.2.2). The frameshift mutant, UbN (27), which is produced as a result of mRNA 
editing, is not expected to be hydrolysed by deubiquitinating enzymes. Work by 
Hodgins8 and by Cienchanover 9 has shown that if the residue at the 76 position is 
mutated from glycine to alanine then conjugation of ubiquitin becomes irreversible, 
i.e. deubiquitination is not possible. 
Given that the UbN mutant protein was expected to persist in the Alzheimer's brain, 
there exists the possibility that it could somehow compromise the ubiquitin 
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dependent proteolytic system. The main objective of this work was, therefore, the 
synthesis and purification of the UbN moiety in order to subject it to biological 
testing. It was anticipated that testing of the mutant could establish how it interacts 
with the ubiquitin system. The following hypotheses were proposed: 
UbN will not be processed by deubiquitinating enzymes but instead would lead to 
inhibition of deubiquitination; 
The protein could inhibit ubiquitin conjugation; 
UbN could be an inhibitor of the 26S proteasome. 
It was believed that a combination of the above effects could contribute to the 
misfunction of the ubiquitin system during ageing. 
2.2 Results and discussion 
2.2.1 Chemical synthesis and purification of UbN 
The protein was synthesised using the Fmoc/ tBu approach described in Chapter 1, 
with DIC/HOCt' ° based in situ activation of each amino acid. Single coupling cycles 
were employed, with the exception of the final ten cycles, which were double 
coupled. The synthesis was performed on an O.lmmol scale as previous experience 
from within the research group in the synthesis of large (Ca. 100 residue) proteins 
indicated that loadings in this region gave optimum results. This fact has been 
corroborated by the work of Tam" who demonstrated that problems encountered 
during synthesis by inter-chain clustering can be exacerbated by the using of high 
loaded resins. 
The progress of the synthesis was followed by monitoring the absorbance of the 
fulvene-piperi dine adduct, as described in Section 1.1.2.1. The deprotection profile 
obtained is shown in Figure 2.3. From the deprotection profile, it can be seen that 
assembly of the analogue was reasonably efficient, with only one significant drop in 
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coupling efficiency at approximately half way. Following completion of synthesis, 
an Fmoc loading test was performed, indicating that the N-terminal functionality was 
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Figure 2.3: Deprotection profile for the synthesis of UbN. 
Following assembly of the analogue, a strategy for its purification had to be devised. 
To this end, the Tbfmoc group' 2 (Figure 2.4) has been developed for use as a 
primary purification aid. 
0 
LI 
Figure 2.4: The Tbfrnoc group for peptide/protein purification. 
The Tbfmoc probe was designed to possess certain properties which could be 
exploited for peptide/protein purification. The first of these is that the group itself is 
essentially planar, which confers a high affinity for porous graphitised carbon or 
charcoal. This affinity then facilitates separation of the labelled target sequence by 
selective binding from any acylated truncated sequences which have arisen due to 
incomplete coupling reactions. The additional hydrophobicity of the Tbfmoc group 
makes RP-HPLC based purification more straightforward. In addition, the labelled 
compound can be easily identified by its unique UV absorbance at 364nm. 
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The analogue was purified by harnessing the affinity of the Tbfmoc group for 
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Figure 2.5: Purification of UbN by the Tbfrnoc/charcoal approach. 
Immediately prior to removal of the N-terminal Fmoc group, the resin was swollen in 
DCM and capped with acetic anhydride. The Tbfmoc group was introduced as its 
chloroformate, with sonication in DCM. After loading of the Tbfmoc group, the 
protein was cleaved from the resin using TFA!water together with a scavenger 
cocktail of EDT, thioanisole, TIS and phenol. The resulting crude mixture of Tbfmoc 
labelled protein and truncated sequences were then separated on charcoal, and the 
target sequence was removed from the affinity support by treatment with a dilute 
piperidine solution. Sequential dialysis was then applied to remove piperidine salts, 
and to permit refolding of the analogue. Amino acid analysis at this stage suggested 
that further purification of the analogue was required. Both anion exchange and size 
exclusion chromatography were examined, with the latter proving highly satisfactory. 
An alternative support for affinity chromatography using the Tbfmoc group was also 
examined. Porous graphitised carbon offers excellent results in the affinity based 
purification protocol, but is prohibitively expensive. Charcoal, by comparison is very 
inexpensive, but requires extensive pre-treatment to remove fines before it can be 
used for purification purposes. It was proposed that chromatographic grade 
polystyrene could be employed in the Tbfmoc based purification protocol. In 
addition to having a set of face-on vt-stacking interactions, it was envisaged that 
Tbfmoc could interact in an edge-on fashion with the aromatic rings of the polymer. 
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Indeed, work by Petsko' 3 has suggested that edge-on t-interactions are stronger than 
face-on. 
Following loading of the Tbfmoc moiety and acidolytic cleavage as detailed before, 
the crude protein mixture was subjected to polystyrene based chromatography. The 
crude mixture was solubilised in a 20% v/v acetic acid solution and then adsorbed 
onto polystyrene. After extensive washing with 20% v/v acetic acid and water, the 
labelled protein was cleaved from the support using a 10% v/v solution of piperidine 
in acetonitrile/water (1:1). The protein solution obtained was then desalted, before 





UbN fusion protein 	 After 
	
SDS-PAGE 
before polystyrene polystyrene 	 analysis 
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Figure 2.6: HPLC and SDS-PAGE anal vsis of UbN. 
The HPLC trace obtained (Figure 2.6) shows that the protein to be significantly 
cleaner than the material before the polystyrene based purification. SDS-PAGE 
confirmed the purity of the material, and also indicated that the product was in the 
correct molecular weight range. Amino acid analysis results were also acceptable, 
and compared well with the product of the charcoal purification. Edman degradation 
of the first five residues were in accord with the anticipated sequence. 
Previous work by Wilken 14 had shown that the use of Tbfmoc could sensitise the 
ubiquitin N-terminal methionine to oxidation. In contrast, no evidence for such 
oxidation could be observed for the UbN system, with the MALDI-TOF-MS (Figure 
2.7) showing only the protonated molecular ion. 
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Figure 2.7: MALDI-TOF-MSofUbN. 
The use of polystyrene has, therefore, been shown to be highly effective in the rapid 
purification of this system. In addition, this approach allowed for the preparation of 
significant (Ca. 100mg) quantities of this protein. 
2.2.2 Structural analysis of UbN 
Some limited structural analysis was carried out on the analogue. High field 
(600MHz) n.mr spectroscopy was employed in the first instance (Figure 2.8). 
Upon examination of the I D nmr it was apparent that no significant level of structure 
was present in the protein. This is judged by the absence of signals at the high field 
end of the spectrum and lack of definition in the amide region, both of which 
characterise folded states in proteins. 
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Figure 2.8: 600MHz nmr spectrum of UbN in 50mMCD 3CO2Na, pH 4.5. 
The analogue was also studied by the use of circular dichroism (CD) in order to 
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Figure 2.9: Circular dichroism of UbN at 0.33mg1mi concentration. 
A full analysis of the spectrum was performed using the CONTIN algorithm' 5 which 
relates the observed spectrum to secondary structure by comparison with known 
structures whose CD spectrum has been accurately determined. The data obtained 
revealed that only 1 ± 0.69% a-helix and 43 ± 0.93% n-sheet existed, with 57 ± 1.3% 
making up the remainder. 
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The molecular chaperones groEL and groES (Section 1.3.2) were then employed in 
order to establish if any tertiary structure could be induced. Each chaperone was 
overexpressed in E.coli using BL2I cell lines with plasmid DNA which was obtained 
from the group of Professor Paul Sigler. Expression levels of 50mgIL for groEL and 
1 Omg/L of groES were obtained. GroEL was purified to complete homogeneity by 
application of mono Q anion exchange chromatography following cell lysis. 
GroELswas subjected to a 3 stage purification protocol using mono Q anion 
exchange, superdex 200 size exclusion chromatography and finally resource Q anion 
exchange chromatography. Figure 2.10 shows the SDS-PAGE results for the 
purified chaperones. 
VWWO 
groES groEL standards 
Figure 2.10: SDS-PAGE ofpurfIed molecular chaperones. 
With significant quantities of the chaperones in hand, several approaches to the 
refolding of UbN were examined, monitoring the process by RP-HPLC. The use of 
pre-formed chaperone complexes in both catalytic and excess quantities, in the 
presence of ATP did not produce any reaction. Sequential addition of UbN to a 
solution of groEL and ATP, followed by addition of groES, was also unsuccessful. 
The fact that the analogue has proved to be difficult to refold is unlikely to be a 
shortcoming of the purification protocol. A more likely explanation is that linearly 
extended ubiquitin systems do not have any structure. Previous studies by Muir'°on 
the UbCEP52 protein 17  demonstrated that this molecule had no apparent structure. 
The above observations would tend to support the belief that ubiquitination leads to 
the unfolding of a protein 18 
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2.2.3 In vitro testing of the analogue. 
As discussed in the project overview, it was anticipated that the presence UbN in the 
brains of diseased patients could lead to the ubiquitin system being compromised. 
Having synthesised and purified the analogue, it was then possible to establish the 
role of the protein in the pathology of Alzheimer's Disease. In vitro testing was 
carried out at the University of Nottingham Medical School by Professor John Mayer 
and Dr Robert Layfield. 
2.2.3.1 Studies on the in vitro processing of the analogue 
The first series of tests were to determine the ability of deubiquitinating enzymes to 
process UbN. Incubation of the analogue with protein gene product 9.5 (PGP 9.5), a 
ubiquitin carboxyl hydrolase found in ubiquitinated inclusion bodies 19 , showed that 
the mutant protein was not processed. The anti-ubiquitin Western blots shown in 
Figure 2.11, illustrate the contrast between UbCEP52, a normal gene product and 
UbN. 	
UbCEP52 	 UbN 
-DUB +DUB 	-DUB +DtJB 
Figure 2.11: Anti-ubiquitin Westerns blots for treatment with PGP9. 5. 
The findings of these experiments agree with the previously reported studies which 
showed the importance of glycine at the 76 position for deubiquitination to occur 8 ' 9 . 
The human brain enzymes 14-3-3 were originally identified as being activators of 
tyrosine and tryptophan hydroxylases 20, hence are involved in signalling. Studies 
performed by Mayer et a!21 revealed a novel cysteine protease activity from human 
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brain extracts and found it was attributable to a pair of 14-3-3 isoforms. The 14-3-3 
was found not to cleave UbCEP52 in the same place as ubiquitin hydrolases 
(UCH's). but attacks a site seven residues distant from the UCH cleavage site. Given 
that 14-3-3 has recently been identified in the neurofibrillary tangles of Alzheimer's 
Disease, the analogue UbN was incubated with purified bovine brain 14-3-3 in order 
to determine if processing was possible in this way. 
UbCEP52 	 UbN 
.rn 
dW 
- 14.3.3 +14.3.3 	 - 14.3.3 +14.3.3 
Figure 2.12: Treatment with bovine brain 14.3.3. 
As Figure 2.12 clearly shows, no processing of the analogue is observed using the 
14.3.3 enzyme, whereas UbCEP52 is cut by the same enzyme. 
The next stability test that was carried out on the mutant was to treat a sample with 
crude human protein brain extract. Contrary to expectation, the analogue was 
processed into a fragment with the approximate molecular weight of ubiquitin, 
shown by inspection of the Western blot (Figure 2.13). The precise reasons why the 
analogue was being cleaved by human brain protein extract remained unclear until 
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Figure 2.13: Incubation with crude human brain protein extract. 
Mass spectral analysis revealed that the product of the digest had an apparent 
molecular mass of 8455.613a. From consideration of the sequence of the starting 
material, it was evident that this fragment corresponded to the sequence 
Ub( 1-74). It has been well established from early work on the structure of ubiquitin 
that the arnide bond between Arg74 and G1y75 is labile to trypsin 22 . Indeed, the 
agent involved in intracellular proteolysis was not initially thought to be ubiquitin, 
but instead was labelled ATP-dependent proteolysis factor I (APF-1), as it only 
contained 74 residues whereas ubiquitin has 76. It was not until 1980 that 
Wilkinson 23  was able to unify the two entities. 
Although the analogue was processed in the above experiment, the digest does not 
furnish mature ubiquitin. It is possible that the Ub(1-74) system produced by the 
digest could interact with the ubiquitin system in some other way. 
2.3.2.2 Inhibition of deubiquitinating enzymes 
The next hypothesis examined was that the analogue, VbN, could inhibit 
deubiquitinating enzymes. If this was found to be the case, then the accumulation of 
ubiquitinated enzymes in neurofibrillary tangles could be rationalised. 
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Incubation of UbCEP52 with a purified ubiquitin carboxyl hydrolase in the presence 
of UbN was carried out, and the digest was examined by Western blotting in the 
usual way. However, the situation was complicated by the fact that the substrate 
(UbCEP52). the product (ubiquitin) and the supposed inhibitor (UbN) were all 
recognised on the Western blot. 
UbCEP52 






Figure 2.14: Western blot analysis of inhibition of deubiquitination. 
A clearer indication of what was happening in the reaction could be obtained by 
following the DUB catalysed disappearance of UbCEP52 in the presence of varying 
amounts of the supposed inhibitor (Figure 2.15). 
Moles of Lb-nonsense added 
per. nDIe UBICEP52 
0 	- 	 - UBICEP52 
001 	 - 
-DUB +DUB 
0 
2 hrs at 37 C 
Figure 2.15: DUB catalysed processing of UbCEP52 in the presence of varying quantities 
of the mutant UbN. 
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With no UbN present in the digest, it was evident that processing of UbCEP52 into 
ubiquitin and CEP52 was occurring, as judged by the reduction of the intensity of the 
band corresponding to the starting material. When up to one equivalent of UbN was 
added, inhibition of deubiquitination could be detected. These experiments provide 
some explanation as to why the tau protein is ubiquitinated in neurofibrillary tangles, 
despite the presence of deubiquitinating enzymes within the same tangles. 
2.2.3.3 Inhibition of the 26S proteasome 
One other proposed role of the UbN protein in the pathology of Alzheimer's disease 
was that inhibition of the proteasome was possible. As previously discussed (Section 
1.2.2), polyubiquitin chains which do not anchor to a target protein are known to 
dock with the proteasome at the S5a protein24, a subunit of the 19S domains 
responsible for recognition of polyubiquitin chains (Figure 2.16). In the usual 
ubiquitin pathway, such unanchored chains are recycled to ubiquitin by the action of 
isopeptidase T 2 , hence preventing competitive inhibition of the 26S proteasome and 
preserving the pool of free ubiquitin in the cell. 
Figure 2.16: Binding ofpolyubiquitin chains to the S5a subunit of the proteaseome. 
It was reasoned that if UbN was capable of being incorporated into these 
polyubiquitin chains by the ubiquitin conjugating enzyme E2, then such chains may 
not be processed by isopeptidase T. If these mutant containing chains did persist, 
then proteasome inhibition by competitive binding would result26. 
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In order to test this hypothesis, the synthesis of these chains was carried out by 
Professor Cecile Pickart and colleagues at the John Hopkins University in Baltimore. 
The methods of assembling the chains are discussed below. 



















Figure 2.17: In vitro assembly of a reiraubiquitin chain. 
The approach taken 27  relies on two ubiquitin mutants, UbAsp77 (29) and K48C Ub 
(30), and exploits the requirement for a glycine at the C-terminus and a lysine residue 
48 for El/E2 mediated isopeptide bond formation. The first mutant (29) is blocked 
at the C-terminus, and is therefore, not capable of being activated by the El /E2(25k) 
combination. Hence, this may only condense with another activated ubiquitin 
molecule. The second system (30) has a free C-terminus, but lacks Lys48 so cannot 
self condense. This design results in only the diubiquitin species (31) being formed. 
The diubiquitin moiety is then alkylated, giving a pseudo-Lys48 containing species 
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(32) which can then condense with a deblocked diubiquitin unit (33). furnishing the 
ubiquitin tetramer. 
With significant quantities of the tetramer in hand, it was then possible to examine 
the incorporation of UbN into the chains. As discussed above, only those species 
which contain glycine as the C-terminal residue are capable of being activated by the 
El/E2 combination. UbN was expected to behave as a nucleophile via Lvs48. and 
condense with the electrophilic Ub 4 system. Deblocking of the tetramer (34) and 
incubation with E2(25k) and UbN revealed that incorporation of UbN into the 
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Figure 2.18: SDS-PAGE showing assembly of Ub. 
The Ub5,1 chain was then isolated using cation exchange chromatography, and up to 
1mg of the pentamer was isolated in this way. 
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The purified Ub 1 system was then subjected to treatment with isopeptidase T. in 
order to establish if the pentamer could be hydrolysed. As Figure 2.19 shows. no 
processing of the pentamer was observed. Also. even after extended incubation times 
at high concentrations of isopeptidase T. no hydrolysis could be observed. In 
contrast. the Ub 4 system was readily hydrolysed by isopeptidase T. This observation 
confirms the suggestion that polvubiquitin chains containing the mutant protein could 
accumulate in the brains of Alzheimer's patients. 
A. Ub5+1 	 B. Ub4 
[isol] 	 ç b 
\ ____-I SobI 
Ub5+1 
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Figure 2.19: Incubation of (A) Ub 51 and (B) Ub 4 with isopeptidase I 
The possibility that the mutant containing Ub5.- 1 chains could inhibit proteolysis was 
next examined. Inhibition of proteolysis of a multiply ubiquitinated dihydrofolate 




The data obtained (Figure 2.20) showed that both systems inhibited the 26S 
proteaseome. however the Ub 5 ,. 1 system was found to bind twice as tightly to the 
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Figure 2.20: 26Sproteaseoine inhibition by (A) Ub 4 and (B) Lib,. 
2.2.4 Generation of antibodies 
Another goal of this work was to elicit antibodies to synthetic peptides related to the 
amino acid sequence of UbN. It was envisaged that antibodies raised in this way 
could be used in a robust diagnosis of Alzheimer's disease by examining the cerebral 
spinal fluid of patients who are believed to have the condition. 
Three antigentic determinants were synthesised (Figure 2.21): 
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H2N.-YADLREDPDR-OH (35) 	H2N-QDHHPGSGAQ-OH (36) 
HN-YADLREDPDRQDHHPGSGAQ-OH (37) 
Figure 2.21: Antigenic determinants from the UbN sequence. 
Peptides 36 and 37 were synthesised using standard Fmoc/ tBu chemistry, with in situ 
activation using the DIC/HOCt approach. Compound 35 was prepared independently 
in the same manner. Prior to cleavage, one half of each peptide was removed and 
cysteine was manually coupled to the N-terminus. This was to facilitate covalent 
attachment to a carrier protein, via the bifunctional reagent m-malimidobenzoyl-N-








Carrier protein 	 ANTIGEN 
Figure 2.22: Coupling of an antigenic determinant to a carrier protein. 
The cysteine containing peptides were cleaved from the solid support and purified by 
RP-HPLC before being linked to keyhole limpet haemocyanin (KLH). The role of 
the carrier protein is twofold: as well as stimulating the animal's immune system, it 
enhances the bioavailability of the peptide 28 . Antibody production was carried out 
using New Zealand white rabbits by Dr Robert Layfield of the University of 
Nottingham Medical School. Ten weeks after immunisation, the animals were bled 
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Figure 2.23: Western blots probed using antibodies raisedfrom sequence 37. 
The resin bound peptides which were not tagged with cysteine were cleaved and 
purified in the usual way and were examined by 'H nmr (Appendix 1). Application 
of 2-dimensional nmr techniques confirmed that no structure was present in any of 
these systems, which could have affected antibody production. 
Work is currently in progress in order to determine if these antibodies can be used to 
detect high molecular weight UbN conjugates in the brains of Alzheimer's patients 
2.2.5 Summary and conclusions 
The powerful technique of solid phase synthesis combined with a new, highly 
efficient purification protocol has facilitated the isolation of significant quantities of a 
novel ubiquitin related protein. Extensive in vitro testing has for the first time 
revealed how this protein can exert a deleterious effect in the brains of Alzheimer's 
patients. With suitable antibodies in hand, detection of the mutant in patients could 
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Chapter 3: Synthesis of Fluorinated Ubiquitin Analogues. 
3.1 Research overview 
Physical methods that enable protein folding to be followed are of tremendous value 
in identifying intermediates in the folding pathway. Ultimately, it is envisaged that 
knowledge of common intermediates will reveal the details of how proteins fold and 
hence allow prediction of tertiary structure from a known sequence. Some of the 
techniques, including nmr and circular dichroism, which are routinely applied to 
study protein folding have been discussed in Chapter 1. 
By application of chemical synthesis, the incorporation of a heteroatom, specifically 
fluorine into the core of a small protein at a predetermined site is possible. By 
replacement of leucine with a fluorinated leucine analogue, 2S,4S-5-fluoroleucine' 
(Figure 3.1) it was proposed that protein folding could be followed using ' 9F nmr. 
When using fluorine as a probe, it was anticipated that no significant effect would be 
imposed on the structure owing to the small size of the atom. 
H 2N CO2 H 
Figure 3.1: 2S,4S-5-fiuoroleucine. 
Fluorinated aromatic amino acids such as 3-fluorotyrosine have previously been 
incorporated into proteins biosynthetically 2 and used to examine the effects of ligand 
binding by 19F nmr. Feeney3 has recently incorporated 2S,4S-5fluoroleucine into 
dihydrofolate reductase by biochemical means. The 19F nmr for the analogue showed 
a large (Ca. 1 5ppm) chemical shift range for the 12 fluoroleucine residues. 
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The most obvious advantage associated with the use of fluorine as a probe in an nmr 
experiment is the simplified spectra that are obtained. Additionally, the 19F nucleus 
is almost as receptive as the proton itself in an nmr experiment and is 100% 
abundant, making it an excellent choice for nmr studies. 
A synthetic approach to fluorinated protein analogues would be clearly superior to 
the biochemical approaches taken in the past as the fluorinated amino acid can be 
incorporated at a pre-determined position. In addition, other nuclei such as 
' 5N or 2H 
could be incorporated into the same amino acid in order to further simplify nmr 
experiments. 
The protein selected for study in this way was ubiquitin. Previous work by Muir 4 had 
demonstrated that the synthesis was feasible, and in addition much was known about 
the structure of ubiquitin. Both x-ray crystallography  and nrnr 6 data were available, 
allowing for direct comparison of the analogues synthesised with the native structure. 
The primary amino acid sequence of ubiquitin is shown in Figure 3.2, with the 
leucine residues present in the core highlighted. It was these residues that were 
considered for replacement with the fluoroleucine moiety. 
Met-Gin-I ie - Phe -Vai -Lys -Thr_Leu_Thr_G1y_Lys_Thr_I1e_Th. 
Leu -Giu -Val - G 1 u - Pro- Ser --Asp_Thr_Ile_Giu_Asn_Vai_Lys_Aia 
Lys-I ie -Gln-Asp-Lys -G1u .- Ile_ProPro_Asp_Gin_G1n_Arg_Le_ 
lie- Phe -Ala -Gly-Lys -Gln-Leu -Asp-Gly-Arg_Thr_Leu..ser.Asp_ 
Tyr -Asn -Gln-Lys-Giu-Ser-}-ijs -Leu -Vai -Leu-Arg-Leu-Arg-Giy-
Giy 
Figure 3.2: Bovine ubiquilin with core leucine residues highlighted. 
Wilken 7  had synthesised a number of analogues of this system and had succeeded in 
purifying ubiquitin Fleu(50/67), allowing reasonable nmr data to be obtained. This 
indicated that a native fold was attained upon replacement of leucine with 
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fluoroleucine. However, more extensive characterisation of the protein was required 
in order to fully assess the effect of incorporating fluorine atoms into the structure. 
The aim of this project was to synthesise a greater quantity of the UbFleu(50/67) 
analogue, and to examine it by x-ray crystallography, 19F nmr and circular dichroism, 
in order that a complete analysis of the compound could be obtained. 
3.2 Results and discussion 
3.2.1 Chemical synthesis and purification of UbFIeu(50/67) 
Using the Fmoc/'Bu approach (Chapter 1), the analogue was synthesised on an 
0.25mmol scale. Each amino acid was automatically coupled with DIC/HOCt 
activation, with the exception of the fluoroleucine residues which were manually 
coupled in order to maximise the coupling yield. The assembly was followed by 
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Figure 3.3: Deprotection profile for the assembly of UbFleu(50167). 
The profile obtained indicates that the assembly proceeded reasonably well. The N-
terminal functionality was found to be 54% of the theoretical maximum, which 
correlates well with the deprotection data. 
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Following completion of the synthesis, the analogue was acidolytically cleaved from 
the solid support in the presence of the usual compliment of scavengers, and the 
crude protein was isolated by precipitation into ether. In order to solubilise the crude 
mixture and to unfold any misfolded forms, the precipitate was dissolved a solution 
of 8M urea. Dithiothreitol (DTT, Cleland's reagent) was included in the buffer at a 
concentration of 10mM as it was believed that this could sacrificially protect the N-
terminal methionine against oxidation. 
The initial purification step employed was size exclusion chromatography using a 
Superdex 3ØTM  FPLC column running in 8M urea. Using this system, it was possible 
to rapidly purify large quantities of the protein in a batchwise fashion. Following 
size exclusion, the desired fractions were identified by RP-HPLC, and were pooled 
before being dialysed, removing urea over a period of several days. This measure 
was introduced to allow refolding of the analogue to its native tertiary structure. 
Upon completion of the dialysis step, the protein solution was freeze dried to 
facilitate convenient storage. Analysis using RP-HPLC and MALDI-TOF-MS was 
carried out at this stage (Figure 3.4) which indicated the presence of a number of 
other components in addition to the desired material. These impurities present were 
too close in molecular weight to be able to separated by gel filtration alone. Further 
purification was, therefore, required before any reasonable degree of structural 
analysis could be conducted. 
MO 




Figure 3.4: RP-HPLC & MALDI- TOF-MS of gelfihtered/refolded UbFleu(50167). 
The use of cation exchange chromatography using CM-sepharose had been 
moderately successful in a previous ubiquitin campaign  and so it was decided to 
attempt this in the first instance. However, despite repeated attempts, it proved 
difficult to isolate any of the required material from the column, leading to this 
approach being abandoned. 
An alternative cation exchange resin was then examined. Resource STM  is a strong 
cation exchanger, based on monodisperse polystyrene/divinylbenzene beads 
functionalised with methyl sulfonate groups. Using this system. with 50mM 
ammonium acetate buffer at pH 4.5, it was possible to bind protein to the column. 
Protein could then be eluted from the column by the application of a sodium chloride 
gradient. 
However, extensive optimisation of the method was necessary in order to obtain 
highly purified material. The optimised gradient system, shown in Figure 3.5, 
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Figure 3.5: Optimised gradient system for Resource S cation exchange of UbFleu(5015 7). 
Each fraction was examined by RP-HPLC, and the material of interest was found to 
elute during the isocratic period. Loadings of greater than 5mg were found to 
diminish resolution, hence it was necessary to perform chromatography in a number 
of batches. Analysis of the analogue using RP-HPLC (Figure 3.6) revealed that it 
was highly pure, and the corresponding MALDI-TOF-MS spectrum confirmed that 
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Figure 3.6: RP-HPLC and MALDI-TOF-MS ofpurfled UbFleu(5 0/6 7). 
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3.2.2 Structural analysis of UbFIeu(50/67) 
3.2.2.1 Nmr studies 
With significant quantities of the purified analogue in hand, the protein was then 
examined using 1D proton nmr (Figure 3.7) to confirm that folding of the protein 
had been successful. By inspection of the spectrum it was evident that the system 
was properly folded. The high field signal corresponding to lie 616  at -0.22 ppm was 
present, and there were a number of low field signals, together with excellent 
definition in the amide region. All of the above spectral features are indicative of a 
properly folded structure. 
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Figure 3.8: ' 9F nmr ofpurfied UbFleu(5 0/6 7) in 50mM CD3CO,Na at pH 4.5. 
The protein was also examined by 19F nmr (Figure 3.8). which gave results 
consistent with those of Wilken 7 . Two main signals were observed, corresponding 
with each of the fluoroleucine residues. Some additional resonances were observed 
in the spectrum, and it is believed that these could correspond to additional 
conformations of the 6-carbons bearing the fluorine atoms. 
Interestingly, when the 19F nmr spectrum was recorded in a mixture of 
acetonitrile/water (1:1), it appeared that the protein had been subject to unfolding. 
The spectrum obtained (Figure 3.9) shows the two resonances of the folded form, 
and an additional Set of two resonances at lower field, in the ratio of 1:4. 
The set of lower field resonances are very well defined doublets of triplets. 
suggesting considerable freedom of motion in this form of the protein. The role of 
the acetonitrile could be to disrupt hydrophobic contacts in the core by preferentially 
solvating the hydrophobic residues, leading to the destabilisation of the native state. 
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Such a mode of action has long since been established for urea 8.  More recently. 
Wallqvist9  has shown that urea may preferentially adsorb onto the charged surface 
residues, leading to a repulsion between them and subsequent swelling of the protein. 
This allows water to access the core of the protein, again causing destabilisation. A 
similar mechanism could be envisaged for acetonitrile, leading to the FIeu moieties 
moving away from the hydrophobic core. 
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Figure 3.9: 19F nmr spectrum of UbFleu(50167) in H20/acetonirrile. 
3.2.2.2 Circular dichroism studies 
The analogue was also examined by the technique of circular dichroism (Figure 
3.10) and the data compared to bovine ubiquitin. This revealed that the analogue was 
essentially indistinguishable from the wild type protein. Application of the CONTIN 
algorithm' 0  was made to deconvolute the spectrum into proportions of secondary 
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Figure 3.10: Circular dichrois,n of UbFleu(5016 7) in 50mM phosphate at pH 6.0. 
Broken line = native Ub, solid line = analogue. 
3.2.2.3 X-ray crystallography of UbFleu(50/57) 
In order to obtain a definitive comparison of the analogue structure with the native 
compound, it was decided to attempt crystallisation of the protein. Crystals were 
grown by application of repeated seeding with crystals of bovine ubiquitin, as only 
this method was successful in yielding crystals in the previous ubiquitin campaign 4 . 
Crystallisation was carried out by Dr Lindsay Sawyer and colleagues at the Structural 
Biochemistry Department of Edinburgh University. In these experiments, a single 
seed of wild type ubiquitin was added to a I Ojtl drop of concentrated analogue 
solution (5.tl, 20mg/mi) and buffer (30% wlv PEG 4000, 50mM cacodylate/HCI, pH 
5.6). The resulting small crystals were then transferred into fresh drops of identical 
composition, and this gave rise to crystals of the analogue of suitable size for x-ray 
diffraction. 
X-ray diffraction was carried out at 80K using the synchrotron radiation facility at 
Daresbury. The data collected was processed by Dr Dima Alexeev by fitting the 
observed reflections to the published structure of ubiquitin. 
Refinement was then made by use of electron difference density maps to give the 





same space group (P2 1 2 1 2 1 ) as the native compound and had similar unit cell 
dimensions. 
Superposition of the analogue structure with the natural product (Figure 3.11) shows 
an excellent correlation between the two. The only discernible difference is at the C-
terminus where it is known that considerable conformational flexibility exists in the 
structure. Such flexibility is extremely important in considering the biological role of 
ubiquitin in conjugating to other proteins and forming multi-ubiquitin chains. 





Figure 3.12: Electron density map showing the fluoroleucine residues in the core. 
The two fluorine atoms in the core were clearly visible at this resolution (Figure 
3.12). It was apparent that in the crystal form, two conformations existed for the - 
carbon of the Fleu 50 residue, making dihedral angles with the 5-carbon of the FIeu 
67 residue of 1390  and 00  The crystal data authenticates the suggestion that different 
conformations exist for the Fleu residues, as indicated by the 
' 9F nmr spectrum of the 
purified analogue. 
3.2.2.4 Differential scanning calorimetry 
The process of unfolding proteins at elevated temperatures may be directly followed 
by use of differential scanning calorimetry (DSC)". In a DSC experiment, a protein 
solution, generally at low concentrations, is heated at a constant rate and any changes 
in enthalpy are detected. Such experiments offer information on the thermodynamics 
of unfolding of a protein and hence its stability. The technique was applied to 
UbFleu(50167) and bovine ubiquitin, as a control, to determine what if any effect 
74 
Chapter 3 
incorporation of fluoroleucine has on the stability of the system. Figure 3.13 shows 
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Figure 3.13: DSC scans for bovine ubiquitin and UbFleu5O/6 7,). 
From the shape and area of each curve, thermodynamic data concerning the 
unfolding process can be inferred; the area under each peak refers to the heat uptake. 
AHca t. for the transition and the midpoint temperature. T m, relates to the point at 
which the half the molecules in the system are unfolded. 
The results obtained for the analogue showed a slightly lower midpoint temperature 
than the natural product which may be indicative of some destabilisation of the 
structure upon incorporation of the fluoroleucine residues. The difference could also 
be appreciated on a qualitative level by considering that the analogue structure would 
have a higher entropy owing to the number of possible conformations, hence leading 
to a lower Tm. Another difference between the analogue and the native was that the 
heat uptake for the transition was lower which could suggest that not all the sample 
was folded properly. Such a result contrasts with the nmr data obtained, which was 
consistent with the system being correctly folded. 
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3.2.3 In vitro testing of UbFleu(50/67) 
The ability of the fluorinated protein to participate in conjugation reactions with 
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Figure 3.14: A TP-dependant conjugation of ubiquitin to h'sozyrne. 
The assays, shown in Figure 3.15, were conducted by Dr Rob Layfield of the 
University of Nottingham Medical School. 
1  High molecular weight 
conjugates 
cubation time (mm) 
Bovine Ub UbFleu(50/67) 
Figure 3.15: Anti-western blot of conjugation to lysozyme. 
The protein was dissolved in 50mM tris, 5mM DTT at pH 7.5, using a concentration 
of 1mg/mi protein. In order to effect conjugation, the buffer also contained 10mM 
ATP and 5mM MgCl 2 . Incubation was carried out and samples were withdrawn after 
30 and 120 minutes, and resolved by SDS-PAGE. The SDS-PAGE slab was then 
blotted onto nitrocellulose, and the whole was probed with rabbit anti- 
ubiquitin/peroxidase swine anti-rabbit. The results demonstrate that the analogue is 
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capable of forming high molecular weight conjugates of with lysozyme, with a 
similar efficiency to the natural product. From this result, it can be asserted that the 
analogue must be recognised by the reticulocyte activating and conjugating enzymes. 
This fact lends additional support to the observation that no significant departure 
from the native structure occurs when the fluoroleucine residues are incorporated. 
3.2.4 Synthesis and purification of UbFleu(43/50) 
A second analogue, again containing a double replacement of leucine with 
fluoroleucine was also examined. In this system, residues at 43 and 50 were replaced 
by fluoroleucine. The synthesis was carried out in an analogous fashion to that above 
on an 0. 15mrnol scale with manual coupling of the fluoroleucine residues. The 
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Figure 3.16: Deprotection profile for the synthesis of UbFleu(43150). 
As Figure 3.16 indicates, the assembly of the UbFleu(43150) analogue was not as 
efficient, resulting in the accumulation of a significant amount of truncated 
sequences. In order to facilitate a rapid purification of the analogue, it was decided to 
introduce the N-terminal amino acid, methionine, as its Tbfmoc derivative (Figure 
3.17). By incorporating the Tbfmoc moiety as part of the final amino acid, it was 




The appropriately labelled amino acid was readily prepared in a one-pot procedure 
developed by Lorthioir' 2 (Figure 3.17). 
Is 
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Figure 3.17: Synthesis of Tbfmoc-Met-OH. 
Following chromatographic purification. Tbfmoc-Met-OH was obtained in a modest 
yield and in an analytically pure form as determined by RP-HPLC. 
The Tbfmoc amino acid was manually incorporated onto the resin as its HOCt active 
ester and the reaction was followed by use of the Tbfmoc loading test (Section 
4.3.4). Following coupling of the N-terminal amino acid, the protein was cleaved off 
the solid support in the presence of a scavenger cocktail, and analysis of the resulting 
crude product revealed that incorporation of the Tbfmoc moiety had been successful 
(Figure 3.18). The HPLC trace of the crude mixture also confirmed the presence of 
a number of truncated sequences which had similar retention times to the unlabelled 
target sequence, which would have made HPLC based purification of the unlabelled 
sequence extremely difficult. 
Purification of the analogue was carried out by using porous graphitised carbon 
(PGC) as the stationary phase, giving a product of much greater purity. MALDI-
TOF-MS confirmed the identity of the product, with no obvious sign of oxidation of 
the N-terminal methionine (Figure 3.19). Amino acid analysis results at this stage 
were also highly satisfactory. 
78 
Chapter 3 




Figure 3.19: MALDI- TOE-MS of Tbfmoc purified UbFleu"43150j 
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The analogue was then dialysed to remove urea, with concomitant removal of 
piperidine salts. The Tbfmoc purified protein was then subjected to cation exchange 
chromatography on Resource STM media. However, following elution from the 
column, the HPLC of the analogue remained broad compared to the UbFleu(50/67) 
system, which is suggestive of the protein having no or at best ill-defined tertiary 
structure. 
Circular dichroism studies (Figure 3.20) indicated that the structure obtained was not 
consistent with a properly folded system. Use of the CONTIN algorithm' 0 showed 
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Figure 3.20: Circular dichroism of UbFleu(43150) in 50mM phosphate buffer at pH 6.0. 
High field 'H and 19F nmr were also employed to determine if folding had been 
successful (Figures 3.21, 3.22). The results obtained confirmed the suspicion that no 
native structure was present, as judged by the absence of the high field Ile 61 signal. 
The ' 9F nmr spectrum endorsed this fact, displaying resonances that were 
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Figure 3.21: 'Hnmr of UbFleu(43150) in 50mM CD 3CO2Na at pH 4.5. 
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Figure 3.22: 19F nmr of UbFleu(43150) in 50mM CD 3CO2Na at pH 4.5. 
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The fact that this analogue has proved recalcitrant to refolding could be an artefact of 
the Tbfmoc based purification protocol. Wilken 7 has previously shown that non-
native folds have been obtained when using the Tbfmoc moiety to purify ubiquitin 
and suggested that this was attributable to the Tbfmoc group serving as a template 
during folding. 
It is possible that the native structure could be accessed by use of the molecular 
chaperones groEL and groES 13 . One particularly attractive approach would be to 
employ the technique of "refolding chromatography" which has been developed by 
Fersht' 4 . The technique exploits so-called "mini-chaperones", the residues of groEL 
which are critical for refolding, bound to a polymer support. The denatured protein is 
applied to a column composed of this matrix and elutes in a folded form from the 
column. This obviates the need to separate the refolded protein from the chaperone 
complex and allows for facile re-use of the chaperone. 
3.2.5 Summary and conclusions 
This work has shown the value of solid phase protein synthesis in producing 
specifically substituted protein analogues. In addition, the use of fluorine as a handle 
to explore protein folding would appear to be viable, since in the case of 
UbFleu(50/67) the substitutions had no significant effect on the structure or the 
activity of ubiquitin. 
Future work could include the use of 19F nmr to monitor folding in an nmr tube in 
order to detect intermediates in the folding pathway of ubiquitin by monitoring the 
nmr spectrum as a function of time. Other fluorinated amino acids could be 
synthesised and incorporated into ubiquitin and employed in the same manner. The 
approach taken here could also be generalised and employed in the study of folding 
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Chapter 4: Experimental 
4.1 General notes 
All Fmoc amino acids were purchased from either Bachem, Novabiochem or PE 
Biosystems and are of L-configuration. The p-alkoxybenzylalcohol resin (Wang) was 
supplied by Bachem or Novabiochem. Peptide synthesis grade dimethylformamide 
(DMF), 1,4-dioxane and piperidine were supplied by Rathbum Chemicals. N,N-
diisopropylethylamine (DIEA) and trifluoroacetic acid (TFA) were peptide synthesis 
grade and purchased from PE Biosystems. 1-Hydroxy-4-ethoxycarbonyl-1,2,3-
triazole (HOCt)', tetrabenzo[a,c,g,i] fluorenyl- 1 7-methoxycarbonyl (Tbfmoc) 2 , were 
both synthesised within the research group. Adenosine triphosphate (ATP) was 
purchased from Sigma. Bovine Serine Albumin solutions were obtained from 
Promega. Plasmid DNA in a pET vector system for groEL and groES were provided 
by Professor Paul Sigler of Yale University 
Melting points were recorded in open capillaries using a Buchi 510 oil immersion 
melting point apparatus. Analytical thin layer chromatography (TLC) was performed 
using aluminium sheets precoated with silica gel 60 F 254 (Merck) using the solvent 
systems indicated in text. Infrared (IR) spectra were recorded on a Bio-Rad SPC 3200 
instrument. Ultraviolet (UV) spectra were recorded on a Varian Cary 210 double 
beam spectrophotometer in the solvents described in the text. Proton nuclear 
magnetic resonance (NMR) spectra were recorded on a Brucker AC-250 or a Varian 
600 instrument. High and low resolution mass spectra (FAB-MS) were obtained 
using a Kratos MS-SO instrument, using either thioglycerol, 3-nitorbenzylalcohol or 
glycerol as a matrix. Matrix assisted laser desorption ionisation time of flight mass 
spectra (MALDI-TOF-MS) were recorded on a PerSeptive Biosystems VoyagerTM 
BiospectrometryTM Workstation using either a-cyano-4-hydroxycinnamic acid or 3,5-
dimethoxy-4-hydroxycinnamic acid as a matrix. Amino acid analysis (AAA) were 
performed on a Pharmacia Biochrom 20 LKB 4150 alpha acid analyser on the 
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hydrolysate obtained after heating samples in 6M HC1 at 110 °C in sealed Carius 
tubes for the length of time indicated in the text. 
Circular dichroism (CD) spectra were recorded at 20 °C on a JASCO J600 
spectropolarimeter (University of Stirling). 
All buffers described were prepared using Milli-Q grade water, Biochemika 
Microselect grade guanidine hydrochloride (Gu.HC1) and urea (Fluka). High 
performance liquid chromatography (HPLC) was carried out using either an ABI 
system comprising 2x1406A solvent delivery systems, a 1480 injector/mixer and a 
1783 detector/controller, or a Gilson system comprising 2006 solvent delivery 
systems, an 811 c dynamic mixer, an 805 manometric module, a 119 UV/Vis detector 
and a Gilson 715 software-driven gradient controller. Peptides were eluted from 
various columns using a linear gradient of acetonitrile (HPLC grade, Rathburn 
Chemicals) in Milli-Q grade water, where both solvents contained 0.1% v/v of HPLC 
grade TFA (Lancaster). Fast protein liquid chromatography (FPLC) was carried out 
on a Pharmacia FPLC system with Liquid Chromatography Controller LCC-501 
Plus. Ion exchange was carried out with the media (Pharmacia) indicated in the text 
using Pharmacia LKB apparatus comprising 2xLKB 2138 UVCords, a Pharmacia 
2132 Microperpex peristaltic pump, a LKB 2112 redirac fraction collector and a 
Pharmacia GM-1 gradient mixer. Retrospective assays of each fraction were also 
carried out by determination of the optical density at 280nm of each sample using a 
Unicam UV/Vis double beam spectrophotometer. Dialysis tubing used was obtained 
from Spectrum ®, were  SpectralPor®  CE (cellulose ester) membranes with molecular 
weight cut-offs as described in the text. Samples were centrifuged using a MSE 
Mistral 2000R (Sanyo). Sample concentration employed Amicon centricon® cells or 
the Amicon®  Ultrafiltration cell 8050 using Spectrum Molecular/Por® membranes, 
with the molecular weight cut off as detailed in the text. 
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4.2 Solid phase protein synthesis 
All peptides were synthesised on an ABI 430A automated peptide synthesiser with 
on-line UV monitoring using an ABI 758A detector. All peptides were synthesised 
using the Fmoc/tBu strategy of Atherton et a13  with the following specific protecting 
groups: 
No protection for Ala, Gly, lie, Leu, Met, Phe, Pro & Val; t-butyl (Bu) ethers for Ser, 
Thr & Tyr; 'Bu esters for Asp & Glu; t-butoxycarbonyl (Boc) for Lys; t-
triphenylmethyl (Trt) for Asn, Gin & His; 2257,8-pentamethy1chroman-6-suiphonyl 
(Pmc) for Arg. 
4.2.1 Automated SPPS 
All peptides and proteins were synthesised using an Applied Biosystems 430A 
automated peptide synthesiser. Each cycle comprises the following sequence of 
events 
Capping: acylation of any unreacted amino termini. 
Deprotection: cleavage of the Fmoc A la protection. 
Coupling: a) activation of the desired amino acid. 
b) amide bond formation with the free N-terminus. 
After each step, the resin was washed extensively with copious amounts of DMF/l ,4-
dioxane. 
1. Capping 
The resin was vortexed with a solution of acetic anhydride (0.5M), DIEA (0.125M) 
and HOBt (0.2% w/v) in DMF/1,4-dioxane (1:1, lOml) for 10 minutes before the 
solution was drained from the reaction vessel and the resin washed with 6 portions of 




The resin was vortexed with a solution of 20% piperidine DMF/1,4-dioxane (1:1, 
1 Oml) for 10 minutes before being drained, passing the solution through a UV 
detector. After washing with DMF/ 1 ,4-dioxane (1:1, 4 times), the resin was treated 
with a further portion of piperidine solution (lOmi) vortexing for 1.5 minutes. The 
resin was then washed with 6 portions of DMF/1,4-dioxane (1:1). 
The progress of the synthesis following every deprotection was monitored in the 
following way: an aliquot of filtrate is diluted and passed to a UV detector with on-
line integration. The absorbance at 302nm can then be related to the efficiency of 
coupling of each amino acid. 
Coupling 
Activation: prior to coupling, every amino acid was converted to the corresponding 
active ester using HOCt. 
Formation of HOCt active ester: Fmoc amino acid (immol) was treated with HOCt 
(immol) and DIC (immol) in DMF/1,4-dioxane (1:1, 8m1). After 15 minutes, the 
active ester was transferred to the reaction vessel. Note that histidine was coupled as 
the HOBt4 active ester using 2mmol of HOBt in the cartridge. 
Coupling: Following addition of the active ester to the resin, the mixture was 
vortexed for 30 minutes before the solution was drained and the resin washed with 
DMF/1,4-dioxane (1:1,4 times). 
4.2.2 Manual coupling of amino acids 
The Fmoc protected resin was sonicated in 20 % v/v piperidine/DMF (20ml) for 15 
minutes before the resin was isolated by filtration. The free amino resin was then 
washed with DMF (50m1), 1 ,4-dioxane (50ml) and DCM (50ml). The resin was then 
reswollen in the minimum volume of DMF/1,4-dioxane (--4ml, 1:1). The desired 
amino acid (1 mmol) was dissolved in DMF (4m1) and to the solution was added DIC 
(157p.l, immol) and HOCt (157mg, immol). The whole was then stirred for 10 
minutes before being added to the swollen resin and sonicated for 4 hours. The resin 
was collected by filtration and extensively washed with DMF (SOml), 1 ,4-dioxane 
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(50m1) and DCM (50m1). The extent of coupling was then determined by the Fmoc 
loading test (Section 4.3.2). 
4.3 General Procedures 
4.3.1 Loading of the C-terminal amino acid onto the solid support 
4-alkoxybenzylalcohol (Wang) resin  was employed in all cases and loaded following 
one of the protocols outlined below: 
4.3.1.1 For resin loadings 0.5 - 0.6 mmoL'g 
The C-terminal Fmoc amino acid (6 equivalents) was dissolved in DMF (lOmi) 
before DIC (3 equivalents) was added and the solution sonicated for 15 minutes. 
Following the formation of the symmetrical anhydride, the solution was added to 
Wang resin (ig) pre-swollen in the minimum quantity of DMF, mixed with a 
catalytic amount of DMAP (approx. 10mg). The mixture was then sonicated for 2 
hours at room temperature. The resin was separated by filtration and washed with 
DMF (50ml), 1,4-dioxane (50m1), DCM (50m1) and diethyl ether (25m1) before being 
dried under vacuum. The extent of loading was then determined using the Fmoc 
loading test (Section 4.3.2) 
4.3.1.2 For resin loadings 0.1 - 0.2 mmoL'g 
2 equivalents of Fmoc amino acid and 1 equivalent of DIC were employed. 
Following addition to the pre-swollen resin, the mixture was left to stand for 30 
minutes before it was washed and dried as described above. The level of loading was 
then measured using the Fmoc loading test (Section 4.3.2). 
4.3.2 The Fmoc loading test 
The loading of the functionalised resin was determined by treating a known quantity 
of resin (-5mg) with 20% piperidine/DMF (1 Omi). This solution was sonicated for 
10 minutes before the UV absorbance of the supernatant was measured between 280 
and 320nm, noting the absorbance at 302nm. The resulting resin functionality 
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(rnmol/g) was determined by use of the Beer-Lambert law (E = 7800 for the Fmoc-
piperidine adduct 6). 
4.3.3 Loading of Tbfmoc onto peptide-resin 
Following completion of a synthesis, the A1aFmoc  group was removed by sonication 
of the resin in 20% v/v piperidine/DMF (15m1) for 10 minutes. The resin was then 
filtered and washed with DMF (50m1), 1,4-dioxane (50 ml) and DCM (SOml). The 
resin was reswollen in freshly distilled DCM (quantity as indicated in the text). 
Tbfmoc chloroformate (3 equivalents with respect to the N-terminal functionality 
measured by the Fmoc loading test) was added to the resin followed by DIEA (1 
equivalent). The whole was then sonicated with occasional agitation whilst protected 
from the light for 3 hours, before the resin was filtered and washed with 1 ,4-dioxane 
(lOOml) and DCM (200ml). The resin was then stored in 1,4-dioxane at 4°C and 
protected from the light until required. 
4.3.4 The Tbfmoc loading test 
The loading of the functionalised resin was determined by treating a known quantity 
of resin (-5mg) with 20% v/v piperidine/DMF (lOmi). After sonicating the solution 
for 10 minutes, the UV absorbance of the supernatant between 320 and 400nm was 
determined. The Tbfmoc-peptide-resin functionality and resulting coupling efficiency 
is then calculated from the following equations: 
0.613 x Ab5 364nm  
Resin funtionality (mmol / g) = Weight of resin (mg) 
Coupling efficiency of Tbfmoc = 
Resin funct. (Tbfmoc peptide) 
Resin funct. (peptide) 
4.3.5 Acidolytic cleavage from Wang resin 
The resin bound product was swollen in a cocktail of scavengers composed of EDT, 
water, thioanisole, TIS and phenol (quantities as detailed in the text) for 30 minutes 
under an atmosphere of nitrogen. TFA (quantity as indicated in the text) was then 
added and the whole is gently stirred for the time denoted in the text under an 
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atmosphere of nitrogen. The resin was then removed by filtration and the 
peptide/protein was precipitated using ice cold diethyl ether (1 OOml). The precipitate 
was brought to a pellet by centrifugation (3000 r.p.m. for 2 minutes). The 
supernatant was then discarded and the precipitate vortexed in diethyl ether (40m1) 
and centrifuged a further three times before the pellet was dried using nitrogen. The 
product was then further purified as described in the text. 
4.3.6 Tbfmoc purification using charcoal. 
Adsorption: Tbfmoc-peptide, dissolved in 8M urea (30m1) was mixed with washed 
activated charcoal. Adsorption was monitored using dual wavelength analytical 
HPLC (monitor set at214 & 364nm) and was deemed to be complete when the 
364nni absorbance diminished to baseline. The mixture was then centrifuged to yield 
a carbon pellet and the supernatant was decanted. 
Wash: The charcoal was washed using 8M ureali-propanol (1:1, 4 x 40ml) in order 
to remove all truncated sequences and material still in solution. For each wash the 
mixture was vortexed for 10 minutes, centrifuged and the supernatant decanted. The 
last wash was analysed by HPLC (monitoring at 21 4nm) to ensure no truncated 
sequences remain. 
Cleavage: The charcoal was vortexed in 10% piperidine/8M ureali-propanol (1:1, 
30m1) for 10 minutes, releasing the peptide from the Tbfmoc moiety. Following 
centrifugation, i-propanol was removed under reduced pressure and the pH of the 
solution was altered using AcOH (pH 6-7). The material was then further purified as 
indicated in the text. 
4.3.7 High pressure liquid chromatography 
HPLC was performed using one of the instruments described above with the 
following conditions: 
4.3.7.1 Analytical HPLC 
Columns used were either an Aquapore C18 OD-300 (220x4.6mm) or an Aquapore 
C8 (220x4.6mm) with the following conditions: 2ml loop; 0-2 min isocratic at 
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10%B; 2-32 min linear gradient to 90%B; 32-34 min linear gradient to lO%B; 1 
ml/min flow rate; monitoring at 214 or 364nm as indicated in the text. 
4.3.7.2 Semi-preparative HPLC 
An Aquapore C18 (220x15mm) was used with the following conditions: 5 ml loop; 
0-2min isocratic at 10%B; 2-32 min linear gradient to 50%B; 32-34 min linear 
gradient to 1 O%B; 5 ml/min flow rate; monitoring at 214nm. 
4.3.8 Preparation of E.coli competent cells 
LB media (lOmi) was inoculated with a frozen stock of BL21 cell line and allowed 
to grow overnight (37°C, vortexing at 250r.p.m.). Fresh LB (lOml) which contains 
1M MgCl2 (0.2m1) was seeded with an aliquot of the overnight culture (0.2m1). The 
cells were then allowed to grow for a further hour (OD600nm 0.2) before being 
chilled on ice for five minutes. The cells were then centrifuged (2000g, 15min at 
4°C), the supernatant discarded and the pellet suspended in cold transformation 
buffer (50mM CaCl 2 , 10mM Tris, pH 8.0, 4m1). The cells were then placed on ice 
and agitated gently before being left for 30 min. Centrifugation was then applied to 
pellet the cells (3000g, 15min at 4°C). The supernatant was then discarded and the 
cells were suspended in cold transformation buffer (0.4m1). The competent cells 
were then left on ice for 2 hours before use. 
4.3.9 Transformation of E.coli competent cells with recombinant DNA 
An aliquot of the competent cell suspension (1 OOpi) was transferred to a sterile 
Eppendorf tube and left on ice (15mm). Recombinant DNA was then added and the 
tube was gently agitated and left on ice (30 mm). The cells were then heat shocked 
(37°C, 5 mm) and warm LB (37°C, imi) was added. The cells were then incubated 
(37°C, 1 hour) and then centrifuged (10000g, is mm). The supernatant was then 
discarded and the pellet suspended in fresh LB (50j.tl), This was then streaked on an 
agar plate which was incubated overnight (37 0C). 
LB media is composed of NaCI (lOg), bacto-tryptone (lOg), yeast extract (5g) in water (II, pH 7.5) 
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4.3.10 Overexpression of recombinant proteins in E.Coli. 
LB media (2x125m1) was inoculated with a single bacterial colony from an agar plate 
and these were incubated overnight (37°C, vortexing at 250 r.p.m). The suspension 
was then diluted with LB media (2.251) along with a solution of ampicillin in water. 
The cells were then allowed to grow (37'C, vortexing at 250 r.p.m, ihour) by which 
time the 0D60 0=1 .2. A solution of IPTG (2.5m1, 1mM) in water was added and the 
cells left to grow for a further 3 hours before being centrifuged to a pellet (1000g, 
15mm). The cells were suspended in a buffer consisting of 50mM tris, 10mM 
MgCl2 , 1mM DTT and 1mM EDTA (pH 7.5, 4m1/g cells) and then lysed by 
sonication (10x45 sec at 4°C). The mixture was then centrifuged (I 000g, 5mm) and 
the pellet discarded. The supernatant was then purified as described in the text. 
4.3.11 Determination of protein concentration in solution. 
The method of Bradford  was employed using the following solutions: 
Bradford Stock Solution- ethanol (lOOml), phosphoric acid (88%, 200m1), 
Coomassie Brilliant Blue G-250 (350mg). 
Bradford Working Buffer- distilled water (425m1), ethanol (lSml), phosphoric acid 
(88%, 30m1), Bradford Stock Solution (30ml). 
The assay was performed by pipeting the protein solution (<100.tl) into an 
eppendorph tube. The experimental buffer was then added to give a total volume of 
I 00il followed by Bradford Working Buffer (I ml). The solution was then briefly 
votexed and the absorbance at 595nm was then determined after standing for 5 
minutes. The protein concentration was then determined by use of a standard curve 
generated using a BSA solution of known concentration. A new standard curve was 
generated each day that protein concentrations were determined. 
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4.4 Experimental Procedures 
Chemical synthesis of ubiquitin fusion protein, UbN 
The synthesis was carried out on an 0.lmmol scale (0.49g of Wang resin of 
0.20 lmmol/g functionality) using the protecting group strategy described in Section 
4.2. All amino acids were single coupled as their HOCt active esters with the 
exception of His which was coupled as the HOBt active ester. Following coupling of 
Val-26 approximately one third of the resin was removed and archived for future use. 
The N-terminal Fmoc loading test (Section 4.3.2) indicated that the final 
functionality was 0.026mmol, 58% of the theoretical maximum (determined by a 
computer program). The resin was stored in 1 ,4-dioxane at 4°C until required. 
AAA (24h): Asx 11 11.16, Thr7 7.05, Ser4 4.49, G1x 15 11.65, Gly7 6.76, Ala4 4.39, 
Va14 4.02, Met 1 0.62, 11e 7 6.32, Leu 10 10.05, Tyr2 1.75, Phe2 1.92, His3 3.28, Lys7 
6.63 Ar96 6.72, Pr05 4.98. 
AAA (40h): Asx 11 10.27, Thr7 6.98, Ser4 3.58, G1x 15 10.78, G1y7 6.34, Ala4 4.13, 
Va14 3.39, Met 1 0.57, 11e7 7.16, Leu 10 9.80, Tyr2 1.67, Phe2 2.25, His3 3.42, Lys 7 7.38 
Ar96 7.44, Pr05 5.38. 
Timed cleavage of UbN from resin 
The resin bound protein (5 0mg) was swollen in a scavenger cocktail which consisted 
of EDT (2m1), TIS (0.2m1), thioanisole (imI), phenol (0.75g) and water (lmI) for 30 
minutes before TFA (1 OmI) was added. The whole was stirred under nitrogen and 
aliquots (2ml) were withdrawn at the following intervals: 0.5 hour, 1.5 hours, 3 
hours, 3.5 hours and 4.5 hours. Each aliquot was filtered into ice cold diethyl ether, 
centrifuged and the supernatant discarded. The pellet was dissolved into 
MeCN/water (1:1, 0.5ml) and the solution analysed by HPLC. The optimum 
cleavage time was thus found to be 4 hours. 
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Tbfmoc loading and acidolytic cleavage of UbN from resin 
Resin bound protein (1.17g, 0.031mmol) was washed with DCM (50m1) and then 
swollen in capping reagent (Section 4.2). The whole was then sonicated for 15 mm 
before the resin was filtered off and washed with DMF (50m1) and DCM (50ml). 
The Tbfmoc moiety was then introduced at the N-terminus following the procedure 
in Section 4.3.3 with TbfmocCl (40mg, 0.093mmol) and DIEA (5.2111, 0.03 immol) 
in freshly distilled DCM (1 5m1). Following work-up a portion (500mg) of the resin 
was swollen in a scavenger cocktail consisting of TIS (0.2m1), thioanisole (0.5m1), 
EDT (2m1), water (imi) and phenol (0.75g) for 30 min before TFA (lOml) was 
added. The reaction was continued for 4 hours before being worked up as described 
in Section 4.3.5. The precipitate obtained was then dissolved in a buffer composed 
of 8M urea and 10mM DTT (30m1). The solution was stirred overnight before being 
purified by the Tbfmoc/charcoal approach. 
RP-HPLC (CO:  R1=20.1 minutes (64% MeCN) 
MALDI-TOF-MS: Found 11393.9; C499H766N1360 155S requires 11193.12 
AAA (24h): Asx 1 1 10.27, Tbr7 5.10, Ser4 3.12, G1x 15 13.00, G1y7 6.52, Ala4 3.90, 
Va14 4.67, Met 1 0.71, 11e7 6.10, Leu10 10.63, Tyr2 1.34, Phe2 1.56, His3 2.84, Lys7 
5.32 Argo 5.03, Pr05 4.89. 
AAA (40h): Asx 11 11.94, Tbr7 5.82, Ser4 3.37, G1x 15 15.30, Gly7 7.49, Ala4 4.31, 
Va14 4.15, Met 1 0.50, 11e 7 6.12, Leu 1 0 9.46, Tyr2 1.50, Phe2 1.72, His3 3.18, Lys7 6.45 
Ar96 5.8 5, Pr0 5 5.31. 
Affinity purification of UbN using Tbfmoc/charcoal 
Following denaturation of the protein in urea, charcoal purification was carried out 
following the general procedure given in Section 4.3.6 with charcoal (6.0g) and UbN 
as a solution in 8M urea, 10mM DTT (30m1). Following removal of i-propanol at 
reduced pressure the solution was then diluted to approximately I OOml by adding 
more urea/DTT solution. The protein was then dialysed against the following 
solutions with a molecular weight cut off at 2000Da: 
6M urea, 50mM NH40Ac, 10mM DTT 
Chapter 4 
4M urea, 50mM NH40Ac, 5mM DTT 
2M urea, 50mM NH40Ac, 2mM DTT 
50mM NH40Ac (0) 
Each buffer was at pH 6.0 and of 11 volume and degassed before use. Each step 
required 24 hours and was performed at 4°C. Following dialysis the sample was 
concentrated to a volume of approximately 1 Oml by lyophilisation before being 
desalted. 
Desalting of UbN following dialysis 
The concentrated protein solution was applied to a SephadexTM G25 (coarse) size 
exclusion column (1 50x2Omm) which had been equilibriated with a 20% v/v acetic 
acid solution. The column was eluted at 30mlfh collecting 15 minute fractions and 
each fraction was retrospectively checked by measuring the OD280 nm . The protein 
eluted in fractions 11-15 (inclusive, approx 110-1 50m1). These fractions were pooled 
and diluted with water before being diluted with water and lyophilised to yield the 
protein as a white solid (15mg). 
RP-HPLC (C8): Rt = 16.4 minutes (52% MeCN) 
MALDI-TOF-MS: Found 10765.9; C468H757N 1 3601 53S requires 10770.21 Da. 
AAA (24h): Asx 11 10.76, Thr7 6.32, Ser4 3.53, G1x 15 14.77, G1y7 7.17, Ala4 4.31, 
Va14 4.16, Met 1 0.68, Ile7 6.35, Leu 10 9.64 Tyr2 1.42, Phe2 1.96, His3 2.70, Lys 7 6.82 
Ar96 5.73, Pr0 5 4.02. 
AAA (40h): Asx j1 10.55, Thr7 5.66, Ser4 3.25, G1x 15 14.52, Gly7 7.25, Ala4 4.28, 
Va14 4.13, Met 1 0.68, lIe7 6.26, Leu10 9.55, Tyr2 1.65, Phe2 1.92 His3 2.66, Lys7 6.62 
Ar96 5.69, Pr05 4.62. 
FPLC size exclusion chromatography of dialysed UbN 
Protein (5mg) was dissolved in a buffer made up of 200mM NaCl and 200mM 
phosphate (3ml, pH 7.5) and applied to a SuperdexTM 75 size exclusion column (620 
x 26mm) which had been equilibriated with the same buffer. The column was eluted 
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at 3m1/min, collecting 1 Omi fractions with in-line monitoring at 21 4nm. The protein 
was found to elute in fractions 12 - 15 (approx. 120 - 1 50m1). These fractions were 
then combined and dialysed (MWCO = 200013a) against a 20%v/v acetic acid 
solution (3 x 11, 12 hours for each step). The solution was then diluted with water 
and lyophilised to give the product as a white powder (1.3mg) 
RP-HPLC: R=16.4 minutes (52%MeCN) 
MALDI-TOF-MS: Found 10770.4Da; C468H757N 1360153 S requires 10770.2 IDa. 
AAA (24h): Asx 11 10.83, Thr7 5.89, Ser4 3.31, Glx 15 15.28, G1y7 6.50, Ala4 4.11, 
Va14 4.22, Met 1 0.78, lIe 7 6.86, Leu 10 10.11 Tyr2 1.62, Phe2 2.18, His3 2.90, Lys 7 6.89 
Ar96 5.98, Pr0 5 4.60. 
AAA (40h): Asx 11 10.91, Thr7 5.75, Ser4 3.18, G!x 15 15.43, G1y7 6.40, A!a4 4.07, 
Va14 4.22, Met 1 0.76, lie7 6.92, Leu 10 10.24, Tyr2 1.62, Phe2 1.97 His3 2.60, Lys 7 6.91 
Arg6 6.02, Pr0 5 4.50. 
Attempted purification of UbN by FPLC based ResourceTM Q anion exchange 
chromatography 
UbN (5mg) which had been partially purified by the Tbfmoc/charcoal protocol 
(Section 4.3.6) and dialysed/desalted as described above was dissolved in a buffer 
which consisted of 50mM tris, 10mM M902 and 1mM DTT (35ml, pH 7.5). This 
solution was applied to a Resource QTM  anion exchange column (lml bed volume). 
The column was eluted at 4m1/min for five minutes, collecting lml fractions. A salt 
gradient (0-1M NaCl) was then commenced (20ml) to elute the protein. Each 
fraction was retrospectively checked by measuring the OD280 nm. No protein was 
found to elute from the column by this method. Various other buffers and conditions 
were also screened: 
50mM tris, 10mM M902, 1mM DTT, pH 7.5, 40ml salt gradient 
50mM tris, 10mM M902, 1mM DTT, pH 8.0, 40ml salt gradient 
50mM NH4HCO3 , pH 9.0, 20ml salt gradient. 
50mM NH4HCO3 , pH 9.0, 40ml salt gradient. 
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No protein was found to elute from the column under any of these conditions. 
Affinity based purification of UbN using a polystyrene support 
TbfmocUbN was cleaved from Wang resin (200mg) using the procedure in Section 
4.3.3 with the following scavenger cocktail: EDT (lml), thioanisole (0.5m1), TIS 
(0.2m1), phenol (0.75g) and water (lml). After swelling for 30 minutes, TFA (1 lml) 
was added and the reaction was stirred for 4 hours before being worked up. The 
crude protein was then lyophilised from acetonitrile/water (50m1, 1:1) to give the 
product as a white solid (84mg). 
To a solution of TbfmocUbN (10mg) in 25% AcOH (1 OmI) was added polystyrene 
(300A pore size, 75im particle size, 200mg) and the suspension was vortexed for 5 
minutes before the whole was then centrifuged (3000 r.p.m, 5 minutes). The 
supernatant was analysed by RP-HPLC (X=214 and 3 64nm) which revealed that 
adsorption was incomplete. To the suspension was added more polystyrene (50mg) 
and the whole was vortexed for 5 minutes before being centrifuged (3000 r.p.m., 5 
minutes). The supernatant was again analysed by HPLC which revealed that 
adsorption was now complete. The polymer was collected by filtration before being 
washed with the following solutions: 25% AcOH (3x2Oml), water (2x2Oml), 20% 
piperidine in MeCN/H20 (2x20m1, 1:1). The piperidine washings were then 
combined and acidified by the addition of glacial AcOH. The acetonitrile was 
removed at reduced pressure and the protein solution was then concentrated to a 
volume of approximately 1 Oml by lyophilisation. The protein was then desalted as 
described below. 
Desalting of UbN purified using Tbfmoc/polystyrene 
The protein concentrated protein solution (approx. I OmI) was applied to a 
SephadexTM G50 (medium) size exclusion column (620x30mm) which had been 
equilibriated with a 30% AcOH solution. The column was eluted at 30mlfh, 
collecting 30 minute fractions and each fraction was checked for protein content by 
measuring the 013280nm . The protein was found to elute in fractions 5-9 (approx.75-
1 35m1). The protein containing fractions were checked by analytical RP-HPLC 
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before being pooled, diluted with water and freeze-dried to give the protein as a 
white solid (4.5mg). 
RP-HPLC (C8): R= 16.4 minutes (52% MeCN). 
MALDI-TOF-MS: 10767. 8Da; C468H7 57N 1 3601 53S requires 10770.21 Da. 
AAA (24h): Asx 11 10.68, Thr7 6.19, Ser4 3.27, G1x 15 14.99, Glyi 6.64, Ala4 3.78, 
Va14 5.07, Met  0.56, Ile7 6.5 6, Leu 10 9.01, Tyr2 1. 10, Phe2 1.95 His3 2.23, Lys7 6.72 
Ar96 6.72, Pro 5 5.13. 
AAA (40h): Asx 11 11.40, Thr7 6.25, Ser4 3.19, G1x 15 15.77, Gly7 6.86, Ala4 4.04, 
Va14 4.15, Met 1 0.75, 11e 7 6.81, Leu 10 9.98 Tyr2 1.64, Phe 2 2.01, His3 2.67, Lys7 6.92 
Ar96 5.86, Pr05 5.06. 
Synthesis of UbN epitopes: 
Synthesis of Cys-UbN(76-95) H2N-CYADLREDPDRQDHHPGSGAQ-OH 
The peptide was synthesised on an 0.3mmol scale (0.5g Wang resin functionalised at 
0.61mmol!g) following the procedure described in Section 4.2. The peptide was then 
cleaved from the resin using the general procedure in Section 4.3.5 with peptidyl-
resin (650mg) swollen for 30 minutes in a scavenger cocktail composed of EDT 
(2ml), thioanisole (0.5ml), TIS (0.2m1), phenol (0.75g) and water (lml). TFA (lOml) 
was added and the reaction continued for 4 hours before precipitation of the crude 
product. The peptide was lyophilised from acetonitrile/water (SOml, 1:1) to give a 
white powder (120mg), half of which was purified by semi-preparative RP-HPLC 
using the column and conditions described in Section 4.3.7 to give the desired 
peptide as a white powder (9mg). 
RP-HPLC (C 1 8): R= 14.4 minutes (38% MeCN) 
MALDI-TOF-MS: Found 2366.38; requires 2366.42. 
AAA (24h): Asx4 4.09, Ser 1 0.82, G1x3 2.90, G1y2 1.95, A1a2 1.91, Cys t 0.67, Leu 1 
0.91, Tyr j 0.79, Hi S2  1.8 1, Ar92 2. 10, Pr0 2 1.87. 
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Synthesis of UbN(76-95) H2N-YADLREDPDRQDHHPGSGAQ-OH 
The peptide was synthesised on an 0.3mmol scale (0.5g Wang resin functionalised at 
0.61mmol/g) following the procedure described in Section 4.2. The peptide was then 
cleaved form the resin using the general procedure in Section 4.3.5 with peptidyl-
resin (500mg) swollen for 30 minutes in a scavenger cocktail composed of EDT 
(0.5m1), thioanisole (0.5m1), TIS (0.5m1), phenol (0.75g) and water (imi). TFA 
(1 0m1) was added and the reaction continued for 4 hours before precipitation of the 
crude product. The peptide was lyophilised from acetonitrile/water (50ml, 1:1) to 
give a white powder (110mg), half of which was purified by semi-preparative RP-
HPLC using the column and conditions described in Section 4.3.7 to give the 
desired peptide as a white powder (62.4mg). 
RP-HPLC (C 18): R3.2 minutes (15%B) 
MALDI-TOF-MS: Found 226 1. 1 Da; Requires 226413a 
AAA (24h): Asx4 4.12, Ser i 0.91, G1x3 3.01, Gly2 2.93, A1a2 1.89, Leu 1 0.89, Tyr i 
0.86, His2 1.97, Ar92 2.12, Pr02 1.91. 
Synthesis of UbN(76-85) H2N-YADLREDPDR-OH 
The peptide was synthesised on an 0.3 mmol scale (0.5g Wang resin functionalised at 
0.61 mmol/g) following the procedure described in Section 4.2. The peptide was then 
cleaved form the resin using the general procedure in Section 4.3.5 with peptidyl-
resin (300mg) swollen for 30 minutes in a scavenger cocktail composed of EDT 
(Imi), thioanisole (0.5m1), TIS (0.5ml), phenol (0.75g) and water (lml). TFA (lOmi) 
was added and the reaction continued for 4 hours before precipitation of the crude 
product. The peptide was lyophilised from acetonitrile/water (50m1, 1:1) to give a 
white powder (102mg), half of which was purified by semi-preparative RP-HPLC 
using the column and conditions described in Section 4.3.7 to give the desired 
peptide as a white powder (12.3mg). 
RP-HPLC (C is): R3.0 minutes (14% MeCN 
MALDI-TOF-MS: Found 1251.37 Da; requires 1249.28 Da. 
Chapter 4 
AAA (24h): Asx3 2.90, G1x 1 1.07, Ala 1 0.92, Leu 1 0.94, Tyr 1 0.88, Ar92 1.99, Pro 1 
0.96 
Synthesis of UbN(86-95) H2N-QDHHPGSGAQOH 
The peptide was synthesised on an 0.3mmol scale (0.5g Wang resin functionalised at 
0.61mmol/g) following the procedure described in Section 4.2. The peptide was then 
cleaved form the resin using the general procedure in Section 4.3.5 with peptidyl-
resin (400mg) swollen for 30 minutes in a scavenger cocktail composed of EDT 
(imI), thioanisole (0.5m1), TIS (0.2ml), phenol (0.75g) and water (imi). TFA (lOmi) 
was added and the reaction continued for 2.5 hours before precipitation of the crude 
product. The peptide was lyophilised from acetonitrile/water (50m1, 1:1) to give a 
white powder (81.2mg), which was purified by semi-preparative RP-HPLC using the 
column and conditions described in Section 4.3.7 to give the desired peptide as a 
white powder (22mg). 
RP-HPLC (Cis): R=3.1 minutes (15% MeCN) 
MALDI-TOF-M5: Found 1033.68 Da (M); requires 1033.02 Da. 
AAA (24h): Asx 1 0.90, Ser 1 0.89, Glx2 2.01, Gly2 1.97, Ala 1 0.92, His2 1.91, Pro 1 
0.97 
Preparation of cys-UbN(76-85): H2N-CYADLREDpDRoH 
Fmoc-Cys(Trt)-OH was manually coupled to resin bound UbN(76-85) using the 
general procedure outlined in Section 4.2.2. Following coupling, the N-terminal 
Fmoc group was removed by sonicating the resin in a 20%(v/v) of piperidine in DMF 
(20m1) for 15 minutes. The resin was then isolated by filtration and washed with 
DMF (50m1) and DCM (1 OOml) before being dried under vacuum. The peptide was 
obtained from the solid support by acidolytic cleavage using the procedure outlined 
in Section 4.3.5 with the following quantities of scavengers: water (lml), TIS 
(0.5m1) EDT (0.2m1), thioanisole (0.5m1) and phenol (0.75g). The reaction was 
allowed to proceed for 4 hours before being worked up as described above. The 
crude peptide was purified by semi-preparative RP-HPLC using an Aquapore C 1 8 
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column as described in Section 4.3.7.2 to give the target sequence as a white solid 
(12.7mg). 
RP-HPLC (C 18): R1=15.2 minutes (45% MeCN) 
MALDI-TOF-MS: Found 1352.49 Da (MH); requires 1351.42 Da 
AAA (24h): Asx3 3.03, G1x 1 0.94, Ala 1 0.91, Cys 1 0.81, Leu 1 0.91, Tyr 1 0.99, Ar92 
2.11, Pro 1 0.99 
Preparation of cys-UbN(86-95): H2N-CQDHHPGSGAQ-OH 
The peptide was prepared in the same manner as the above compound using resin 
bound FmocUbN(86-95) to give the product as white solid (10.2mg). 
RP-HPLC (C18): R17.0 minutes (53% MeCN) 
MALDI-TOF-MS: Found 1135.92 Da (M); requires 1135.14 Da 
AAA (24h): Asx 1 0.93, G1x2 2.03, Ser 1 0.76, G1y2 1.91, Ala 1 0.99, Cys 1 0.89, His2 
1.73, Pro 1 0.93 
Overexpression and purification of groEL 
Competent cells were prepared and transformed with the groEL plasmid DNA 
following the procedures detailed in Section 4.3.8 and Section 4.3.9. A large scale 
induction was carried out as described in Section 4.3.10. Following sonication and 
centrifugation, the supernatant was applied to a Pharmacia HiLoad Mono QTM  anion 
exchange column (1 OOx26mm) that had been equilibriated with the same buffer. The 
column was eluted at 4ml/min, collecting 20ml fractions. A salt gradient of 0-1M 
NaCl was performed in order to elute the protein. Each fraction was checked for 
protein content by measuring the OD280 nm. Protein containing fractions were also 
examined by SDS-PAGE. The protein of interest was found in fractions 19-23 
(approx. 380-460m1, 0.4M salt). The material was found to be greater than 95% 
homogenous by SDS-PAGE and was then concentrated by ultrafiltration (MWCO = 
1 OkDa) to a volume of approximately 20ml. The protein was stored as a 20% v/v 
glycerol solution at -20°C until required. 
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Overexpression and purification of groES 
Competent cells were prepared and transformed with the groEL plasmid DNA 
following the procedures detailed in Section 4.3.8 and Section 4.3.9. A large scale 
induction was carried out as described in Section 4.3.10. Following sonication and 
centrifugation, the supernatant was applied to a Pharmacia HiLoad Mono QTM  anion 
exchange column (lOOx26mm) that had been equilibriated with the same buffer. The 
column was eluted at 4m1/min, collecting 20m1 fractions. A salt gradient of 0-1 M 
NaCl was performed in order to elute the protein. Each fraction was checked for 
protein content by measuring the OD280 nm. Protein containing fractions were also 
examined by SDS-PAGE. Protein of interest was contained within fractions 11-17 
(approx. 220-240m1, 0.22-0.34M salt. These fractions were then pooled and 
concentrated to a volume of approximately 50m1 by ultrafiltration (MWCO = 5kDa). 
The material was then further purified by FPLC size exclusion chromatography. 
The protein solution was loaded onto a SuperdexTM S200 column (600x26mm) in 
two batches (2x25m1). The column had previously been equilibriated with 50mM 
tris, 100mM NaCl, pH 7.5 and was eluted at 2m1/min, collecting lOmi fractions. 
Each fraction was checked for protein content by determining the OD280 nm. Protein 
of interest was eluted in fractions 9-18 (approx. 90-1 80ml) These fractions were 
examined by SDS-PAGE which indicated that a further purification step was 
required. 
The fractions of interest from the size exclusion step were pooled and diluted with 
water to a volume of approximately 400m1. This was applied to a Resource QTM 
anion exchange column (lml bed volume) in five equal batches. The column was 
washed (20m1) with 50mM tris (pH 7.5) at 4ml/min before a salt gradient was 
commenced (O-IM NaCl, 20ml) while collecting imI fractions. The fractions were 
checked for protein content by measurement of the OD280 nm and by SDS-PAGE. The 
desired material eluted in fractions 5-9 (approx. 25-29m1, 0.25-0.45M NaC1). The 




Attempted refolding of UbN by use of molecular chaperones 
Method A: without denaturation of substrate. 
The protein (2mg, 18.5i.M) was dissolved in 50mM tris-HC1, 50mM M902  and 
10mM DTT, pH 7.5 (3m1). To the solution was added solutions of groEL (11.xM) and 
groES (3.tM)' , followed by ATP (8.2mg, 3mM). The whole was vortexed before 
being incubated at 37°C. The reaction was monitored by analytical RP-HPLC 
(Section 4.3.7.1). No change was observed after up to 7 days incubation. The 
following conditions were also screened without success: 
[substrate] [groEL] [groES] IATP] Temp. Time 
36.7p.M l.iM 7 3mM 30°C 12h 
36.7.iM ltM 3jiM 3mM 30°C 16h 
18.7tM IPM 3jiM 3mM 30°C 12h 
18.7.tM 1.tM 3jiM 3mM 30°C 24h 
Method B: Refolding following denaturation. 
Protein (1mg) was dissolved in 8M urea (50p.!) and was vortexed for 5 minutes 
before being added to a refolding buffer consisting of 50mM tris-HC1, 50mM M902, 
10mM DTT and 1 p.M groEL, pH 7.5 (3 ml). The co-chaperone groES and ATP were 
added to give concentrations of 3p.M and 2mM, respectively. The whole was 
incubated at 37°C and the process monitored by analytical RP-HPLC (Section 
4.3.7.1). No change was observed after 24 hours. The following conditions were 
also screened: 
Concentrations of chaperones were determined using a Bradford Assay (Section 4.3.11) 
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5mM 	37°C 	4h 
5mM 	37°C 	16h 
Method C: Refolding with denaturation to a pre-formed chaperone complex. 
The chaperones groEL and groES were mixed together in a buffer composed of 
50mM tris-HCI, 50mM M902  and 10mM DTT, pH 7.5 (5m1) to give final 
concentrations of 16tM and 32MM, respectively. The substrate was introduced as a 
solution in 8M urea (50 pi) to a concentration of 36.5.tM. ATP was added to a give a 
concentration of 2mM. The whole was vortexed before being incubated at 37°C. 
The process was monitored by RP-HPLC (Section 4.3.7.1). However, no change 
was observed after 24hours. The following conditions were also examined but gave 
no change by RP-HPLC. 
[substrate] [groELJ [groES] [ATP] 	Temp. 	Time 
6.2pM 2.7p.M 10.7M 2mM 	37°C 	lh 
6.2tM 2.7p.M 10.7jiM 2mM 	20°C 	16h 
6.2j.iM 2.7tM 10.7j.iM 2mM 	20°C 	7d 
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Chemical synthesis of ubiquitin Fleu (50/67) 
The synthesis was carried out on an 0.25mmol scale (0.72g of Wang Resin 
functionalised with Fmoc-Gly at 0.35mmol/g) following the procedures for 
automated synthesis detailed in Section 4.2.1. All amino acids were coupled as their 
HOCt active esters with the exception of His which was coupled as the HOBt active 
ester. The fluoroleucine residues were manually coupled using the procedures 
detailed in Section 4.2.2. Thr9 - Met' were introduced using double coupling cycles. 
The N-terminal Fmoc loading test (Section 4.3.2) gave a final functionality of 
0.032mmol/g, 55% of the theoretical maximum. The resin (1.3g) was stored in 1,4-
dioxane at 4°C until required. 
Acidolytic cleavage of the analogue. 
The resin bound protein (580mg) was sonicated in a 20% v/v piperidine/DMF 
solution (15m1) for 10 minutes before the free amino resin was isolated by filtration. 
The resin was then washed with DMF (50m1), 1,4-dioxane (50m1) and DCM (50m1) 
before it was dried under vacuum. The resin was then cleaved following the 
procedures outline in Section 4.3.5 using the following quantities of scavengers: 
EDT (imi), thioanisole (0.5m1), TIS (0.5m1), water (lml) and phenol (0.75g). TFA 
(12m1) was then added and the whole stirred for 3.5 hours before the protein was 
isolated by precipitation. The precipitate was the dissolved in 8M urea, 50mM 
NH40Ac, 10mM DTT, pH 4.5 (12ml) and stirred at 4°C overnight. The mixture was 
initially purified by FPLC based size exclusion chromatography. 
FPLC size exclusion chromatography of UbFleu (50/67) 
The crude protein solution from above was pumped on to a Pharmacia Superdex 3OTM 
size exclusion column (600x26mm) which had been equilibriated with the same 
buffer. The pump was washed with a small amount of buffer (1 Oml) before the 
column was eluted at 2m1/min, collecting 5 minute fractions. Each fraction was 
retrospectively checked for protein content by determining its A2 80 . The protein was 
found to elute in fractions 14-17 (inclusive), approximately 150-180ml solvent. 
105 
Chapter 4 
These fractions were also analysed by RP-HPLC (Section 4.3.7) before being 
combined and dialysed against the following solutions (MWCO2000Da, 21, 24h per 
step at 4°C): 
6M urea, 50mM NH40Ac, 10mM DTT, pH 4.5, 
4M urea, 50mM NH40Ac, 10mM DTT, pH 4.5, 
2M urea, 50mM NH40Ac, 10mM DTT, pH 4.5, 
50mM NH40Ac, pH 4.5 (0). 
The solution was then lyophilised to give the semi-purified protein as a white solid 
(60mg). 
RP-HPLC (C8): R16.6 mm (53%B) 
MALDI-TOF-MS: Found 8608.4Da; Requires 8601.0 Da 
AAA (40h): Asx7 7.89, Thr7 5.50, Ser3 2.21, G1x 12 11.70, G1y6 6.42, Ala2 1.40, Va14 
5.78, Met 1 1.00, Ile 7 6.60, Leu9 7.80, Tyr i 0.73, Phe2 1.82, His 1 1.21, Lys 7 7.25, Ar94 
4.6 1, Pr03 3.10 
Attempted cation exchange of UbFleu (50/67) 
Protein from the dialysis experiment (3 0mg) was disolved in a buffer composed of 
50mM NH40Ac, pH 4.5 (25m1) loaded onto a CM-sepharose 6LB cation exchange 
column (210xl5mm). The column was eluted at 30m1/h, collecting 30 minute 
fractions using the following gradient system: 
pH gradient from 50mM NH 40Ac, pH 4.5 to 50mM NH40Ac, pH 5.5 (SOOml) 
isocratic running, 50mM NH40Ac, pH 5.5 (180m1) 
salt gradient, 50mM NH 40Ac, pH 5.5 to 0.3M NH40Ac (SOOmI) 
Each fraction was retrospectively checked for protein content by measuring the 
A280nm . No protein was detected in any of the fractions so the column was flushed 
using I M NaCl, pH 5.5 (lOOm!) and the eluent examined by analytical RP-HPLC 




ResourceTM S FPLC based cation exchange chromatography of UbFIeu (50/67) 
The analogue (5mg), following size exclusion and dialysis was dissolved in a buffer 
consisting of 50mM NH40Ac, pH 4.5 (lOmi) and was applied to a ResourceTM S 
cation exchange column (imi bed volume) which had been equilibriated with 10 
column volumes of the same buffer at 4m1/min. The column was then ran 
isocratically at 4m1/min until a total of 28m1 of buffer had eluted. A salt gradient 
from 50mM NH40Ac, pH 4.5 to 0.3M NaCl, 50mM NH 40Ac, pH 4.5 over 40 
column volumes was then applied. During the gradient, from lOmi to 28m1, the 
column was ran isocratically at 7.5% elution buffer. The eluent was collected in 2m1 
fractions and each fraction was retrospectively checked for protein content by 
determination of the A280nm. The protein containing fractions were also examined by 
analytical HPLC (Section 4.3.7.1). Protein of interest was found to elute in fractions 
8 to 11 (inclusive), 16 to 22m1 elution buffer. These fractions were then pooled and 
concentrated using an AmiconTM ultrafiltration apparatus (molecular weight cut off = 
1 000Da). The concentrated solution (approximately 0.5ml) was twice diluted and 
reconcentrated to desalt the solution before being freeze dried to yield the purified 
protein as a white powder (1.2mg) 
RP-HPLC (Cs): R16.6 minutes (53%B) 
MALDI-TOF-MS: Found 8601.0 Da; requires 8601.0 Da 
AAA (40h): Asx7 6.96, Thr7 6.49, Ser3 2.33, G1x 12 11.75, G1y6 6.01, Ala2 2.27, Va14 
4.21, Met 1 1.22, lie7 6.62, Leu9 9.04, Tyr i 0.79, Phe2 1.99, His 1 1.09, Lys7 6.92, Ar94 
4.08, Pr03 2.98 
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Chemical synthesis of ubiquitin Fleu (43/50) 
The synthesis was carried out on an O.lSmmol scale (0.5g of Wang Resin 
functionalised with Fmoc-Gly at 0.3mmol/g) following the procedures for automated 
synthesis detailed in Section 4.2.1. Arginine was protected as its Pbf derivative 8 . 
All amino acids were coupled as their HOCt active esters with the exception of His 
which was coupled as the HOBt active ester. The fluoroleucine residues were 
manually coupled using the procedures detailed in Section 4.2.2. Thr9 - Gin  were 
introduced using double coupling cycles. The N-terminal Fmoc loading test (Section 
4.3.2) gave a final functionality of 0.020mmol/g, 33% of the theoretical maximum. 
Tbfmoc-Met-OH was manually coupled following the procedures outlined in Section 
4.2.2 by sonicating the activated amino acid together with the swollen resin for 4 
hours whilst protected from the light. A Tbfmoc loading test (Section 4.3.4) 
revealed that coupling was quantitative after this time. 
Acidolytic cleavage of the analogue. 
The resin bound protein (3 00mg) was cleaved following the procedures outlined in 
Section 4.3.5 using the following quantities of scavengers: EDT (lml), thioanisole 
(0.5m1), TIS (0.5m1), water (imI) and phenol (0.75g). TFA (12ml) was then added 
and the whole stirred for 3.5 hours before the protein was isolated by precipitation. 
The precipitate was then dissolved in acetonitrile/water (1:1, 30m1) and freeze dried 
to give the crude Tbfmoc labelled compound as a white solid (12 1mg). 
RP-HPLC (CO: R=24.8 minutes (70% MeCN) 
AAA (40h): Asx7 5.64, Thr7 7.83, Ser3 1.96, G1x 12 10.97, G1y6 6.13, Ala2 2.23, Va14 
4.03, Met 1 0.30, lie7 5.41, Leu9 7.55, Tyr 1 0.54, Phe2 1.47, His 1 1.58, Lys7 6.06, Ar94 
4.5 1, Pr03 3.73 
Affinity purification of UbFleu (43/50) on PGC 
The Tbfmoc labelled protein from the cleavage step (60mg) was dissolved in 8M 
urea and purified following the general procedure in Section 4.3.6 using porous 
graphitised carbon (PGC) as the support. Following removal of i-propanol under 
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reduced pressure, the protein solution was diluted to a volume of approximately 70m1 
with an 8M urea solution containing 10mM DTT before being dialysed against the 
following solutions (MWCO2000Da, 21, 24hours per step at 4 0C): 
6M urea, 50mM NH40Ac, 10mM DTT, pH 4.5, 
4M urea, 50mM NH40Ac, 10mM DTT, pH 4.5, 
2M urea, 50mM NI-[4OAc, 10mM DTT, pH 4.5, 
50mM N1140Ac, pH 4.5 (x3). 
The solution was then lyophilised to give the semi-purified protein as a white solid 
(12mg) 
RP-HPLC (Cs): 1 6.6minutes (53% MeCN) 
MALDI-TOF-MS: Found 8603 .4Da; requires 8601 .ODa 
AAA (40h): Asx7 6.68, Thr7 6.01, Ser3 2.36, G1x 12 11.47, G1y6 5.67, Ala2 2.25, Va14 
4.22, Met 1 0.22, Ile7 6.96, Leu9 8.15, Tyri 0.45, Phe2 1.72, His 1 0.92, Lys 7 6.68, Ar94 
3.64, Pr03 3.30 
Resource TM  S FPLC based cation exchange chromatography of UbFleu (43/50) 
The analogue (5mg), following size exclusion and dialysis was dissolved in a buffer 
consisting of 50mM NH40Ac, pH 4.5 (lOml) and was applied to a ResourceTM S 
cation exchange column (1 ml bed volume) which had been equilibriated with 10 
column volumes of the same buffer at 4m1/min. The column was then ran 
isocratically at 4m1/min until a total of 28ml of buffer had eluted. A salt gradient 
from 50mM NH40Ac, pH 4.5 to 0.3M NaCl, 50mM NH40Ac, pH 4.5 over 40 
column volumes was then applied. During the gradient, from lOml to 28ml, the 
column was ran isocratically at 7.5% elution buffer. The eluent was collected in 2ml 
fractions and each fraction was retrospectively checked for protein content by 
determination of the A280nm. The protein containing fractions were also examined by 
analytical HPLC (Section 4.3.7.1). Protein of interest was found to elute in fractions 
8 to 11 (inclusive), 16 to 22m1 elution buffer. These fractions were then pooled and 
concentrated using an Amicon TM ultrafiltration apparatus (molecular weight cut off 
100013a). The concentrated solution (approximately 0.5ml) was twice diluted and 
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reconcentrated to desalt the solution before being freeze dried to yield the purified 
protein as a white powder (2.8mg). 
RP-HPLC (C8): R t = 16.6 minutes (53%B) 
MALDI-TOF-MS: Found 8602.8 Da; requires 8601.0 Da 
AAA (40h): Asx7 6.60, Thr7 6. 10, Ser3 2.3 1, G1x 12 11.15, G1y6 5.7 1, Ala2 2.20, Va14 
4.20, Met 1 1. 18, lie7 6.60, Leu9 8.74, Tyr i 0.76, Phe2 1.92, His 1 1.06, Lys 7 6.72, Ar94 
4.88, Pr03 2.76 
Synthesis of Tbfmoc-Met-OH 
L-methionine (187mg, 1.25mmol) was suspended in an acetone/water solution (5:1, 
1 20m1). To the solution was added TbfmocCl (460mg, 1 mmol) followed by N,N-
dimethylaniline (298j.tl, 2.35mmoI) and the whole was stirred overnight at room 
temperature. The reaction mixture was then concentrated in vacuo, before being 
taken up into DCM (lOOmI) and washed with saturated citric acid (2x250m1) and 
water (2x50m1) before being dried over MgSO 4 . The solvent was then removed 
under reduced pressure to yield a gum. This was dissolved in the minimum volume 
of DCM (approximately 3m1) and precipitated from hexane (200m1). The precipitate 
was then further purified by flash column chromatography (CHC13:MeOH:AcOH, 
97:2:1) to yield the product as a white powder (13 1mg, 23%). 
CO2H 
H 
Rf (CHCI3:MeOH:AcOH, 97:2:1) = 0.15; [aI D =-2.5° (c = 
7.5, DMF); m.p. 164-166°C; FTIR Vmax/ cm' (CHBr3) 
1714 (br, C=O), 2972 (aliphatic C-H), 2019 (aromatic C-
H), 3416 (OH); A. max/nm (methanol, c/dm3moF'cm') 
379 (28107), 364 (29864), 299 (74660), 287 (67633), 257 
(113307), 238 (94862); 'H nmr (CDCI3 , 250MHz, 
s/ppm) 8.68-8.52 (6H, m, aromatic), 8.26-7.80 (2H, m, 
aromatic), 7.62-7.48 (8H, m, aromatic), 5.22 (1H, d, NH), 
4.96-4.93 (1 H, m, CH), 4.70-4.64 (1H, m, Ha(CH 2)), 4.46-4.44 (1H, m, aCH), 4.30- 
4.21 (1H, m, Hb(CH 2)), 2.38-2.35 (1H, m, -S-CH2-),1.98 (3H, s, CH3-S); ' 3C {'H} 
nmr (CDC13 , 63MHz) 176.4 (CO, carboxylic acid), 155.9 (CO, urethane), 142.4, 
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141.0, 136.7, 136.4, 131.4, 130.2, 130.1, 128.5, 128.1, 127.7 (aromatic quaternary 
C's), 127.2, 126.8, 126.6, 125.8, 125.4, 124.9, 124.1, 123.4, 123.1 (aromatic CH's), 
69.1 (CH2), 52.6 (ctCH), 47.3 (CH), 31.0 and 29.6 (P and  CH2), 15.1 (-S-CH3); MS 
(FAB, M4 /z) C36H 29N04S requires 571.1817, found 571.1807. 
Synthesis of 1 -Hydroxy-4-ethoxycarbonyl-1 ,2,3-triazole (HOCt) 
Synthesis of ethyl diazoacetate 
To a solution of glycine ethyl ester hydrochloride (121g, 1 .Smol) in water (300m1) 
was added DCM (SOOml) and the whole was stirred vigorously and cooled to -15°C. 
A solution of sodium nitrite (124.5g, 1.8mmol) in water (200m1) was then added and 
the temperature was lowered to -20°C. A solution of 5% (wlw) H2SO4 in water was 
then added (142.5g) dropwise. Following addition of acid, the reaction mixture was 
then allowed to warm to 0°C and the organic layer was separated. The aqueous layer 
was then extracted with DCM (500m1) and the combined organics were run into an 
ice cold 5% (w/v) sodium carbonate solution (11). The organic layer was again 
separated and the aqueous was extracted with DCM (200ml). The combined 
organics were dried over MgSO 4  and the solvent removed under reduced pressure to 
yield the product as a yellow liquid which was used in the next step without isolation 
(95%) 
Preparation of diazoacetic ester salt 
Freshly distilled thionyl chloride (53m1, 0.73mo1) was added dropwise to N,N-
dimethylformamide (52.8g, 0.72mol) at 0°C with stirring under an atmosphere of 
nitrogen. Following addition, the whole was stirred at room temperature for 30 
minutes before being concentrated in vacuo to yield the Vilsmaier reagent as a white 
solid (95%). This was dissolved in chloroform (400ml) and to this solution was 
added ethyl diazoacetate at 0°C with stirring. Following addition, the reaction 
mixture was stirred at room temperature for 30 minutes before the solvent was 
removed under reduced pressure. Diethyl ether (200m1) was then added to the 
resulting residue to produce a yellow product which was filtered under nitrogen and 
111 
Chapter 4 
washed with more diethyl ether (200m1). The diazoacetic ester salt obtained (130g, 
88%) was used immediately in the next step without isolation. 
C. Preparation of diazoacetic ester hydroxide and cyclisation to HOCt 
Hydroxylamine hydrocholoride (139g, 2mol) was suspended in ethanol (300m1) at 
0°C. To the suspension was added sodium carbonate (106g, imol) , followed by the 
diazoacetic salt (130g, 0.6mol) and the resulting yellow mixture was stirred for one 
hour before the reaction mixture was filtered. The filtrate was then concentrated at 
reduced pressure to yield a yellow solid which was washed with ice cold water and 
filtered. The solid was then dissolved in chloroform (300m1) and dried over MgSO 4 . 
To the dried chloroform solution was added acetic acid (lml) and the solution was 
left to stand until cyclisation was complete, as determined by the disappearance of 
the yellow colour. The solution was then concentrated under reduced pressure to 
yield a white solid which was washed with ethyl acetate (300m1). The solid was then 
recrystallised from ethyl acetate to yield the product as white crystals (30%). 
RfO.21(CHC13); m.p. 108-109°C; FTIRvmax/cm (CHBr3) 1725 
EtOr\ 	(C0), 2976 (aliphatic C-H), 3018 (aromatic C-H), 3437 (br, 
L.. /N OH); 2max/nm (DCM, c/dm3 N moF'cm'); 'H nmr (CDCI 3, 
OH 250MHz, 6/ppm) 1.34 (3H, t, J = 7.211z, OCH 2 j3 ), 4.33 (21-1, q, 
J = 7.2Hz, OCCH 3), 8.09 (1 H, s, aromatic CH), 13.29 (1H, br s, 
OH); ' 3C {'H} nmr (CDCI3, 63MHz) 13.9 (OCH2CH3), 61.7 (OCH2 CH3), 121.8 
(aromatic CH), 136.5 (quaternary aromatic), 159.1 (C=O); MS (FAB, M+/z) 
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Appendix 2 
Appendix 2: Crystal data for UbFleu(50/67) 
COMPND 	ubif 2 
CRYST1 50.795 42.977 	28.320 	90.00 90.00 90.00 P 21 21 21 
SCALE1 0.019687 0.000000 0.000000 0.00000 
SCALE2 0.000000 0.023268 0.000000 0.00000 
SCALE3 0.000000 0.000000 0.035311 0.00000 
ATOM 1 N MET 1 27.524 24.673 2.142 1.000 22.03 
ATOM 2 CA MET 1 26.513 25.718 2.330 1.000 15.32 
ATOM 3 C MET 1 27.118 26.921 3.061 1.000 15.40 
ATOM 4 0 MET 1 28.113 26.818 3.764 1.000 14.53 
ATOM 5 CB MET 1 25.279 25.227 3.070 1.000 19.20 
ATOM 6 CG MET 1 25.491 24.998 4.569 1.000 17.65 
ATOM 7 SD MET 1 24.071 24.166 5.302 1.000 21.67 
ATOM 8 CE MET 1 24.464 24.318 7.032 1.000 19.36 
ATOM 9 N GLN 2 26.504 28.078 2.853 1.000 16.13 
ATOM 10 CA GLN 2 26.976 29.296 3.524 1.000 13.31 
ATOM 11 C GLN 2 26.242 29.455 4.838 1.000 14.60 
ATOM 12 0 GLN 2 25.028 29.249 4.875 1.000 18.59 
ATOM 13 CB GLN 2 26.751 30.508 2.613 1.000 18.07 
ATOM 14 CG GLN 2 27.069 31.851 3.267 1.000 22.11 
ATOM 15 CD GLN 2 26.833 33.019 2.315 1.000 19.67 
ATOM 16 OE1 GLN 2 25.709 33.257 1.871 1.000 27.08 
ATOM 17 NE2 GLN 2 27.900 33.729 1.995 1.000 18.70 
ATOM 18 N ILE 3 26.951 29.806 5.897 1.000 13.89 
ATOM 19 CA ILE 3 26.301 30.283 7.116 1.000 12.66 
ATOM 20 C ILE 3 26.928 31.606 7.545 1.000 13.25 
ATOM 21 0 ILE 3 28.019 31.945 7.023 1.000 13.89 
ATOM 22 CB ILE 3 26.397 29.260 8.250 1.000 14.38 
ATOM 23 CG1 ILE 3 27.831 28.913 8.643 1.000 12.41 
ATOM 24 CG2 ILE 3 25.633 27.982 7.915 1.000 15.31 
ATOM 25 CD1 ILE 3 27.921 28.314 10.039 1.000 12.87 
ATOM 26 N PHE 4 26.260 32.331 8.427 1.000 11.71 
ATOM 27 CA PHE 4 26.746 33.616 8.922 1.000 11.93 
ATOM 28 C PHE 4 27.118 33.505 10.390 1.000 13.60 
ATOM 29 0 PHE 4 26.439 32.757 11.112 1.000 16.36 
ATOM 30 CB PHE 4 25.655 34.692 8.753 1.000 12.20 
ATOM 31 CG PHE 4 25.276 34.890 7.280 1.000 13.01 
ATOM 32 CD1 PHE 4 24.202 34.231 6.735 1.000 13.00 
ATOM 33 CD2 PHE 4 26.012 35.743 6.470 1.000 14.08 
ATOM 34 CE1 PHE 4 23.866 34.407 5.395 1.000 16.53 
ATOM 35 CE2 PHE 4 25.688 35.925 5.124 1.000 15.72 
ATOM 36 CZ PHE 4 24.604 35.248 4.581 1.000 14.14 
ATOM 37 N VAL 5 28.162 34.197 10.836 1.000 11.06 
ATOM 38 CA VAL 5 28.506 34.227 12.256 1.000 10.88 
ATOM 39 C VAL 5 28.513 35.681 12.691 1.000 13.99 
ATOM 40 0 VAL 5 29.426 36.410 12.268 1.000 12.83 
ATOM 41 CB VAL 5 29.862 33.551 12.527 1.000 13.21 
ATOM 42 CG1 VAL 5 30.252 33.571 13.996 1.000 13.43 
ATOM 43 CG2 VAL 5 29.800 32.112 12.009 1.000 14.68 
ATOM 44 N LYS 6 27.523 36.069 13.494 1.000 12.67 
ATOM 45 CA LYS 6 27.450 37.460 13.965 1.000 14.54 
ATOM 46 C LYS 6 28.261 37.655 15.228 1.000 13.68 
ATOM 47 0 LYS 6 27.976 37.029 16.254 1.000 13.78 
ATOM 48 CB LYS 6 25.971 37.837 14.150 1.000 16.67 
ATOM 49 CG LYS 6 25.748 39.324 14.386 1.000 19.48 
ATOM 50 CD LYS 6 24.298 39.727 14.583 1.000 22.10 
ATOM 51 CE LYS 6 23.335 38.769 13.904 1.000 34.75 
ATOM 52 NZ LYS 6 23.620 38.591 12.455 1.000 45.11 
ATOM 53 N THR 7 29.286 38.498 15.162 1.000 13.39 
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ATOM 54 CA THR 7 30.078 38.771 16.369 1.000 13.24 
ATOM 55 C TI-IR 7 29.503 39.954 17.128 1.000 15.94 
ATOM 56 0 TFIR 7 28.605 40.652 16.649 1.000 21.36 
ATOM 57 CB THR 7 31.562 39.050 16.079 1.000 15.11 
ATOM 58 OG1 TI-IR 7 31.717 40.362 15.531 1.000 19.17 
ATOM 59 CG2 THR 7 32.098 38.086 15.019 1.000 19.64 
ATOM 60 N LEO 8 30.028 40.204 18.324 1.000 17.39 
ATOM 61 CA LEO 8 29.520 41.320 19.125 1.000 17.47 
ATOM 62 C LEO 8 30.199 42.627 18.764 1.000 23.48 
ATOM 63 0 LEO 8 29.916 43.662 19.379 1.000 26.23 
ATOM 64 CB LEO 8 29.707 41.013 20.620 1.000 24.37 
ATOM 65 CG LEO 8 28.506 40.376 21.331 1.000 27.93 
ATOM 66 CD1 LEO 8 27.689 39.481 20.414 1.000 29.26 
ATOM 67 CD2 LEO 8 28.958 39.593 22.558 1.000 26.06 
ATOM 68 N THR 9 31.097 42.641 17.770 1.000 26.72 
ATOM 69 CA TI-IR 9 31.705 43.909 17.350 1.000 24.35 
ATOM 70 C THR 9 30.870 44.607 16.291 1.000 25.71 
ATOM 71 0 THR 9 31.116 45.784 16.018 1.000 37.20 
ATOM 72 CB THR 9 33.129 43.740 16.803 1.000 21.33 
ATOM 73 OG1 THR 9 33.072 43.145 15.504 1.000 24.00 
ATOM 74 CG2 THR 9 33.941 42.773 17.657 1.000 30.88 
ATOM 75 N GLY 10 29.901 43.927 15.675 1.000 26.21 
ATOM 76 CA GLY 10 29.161 44.524 14.574 1.000 34.96 
ATOM 77 C GLY 10 29.628 43.951 13.246 1.000 31.29 
ATOM 78 0 GLY 10 29.144 44.292 12.163 1.000 29.26 
ATOM 79 N LYS 11 30.601 43.047 13.341 1.000 20.85 
ATOM 80 CA LYS 11 31.064 42.311 12.173 1.000 18.02 
ATOM 81 C LYS 11 30.351 40.958 12.093 1.000 15.67 
ATOM 82 0 LYS 11 30.204 40.282 13.107 1.000 17.79 
ATOM 83 CB LYS 11 32.571 42.097 12.225 1.000 24.38 
ATOM 84 CG LYS 11 33.221 41.644 10.920 1.000 27.14 
ATOM 85 CD LYS 11 34.700 41.327 11.155 1.000 27.83 
ATOM 86 CE LYS 11 35.563 42.052 10.138 1.000 36.42 
ATOM 87 NZ LYS 11 36.412 41.145 9.327 1.000 44.89 
ATOM 88 N THR 12 29.923 40.602 10.903 1.000 15.93 
ATOM 89 CA THR 12 29.372 39.303 10.580 1.000 15.49 
ATOM 90 C THR 12 30.295 38.671 9.550 1.000 19.37 
ATOM 91 0 THR 12 30.606 39.229 8.494 1.000 20.52 
ATOM 92 CB THR 12 27.966 39.336 9.956 1.000 16.05 
ATOM 93 OG1 THR 12 27.053 39.864 10.929 1.000 18.57 
ATOM 94 CG2 THR 12 27.512 37.946 9.598 1.000 17.54 
ATOM 95 N ILE 13 30.736 37.454 9.876 1.000 18.64 
ATOM 96 CA ILE 13 31.533 36.808 8.832 1.000 22.70 
ATOM 97 C ILE 13 30.773 35.643 8.234 1.000 17.55 
ATOM 98 0 ILE 13 29.818 35.108 8.791 1.000 18.97 
ATOM 99 CB ILE 13 32.872 36.356 9.414 1.000 20.96 
ATOM 100 CG1 ILE 13 32.677 35.242 10.433 1.000 18.39 
ATOM 101 CG2 ILE 13 33.622 37.549 9.981 1.000 20.96 
ATOM 102 CD1 ILE 13 33.634 34.081 10.239 1.000 38.89 
ATOM 103 N THR 14 31.201 35.281 7.034 1.000 16.58 
ATOM 104 CA THR 14 30.589 34.159 6.351 1.000 13.86 
ATOM 105 C TFIR 14 31.517 32.951 6.353 1.000 16.07 
ATOM 106 0 THR 14 32.757 33.079 6.318 1.000 18.09 
ATOM 107 CB THR 14 30.235 34.609 4.916 1.000 20.68 
ATOM 108 OG1 THR 14 29.040 35.401 4.980 1.000 26.50 
ATOM 109 CG2 TI-JR 14 30.039 33.393 4.045 1.000 45.96 
ATOM 110 N LEO 15 30.930 31.763 6.395 1.000 14.24 
ATOM 111 CA LEO 15 31.710 30.531 6.385 1.000 14.96 
ATOM 112 C LEO 15 31.130 29.576 5.339 1.000 13.42 
ATOM 113 0 LEO 15 29.903 29.577 5.120 1.000 15.29 
ATOM 114 CB LEO 15 31.715 29.807 7.733 1.000 14.99 
ATOM 115 CG LEO 15 32.258 30.514 8.972 1.000 15.53 
ATOM 116 CD1 LEO 15 32.065 29.628 10.201 1.000 17.71 
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ATOM 117 CD2 LEU 15 33.729 30.851 8.821 1.000 17.23 
ATOM 118 N GLU 16 31.961 28.750 4.736 1.000 14.04 
ATOM 119 CA GLU 16 31.465 27.623 3.938 1.000 14.48 
ATOM 120 C GLU 16 31.543 26.354 4.788 1.000 16.50 
ATOM 121 0 GLU 16 32.644 26.032 5.280 1.000 16.63 
ATOM 122 CE GLU 16 32.301 27.512 2.680 1.000 18.24 
ATOM 123 CG GLU 16 31.716 27.276 1.329 1.000 36.96 
ATOM 124 CD GLU 16 30.420 26.531 1.176 1.000 40.00 
ATOM 125 OE1 GLU 16 30.387 25.285 1.278 1.000 69.67 
ATOM 126 0E2 GLU 16 29.383 27.184 0.921 1.000 26.00 
ATOM 127 N VAL 17 30.452 25.632 5.014 1.000 15.62 
ATOM 128 CA VAL 17 30.444 24.472 5.925 1.000 12.85 
ATOM 129 C VAL 17 29.590 23.342 5.371 1.000 16.02 
ATOM 130 0 VAL 17 28.807 23.589 4.436 1.000 17.95 
ATOM 131 CB VAL 17 29.907 24.861 7.312 1.000 14.32 
ATOM 132 CG1 VAL 17 30.725 25.971 7.955 1.000 18.40 
ATOM 133 CG2 VAL 17 28.439 25.297 7.266 1.000 17.24 
ATOM 134 N GLU 18 29.689 22.128 5.897 1.000 13.54 
ATOM 135 CA GLU 18 28.691 21.095 5.645 1.000 14.43 
ATOM 136 C GLU 18 27.913 20.799 6.920 1.000 14.24 
ATOM 137 0 GLU 18 28.481 20.901 8.032 1.000 14.68 
ATOM 138 CB GLU 18 29.306 19.804 5.102 1.000 15.96 
ATOM 139 CG GLU 18 30.107 20.009 3.813 1.000 13.08 
ATOM 140 CD GLU 18 29.199 20.276 2.630 1.000 16.76 
ATOM 141 OE1 GLU 18 27.973 20.084 2.724 1.000 19.54 
ATOM 142 OE2 GLU 18 29.755 20.668 1.577 1.000 21.58 
ATOM 143 N PRO 19 26.641 20.447 6.828 1.000 14.45 
ATOM 144 CA PRO 19 25.919 20.089 8.066 1.000 14.30 
ATOM 145 C PRO 19 26.560 18.952 8.842 1.000 14.08 
ATOM 146 0 PRO 19 26.336 18.819 10.058 1.000 13.84 
ATOM 147 CE PRO 19 24.517 19.707 7.561 1.000 19.17 
ATOM 148 CG PRO 19 24.372 20.490 6.297 1.000 15.96 
ATOM 149 CD PRO 19 25.742 20.406 5.663 1.000 18.75 
ATOM 150 N SER 20 27.390 18.109 8.250 1.000 15.78 
ATOM 151 CA SER 20 28.124 17.043 8.935 1.000 12.14 
ATOM 152 C SER 20 29.349 17.547 9.674 1.000 15.57 
ATOM 153 0 SER 20 29.990 16.775 10.397 1.000 15.86 
ATOM 154 CB SER 20 28.511 15.978 7.882 1.000 13.77 
ATOM 155 OG SER 20 29.120 16.597 6.742 1.000 15.71 
ATOM 156 N ASP 21 29.720 18.813 9.511 1.000 13.94 
ATOM 157 CA ASP 21 30.874 19.346 10.260 1.000 15.57 
ATOM 158 C ASP 21 30.576 19.452 11.753 1.000 13.90 
ATOM 159 0 ASP 21 29.467 19.791 12.183 1.000 14.64 
ATOM 160 CB ASP 21 31.261 20.740 9.754 1.000 13.91 
ATOM 161 CG ASP 21 31.851 20.774 8.363 1.000 20.14 
ATOM 162 OD1 ASP 21 32.380 19.762 7.859 1.000 33.73 
ATOM 163 0D2 ASP 21 31.806 21.846 7.728 1.000 20.56 
ATOM 164 N THR 22 31.569 19.155 12.602 1.000 14.87 
ATOM 165 CA THR 22 31.439 19.348 14.042 1.000 14.85 
ATOM 166 C THR 22 31.545 20.825 14.430 1.000 16.04 
ATOM 167 0 THR 22 32.075 21.698 13.738 1.000 12.87 
ATOM 168 CE THR 22 32.496 18.567 14.858 1.000 16.33 
ATOM 169 OG1 THR 22 33.804 19.004 14.490 1.000 17.46 
ATOM 170 CG2 THR 22 32.401 17.073 14.532 1.000 21.54 
ATOM 171 N ILE 23 30.979 21.117 15.607 1.000 14.79 
ATOM 172 CA ILE 23 31.096 22.470 16.150 1.000 15.21 
ATOM 173 C ILE 23 32.552 22.838 16.366 1.000 14.62 
ATOM 174 0 ILE 23 32.963 23.970 16.098 1.000 13.64 
ATOM 175 CB ILE 23 30.289 22.608 17.448 1.000 15.35 
ATOM 176 CG1 ILE 23 28.788 22.399 17.235 1.000 19.90 
ATOM 177 CG2 ILE 23 30.553 23.964 18.101 1.000 17.46 
ATOM 178 CD1 ILE 23 28.193 23.117 16.037 1.000 16.53 
ATOM 179 N GLU 24 33.364 21.878 16.814 1.000 13.49 
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ATOM 180 CA GLU 24 34.801 22.092 16.906 1.000 15.97 
ATOM 181 C GLU 24 35.429 22.513 15.586 1.000 13.64 
ATOM 182 0 GLU 24 36.203 23.461 15.513 1.000 15.55 
ATOM 183 CB GLU 24 35.500 20.791 17.353 1.000 18.28 
ATOM 184 CG GLU 24 36.967 21.012 17.672 1.000 22.60 
ATOM 185 CD GLU 24 37.705 19.788 18.161 1.000 40.59 
ATOM 186 OE1 GLU 24 37.081 18.905 18.789 1.000 42.32 
ATOM 187 OE2 GLU 24 38.932 19.721 17.912 1.000 55.23 
ATOM 188 N ASN 25 35.098 21.825 14.494 1.000 14.87 
ATOM 189 CA ASN 25 35.599 22.227 13.187 1.000 16.11 
ATOM 190 C ASN 25 35.120 23.607 12.773 1.000 16.14 
ATOM 191 0 ASN 25 35.847 24.373 12.119 1.000 16.69 
ATOM 192 CE ASN 25 35.114 21.199 12.147 1.000 18.07 
ATOM 193 CG ASN 25 35.456 21.668 10.745 1.000 36.55 
ATOM 194 OD1 ASN 25 34.699 22.424 10.134 1.000 54.75 
ATOM 195 ND2 ASN 25 36.600 21.214 10.252 1.000 53.33 
ATOM 196 N VAL 26 33.876 23.967 13.095 1.000 14.10 
ATOM 197 CA VAL 26 33.422 25.328 12.807 1.000 13.52 
ATOM 198 C VAL 26 34.291 26.365 13.524 1.000 14.56 
ATOM 199 0 VAL 26 34.615 27.409 12.938 1.000 15.24 
ATOM 200 CB VAL 26 31.929 25.504 13.125 1.000 13.24 
ATOM 201 CG1 VAL 26 31.467 26.949 12.977 1.000 13.82 
ATOM 202 CG2 VAL 26 31.067 24.605 12.230 1.000 14.18 
ATOM 203 N LYS 27 34.646 26.134 14.787 1.000 12.51 
ATOM 204 CA LYS 27 35.474 27.054 15.567 1.000 12.12 
ATOM 205 C LYS 27 36.861 27.166 14.951 1.000 12.09 
ATOM 206 0 LYS 27 37.434 28.261 14.945 1.000 13.76 
ATOM 207 CE LYS 27 35.559 26.632 17.041 1.000 11.28 
ATOM 208 CG LYS 27 34.234 26.822 17.785 1.000 13.19 
ATOM 209 CD LYS 27 34.315 26.395 19.250 1.000 11.95 
ATOM 210 CE LYS 27 32.927 26.660 19.867 1.000 14.10 
ATOM 211 NZ LYS 27 32.942 26.152 21.275 1.000 17.57 
ATOM 212 N ALA 28 37.375 26.066 14.425 1.000 12.07 
ATOM 213 CA ALA 28 38.651 26.118 13.708 1.000 15.20 
ATOM 214 C ALA 28 38.532 26.978 12.452 1.000 15.81 
ATOM 215 0 ALA 28 39.411 27.787 12.139 1.000 16.92 
ATOM 216 CB ALA 28 39.120 24.717 13.364 1.000 19.04 
ATOM 217 N LYS 29 37.437 26.911 11.713 1.000 13.92 
ATOM 218 CA LYS 29 37.214 27.773 10.565 1.000 13.46 
ATOM 219 C LYS 29 37.148 29.244 10.948 1.000 16.28 
ATOM 220 0 LYS 29 37.619 30.110 10.207 1.000 17.37 
ATOM 221 CB LYS 29 35.884 27.404 9.881 1.000 15.54 
ATOM 222 CG LYS 29 35.930 26.036 9.220 1.000 18.89 
ATOM 223 CD LYS 29 34.639 25.717 8.485 1.000 24.73 
ATOM 224 CE LYS 29 34.871 24.793 7.298 1.000 28.67 
ATOM 225 NZ LYS 29 35.132 23.396 7.724 1.000 34.30 
ATOM 226 N ILE 30 36.548 29.525 12.110 1.000 15.42 
ATOM 227 CA ILE 30 36.506 30.905 12.581 1.000 13.08 
ATOM 228 C ILE 30 37.923 31.337 12.962 1.000 14.89 
ATOM 229 0 ILE 30 38.287 32.492 12.671 1.000 17.53 
ATOM 230 CB ILE 30 35.489 31.090 13.726 1.000 14.43 
ATOM 231 CG1 ILE 30 34.044 30.837 13.257 1.000 11.85 
ATOM 232 CG2 ILE 30 35.651 32.447 14.392 1.000 15.37 
ATOM 233 CD1 ILE 30 33.041 30.702 14.395 1.000 13.83 
ATOM 234 N GLN 31 38.732 30.479 13.570 1.000 13.78 
ATOM 235 CA GLN 31 40.101 30.901 13.864 1.000 15.04 
ATOM 236 C GLN 31 40.885 31.177 12.592 1.000 17.44 
ATOM 237 0 GLN 31 41.679 32.135 12.522 1.000 17.90 
ATOM 238 CB GLN 31 40.799 29.827 14.705 1.000 13.98 
ATOM 239 CG GLN 31 42.221 30.247 15.095 1.000 14.76 
ATOM 240 CD GLN 31 42.920 29.096 15.793 1.000 17.04 
ATOM 241 OE1 GLN 31 42.706 27.915 15.514 1.000 20.30 
ATOM 242 NE2 GLN 31 43.778 29.440 16.752 1.000 20.99 
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ATOM 243 N ASP 32 40.684 30.368 11.566 1.000 15.96 
ATOM 244 CA ASP 32 41.314 30.554 10.266 1.000 20.44 
ATOM 245 C ASP 32 40.988 31.850 9.549 1.000 25.74 
ATOM 246 0 ASP 32 41.812 32.406 8.815 1.000 23.71 
ATOM 247 CB ASP 32 40.850 29.424 9.336 1.000 18.39 
ATOM 248 CG ASP 32 41.517 28.120 9.714 1.000 33.54 
ATOM 249 OD1 ASP 32 42.472 28.195 10.516 1.000 38.35 
ATOM 250 0D2 ASP 32 41.056 27.084 9.188 1.000 47.96 
ATOM 251 N LYS 33 39.774 32.337 9.721 1.000 20.59 
ATOM 252 CA LYS 33 39.336 33.536 9.021 1.000 21.81 
ATOM 253 C LYS 33 39.573 34.807 9.821 1.000 24.05 
ATOM 254 0 LYS 33 39.911 35.804 9.179 1.000 24.30 
ATOM 255 CE LYS 33 37.847 33.367 8.685 1.000 32.60 
ATOM 256 CG LYS 33 37.315 34.356 7.663 1.000 32.51 
ATOM 257 CD LYS 33 36.307 33.687 6.740 1.000 32.42 
ATOM 258 CE LYS 33 36.112 34.494 5.466 1.000 45.42 
ATOM 259 NZ LYS 33 34.702 34.928 5.271 1.000 42.52 
ATOM 260 N GLU 34 39.423 34.780 11.142 1.000 18.57 
ATOM 261 CA GLU 34 39.437 35.924 12.031 1.000 19.40 
ATOM 262 C GLU 34 40.556 35.897 13.061 1.000 19.31 
ATOM 263 0 GLU 34 40.826 36.920 13.699 1.000 26.26 
ATOM 264 CE GLU 34 38.099 36.012 12.782 1.000 26.84 
ATOM 265 CG GLU 34 36.966 36.645 12.006 1.000 38.21 
ATOM 266 CD GLU 34 37.391 37.765 11.081 1.000 45.41 
ATOM 267 OE1 GLU 34 37.517 38.913 11.554 1.000 34.94 
ATOM 268 OE2 GLU 34 37.604 37.509 9.876 1.000 42.77 
ATOM 269 N GLY 35 41.196 34.746 13.267 1.000 17.97 
ATOM 270 CA GLY 35 42.294 34.655 14.204 1.000 17.27 
ATOM 271 C GLY 35 41.946 34.398 15.656 1.000 15.60 
ATOM 272 0 GLY 35 42.863 34.395 16.502 1.000 17.94 
ATOM 273 N ILE 36 40.697 34.186 16.014 1.000 15.07 
ATOM 274 CA ILE 36 40.230 33.971 17.381 1.000 16.44 
ATOM 275 C ILE 36 40.458 32.560 17.872 1.000 15.34 
ATOM 276 0 ILE 36 39.951 31.610 17.258 1.000 14.65 
ATOM 277 CB ILE 36 38.713 34.291 17.508 1.000 18.05 
ATOM 278 CG1 ILE 36 38.388 35.726 17.087 1.000 26.39 
ATOM 279 CG2 ILE 36 38.190 33.991 18.899 1.000 16.99 
ATOM 280 CD1 ILE 36 36.950 35.934 16.648 1.000 22.32 
ATOM 281 N PRO 37 41.188 32.318 18.959 1.000 16.32 
ATOM 282 CA PRO 37 41.367 30.946 19.462 1.000 14.55 
ATOM 283 C PRO 37 40.057 30.246 19.789 1.000 14.57 
ATOM 284 0 PRO 37 39.164 30.869 20.403 1.000 14.12 
ATOM 285 CB PRO 37 42.188 31.121 20.741 1.000 17.69 
ATOM 286 CG PRO 37 42.873 32.433 20.561 1.000 20.33 
ATOM 287 CD PRO 37 41.908 33.308 19.789 1.000 16.45 
ATOM 288 N PRO 38 39.891 28.995 19.376 1.000 15.01 
ATOM 289 CA PRO 38 38.653 28.254 19.670 1.000 15.12 
ATOM 290 C PRO 38 38.226 28.241 21.118 1.000 13.60 
ATOM 291 0 PRO 38 37.036 28.307 21.428 1.000 17.50 
ATOM 292 CB PRO 38 38.991 26.822 19.195 1.000 15.53 
ATOM 293 CG PRO 38 39.838 27.126 18.001 1.000 19.88 
ATOM 294 CD PRO 38 40.787 28.189 18.516 1.000 18.53 
ATOM 295 N ASP 39 39.172 28.151 22.062 1.000 16.04 
ATOM 296 CA ASP 39 38.744 28.057 23.453 1.000 17.46 
ATOM 297 C ASP 39 38.122 29.353 23.971 1.000 16.08 
ATOM 298 0 	AASP 39 37.526 29.351 25.0490.341 10.92 
ATOM 299 CB AASP 39 39.984 27.748 24.310 0.341 20.90 
ATOM 300 CG AASP 39 41.019 28.843 24.084 0.341 16.62 
ATOM 301 OD1AASP 39 42.043 28.562 23.431 0.341 34.92 
ATOM 302 OD2AASP 39 40.796 29.980 24.549 0.341 22.41 
ATOM 303 0 	BASP 39 37.567 29.381 25.069 0.659 32.09 
ATOM 304 CB BASP 39 39.890 27.563 24.330 0.659 22.34 
ATOM 305 CG BASP 39 40.993 28.565 24.560 0.659 22.08 
121 
Appendix 2 
ATOM 306 OD1BASP 39 41.042 29.604 23.877 0.659 28.12 
ATOM 307 OD2BASP 39 41.834 28.277 25.447 0.659 31.70 
ATOM 308 N GLN 40 38.199 30.449 23.207 1.000 14.27 
ATOM 309 CA GLN 40 37.549 31.699 23.549 1.000 15.65 
ATOM 310 C GLN 40 36.150 31.802 22.956 1.000 13.49 
ATOM 311 0 GLN 40 35.393 32.719 23.291 1.000 15.58 
ATOM 312 CB GLN 40 38.376 32.901 23.069 1.000 19.13 
ATOM 313 CG GLN 40 39.639 33.083 23.920 1.000 20.62 
ATOM 314 CD GLN 40 40.534 34.156 23.326 1.000 32.39 
ATOM 315 OE1 GLN 40 41.760 34.028 23.242 1.000 25.57 
ATOM 316 NE2 GLN 40 39.848 35.215 22.915 1.000 24.74 
ATOM 317 N GLN 41 35.780 30.875 22.085 1.000 14.01 
ATOM 318 CA GLN 41 34.540 31.038 21.313 1.000 15.53 
ATOM 319 C GLN 41 33.352 30.322 21.942 1.000 19.50 
ATOM 320 0 GLN 41 33.436 29.106 22.172 1.000 19.77 
ATOM 321 CB GLN 41 34.703 30.511 19.892 1.000 12.64 
ATOM 322 CG GLN 41 35.821 31.148 19.070 1.000 12.43 
ATOM 323 CD GLN 41 35.946 30.481 17.720 1.000 12.24 
ATOM 324 OE1 GLN 41 34.969 29.987 17.128 1.000 12.92 
ATOM 325 NE2 GLN 41 37.151 30.415 17.140 1.000 14.26 
ATOM 326 N ARG 42 32.292 31.097 22.180 1.000 14.74 
ATOM 327 CA ARG 42 30.997 30.526 22.567 1.000 14.24 
ATOM 328 C ARG 42 30.056 30.776 21.396 1.000 14.53 
ATOM: 329 0 ARG 42 29.857 31.932 21.002 1.000 18.13 
ATOM 330 CB ARG 42 30.486 31.121 23.874 1.000 18.19 
ATOM 331 CG AARG 42 29.010 30.885 24.150 0.356 21.93 
ATOM 332 CD AARG 42 28.569 31.543 25.448 0.356 28.04 
ATOM 333 NE AARG 42 29.437 31.215 26.569 0.356 26.70 
ATOM 334 CZ AARG 42 29.633 31.961 27.645 0.356 28.36 
ATOM 335 NH1AARG 42 29.011 33.125 27.777 0.356 29.45 
ATOM 336 NH2AARG 42 30.456 31.540 28.597 0.356 20.50 
ATOM 337 CG BARG 42 29.317 30.401 24.529 0.644 23.03 
ATOM 338 CD BARG 42 29.105 30.833 25.978 0.644 29.93 
ATOM 339 NE BARG 42 28.150 31.920 26.089 0.644 32.10 
ATOM 340 CZ EARG 42 28.334 33.143 26.548 0.644 33.15 
ATOM 341 NH1BARG 42 29.511 33.545 27.005 0.644 33.20 
ATOM 342 NH2BARG 42 27.309 33.989 26.552 0.644 22.70 
ATOM 343 N LEO 43 29.485 29.733 20.824 1.000 12.67 
ATOM 344 CA LEU 43 28.564 29.855 19.680 1.000 12.89 
ATOM 345 C LEO 43 27.147 29.553 20.150 1.000 13.66 
ATOM 346 0 LEO 43 26.915 28.583 20.890 1.000 15.26 
ATOM 347 CB LEO 43 28.954 28.939 18.535 1.000 13.38 
ATOM 348 CG LEO 43 30.221 29.272 17.765 1.000 14.57 
ATOM 349 CD1 LEO 43 30.637 28.115 16.869 1.000 14.58 
ATOM 350 CD2 LEO 43 30.028 30.526 16.902 1.000 17.35 
ATOM 351 N ILE 44 26.216 30.392 19.733 1.000 12.86 
ATOM 352 CA ILE 44 24.828 30.263 20.162 1.000 13.65 
ATOM 353 C ILE 44 23.911 30.199 18.946 1.000 11.82 
ATOM 354 0 ILE 44 24.091 31.003 18.031 1.000 14.37 
ATOM 355 CB ILE 44 24.477 31.456 21.055 1.000 13.27 
ATOM 356 CG1 ILE 44 25.376 31.524 22.299 1.000 17.84 
ATOM 357 CG2 ILE 44 23.011 31.490 21.470 1.000 16.04 
ATOM 358 CD1 ILE 44 25.420 32.909 22.904 1.000 24.65 
ATOM 359 N PHE 45 22.943 29.290 18.942 1.000 13.93 
ATOM 360 CA PHE 45 21.923 29.205 17.887 1.000 12.44 
ATOM 361 C PHE 45 20.592 28.817 18.509 1.000 15.77 
ATOM 362 0 PHE 45 20.577 27.855 19.289 1.000 14.29 
ATOM 363 CB PHE 45 22.312 28.167 16.832 1.000 14.03 
ATOM 364 CG PHE 45 21.331 27.960 15.686 1.000 11.55 
ATOM 365 CD1 PHE 45 21.240 28.913 14.674 1.000 14.91 
ATOM 366 CD2 PHE 45 20.514 26.846 15.627 1.000 15.61 
ATOM 367 CE1 PHE 45 20.367 28.747 13.619 1.000 17.78 
ATOM 368 CE2 PHE 45 19.634 26.659 14.557 1.000 15.43 
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ATOM 369 CZ PHE 45 19.572 27.614 13.563 1.000 18.07 
ATOM 370 N ALA 46 19.515 29.505 18.172 1.000 15.04 
ATOM 371 CA ALA 46 18.174 29.142 18.648 1.000 13.55 
ATOM 372 C ALA 46 18.209 29.047 20.169 1.000 16.27 
ATOM 373 0 ALA 46 17.609 28.148 20.759 1.000 20.63 
ATOM 374 CB ALA 46 17.670 27.880 17.973 1.000 17.33 
ATOM 375 N GLY 47 18.912 29.990 20.808 1.000 15.41 
ATOM 376 CA GLY 47 18.914 30.020 22.262 1.000 20.27 
ATOM 377 C GLY 47 19.753 28.948 22.935 1.000 24.86 
ATOM 378 0 GLY 47 19.677 28.843 24.164 1.000 26.34 
ATOM 379 N LYS 48 20.530 28.171 22.208 1.000 17.30 
ATOM 380 CA LYS 48 21.307 27.036 22.675 1.000 18.03 
ATOM 381 C LYS 48 22.806 27.275 22.536 1.000 17.81 
ATOM 382 0 LYS 48 23.232 27.708 21.471 1.000 13.77 
ATOM 383 CB LYS 48 20.997 25.771 21.860 1.000 24.84 
ATOM 384 CG LYS 48 19.616 25.172 21.982 1.000 25.59 
ATOM 385 CD LYS 48 19.406 24.098 20.920 1.000 29.19 
ATOM 386 CE LYS 48 18.392 24.571 19.892 1.000 41.12 
ATOM 387 NZ LYS 48 17.024 24.637 20.476 1.000 41.49 
ATOM 388 N GLN 49 23.611 26.995 23.566 1.000 15.62 
ATOM 389 CA GLN 49 25.059 27.038 23.379 1.000 16.16 
ATOM 390 C GLN 49 25.455 25.774 22.635 1.000 19.22 
ATOM 391 0 GLN 49 25.022 24.682 23.015 1.000 20.56 
ATOM 392 CB GLN 49 25.803 27.125 24.713 1.000 20.60 
ATOM 393 CG GLN 49 27.300 27.313 24.556 1.000 23.37 
ATOM 394 CD GLN 49 28.051 27.334 25.878 1.000 36.43 
ATOM 395 OE1 GLN 49 28.991 26.559 26.060 1.000 55.68 
ATOM 396 NE2 GLN 49 27.686 28.193 26.821 1.000 32.23 
HETATM 397 N LEF 50 26.269 25.851 21.596 1.000 15.01 
HETATM 398 CA LEF 50 26.657 24.687 20.807 1.000 15.43 
HETATM 399 C LEF 50 27.865 23.950 21.377 1.000 15.11 
HETATM 400 0 LEF 50 28.889 24.557 21.683 1.000 20.54 
HETATM 401 CB LEF 50 26.924 25.142 19.365 1.000 17.08 
HETATM 402 CG LEF 50 25.918 26.077 18.702 0.419 14.28 
HETATM 403 CD1 LEF 50 26.553 26.660 17.442 0.419 13.10 
HETATM 404 CD2 LEF 50 24.604 25.388 18.367 0.419 15.48 
HETATM 405 Fl LEF 50 25.796 27.427 16.771 0.419 14.17 
HETATM 397 N LEF 501 26.269 25.851 21.596 1.000 15.01 
HETATM 398 CA LEF 501 26.657 24.687 20.807 1.000 15.43 
HETATM 399 C LEF 501 27.865 23.950 21.377 1.000 15.11 
HETATM 400 0 LEF 501 28.889 24.557 21.683 1.000 20.54 
HETATM 401 CB LEF 501 26.924 25.142 19.365 1.000 17.08 
HETATM 406 CG LEF 501 25.770 25.986 18.792 0.581 13.29 
HETATM 407 CD1 LEF 501 25.864 26.078 17.274 0.581 12.98 
HETATM 408 CD2 LEF 501 24.424 25.422 19.218 0.581 13.90 
HETATM 409 Fl LEF 501 26.980 26.567 16.879 0.581 18.49 
ATOM 410 N GLU 51 27.727 22.639 21.490 1.000 15.18 
ATOM 411 CA GLU 51 28.717 21.717 22.054 1.000 17.81 
ATOM 412 C GLU 51 29.727 21.248 21.032 1.000 16.94 
ATOM 413 0 GLU 51 29.368 20.797 19.933 1.000 17.96 
ATOM 414 CE GLU 51 27.967 20.504 22.638 1.000 22.12 
ATOM 415 CG GLU 51 27.311 20.719 23.987 1.000 43.13 
ATOM 416 CD GLU 51 26.076 19.891 24.268 1.000 50.41 
ATOM 417 OE1 GLU 51 26.056 18.675 23.971 1.000 29.87 
ATOM 418 OE2 GLU 51 25.082 20.435 24.813 1.000 48.37 
ATOM 419 N ASP 52 31.022 21.317 21.320 1.000 17.82 
ATOM 420 CA ASP 52 32.053 21.019 20.334 1.000 20.12 
ATOM 421 C ASP 52 31.944 19.690 19.596 1.000 22.96 
ATOM 422 0 ASP 52 32.301 19.640 18.408 1.000 21.27 
ATOM 423 CB ASP 52 33.423 21.034 21.028 1.000 19.84 
ATOM 424 CG ASP 52 33.944 22.443 21.195 1.000 23.78 
ATOM 425 OD1 ASP 52 35.078 22.608 21.695 1.000 36.78 
ATOM 426 OD2 ASP 52 33.206 23.372 20.832 1.000 24.92 
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ATOM 427 N GLY 53 31.499 18.611 20.236 1.000 20.43 
ATOM 428 CA GLY 53 31.457 17.273 19.674 1.000 20.78 
ATOM 429 C GLY 53 30.248 16.924 18.844 1.000 16.86 
ATOM 430 0 GLY 53 30.145 15.898 18.160 1.000 22.22 
ATOM 431 N ARG 54 29.251 17.785 18.849 1.000 16.35 
ATOM 432 CA ARG 54 28.066 17.646 18.026 1.000 16.25 
ATOM 433 C ARG 54 28.306 18.239 16.641 1.000 16.76 
ATOM 434 0 ARG 54 29.318 18.922 16.476 1.000 15.69 
ATOM 435 CB ARG 54 26.904 18.409 18.668 1.000 15.68 
ATOM 436 CG ARG 54 25.714 17.532 19.029 1.000 38.79 
ATOM 437 CD ARG 54 26.036 16.600 20.179 1.000 21.00 
ATOM 438 NE ARG 54 26.713 15.391 19.763 1.000 22.41 
ATOM 439 CZ ARG 54 27.648 14.725 20.413 1.000 25.81 
ATOM 440 NH1 ARG 54 28.085 15.131 21.599 1.000 36.01 
ATOM 441 NH2 ARG 54 28.144 13.625 19.846 1.000 29.27 
ATOM 442 N THR 55 27.383 17.991 15.719 1.000 14.34 
ATOM 443 CA THR 55 27.486 18.563 14.377 1.000 12.43 
ATOM 444 C THR 55 26.435 19.652 14.180 1.000 12.73 
ATOM 445 0 THR 55 25.450 19.739 14.908 1.000 13.64 
ATOM 446 CB THR 55 27.303 17.499 13.284 1.000 15.92 
ATOM 447 OG1 THR 55 26.012 16.896 13.430 1.000 15.62 
ATOM 448 CG2 THR 55 28.343 16.385 13.399 1.000 20.20 
ATOM 449 N LEO 56 26.625 20.461 13.138 1.000 12.97 
ATOM 450 CA LEU 56 25.592 21.424 12.774 1.000 12.43 
ATOM 451 C LEU 56 24.236 20.741 12.561 1.000 12.59 
ATOM 452 0 LEO 56 23.203 21.275 12.976 1.000 13.78 
ATOM 453 CB LEO 56 26.015 22.213 11.534 1.000 11.92 
ATOM 454 CG LEO 56 27.266 23.087 11.687 1.000 14.13 
ATOM 455 CD1 LEO 56 27.724 23.606 10.334 1.000 13.84 
ATOM 456 CD2 LEO 56 27.027 24.244 12.649 1.000 13.66 
ATOM 457 N SER 57 24.226 19.590 11.893 1.000 13.44 
ATOM 458 CA SER 57 22.962 18.882 11.652 1.000 13.32 
ATOM 459 C SER 57 22.246 18.503 12.944 1.000 14.17 
ATOM 460 0 SER 57 21.010 18.524 12.938 1.000 15.83 
ATOM 461 CB SER 57 23.201 17.604 10.837 1.000 15.68 
ATOM 462 OG SER 57 24.076 16.725 11.490 1.000 17.59 
ATOM 463 N ASP 58 22.968 18.179 14.002 1.000 12.11 
ATOM 464 CA ASP 58 22.355 17.808 15.290 1.000 12.70 
ATOM 465 C ASP 58 21.461 18.944 15.795 1.000 17.10 
ATOM 466 0 ASP 58 20.485 18.639 16.498 1.000 17.71 
ATOM 467 CB ASP 58 23.416 17.476 16.325 1.000 13.40 
ATOM 468 CG ASP 58 24.158 16.178 16.144 1.000 16.56 
ATOM 469 OD1 ASP 58 25.280 16.050 16.694 1.000 16.71 
ATOM 470 OD2 ASP 58 23.654 15.259 15.452 1.000 16.79 
ATOM 471 N TYR 59 21.802 20.175 15.464 1.000 15.25 
ATOM 472 CA TYR 59 21.121 21.374 15.888 1.000 15.55 
ATOM 473 C TYR 59 20.152 21.925 14.836 1.000 16.24 
ATOM 474 0 TYR 59 19.553 22.993 15.061 1.000 19.32 
ATOM 475 CB TYR 59 22.091 22.497 16.262 1.000 14.76 
ATOM 476 CG TYR 59 22.875 22.226 17.514 1.000 13.18 
ATOM 477 CD1 TYR 59 24.205 21.805 17.390 1.000 15.33 
ATOM 478 CD2 TYR 59 22.342 22.367 18.783 1.000 17.21 
ATOM 479 CE1 TYR 59 24.970 21.541 18.492 1.000 15.45 
ATOM 480 CE2 TYR 59 23.116 22.098 19.902 1.000 16.67 
ATOM 481 CZ TYR 59 24.423 21.692 19.745 1.000 16.52 
ATOM 482 OH TYR 59 25.179 21.422 20.868 1.000 18.64 
ATOM 483 N ASN 60 20.005 21.223 13.726 1.000 16.66 
ATOM 484 CA ASN 60 19.100 21.669 12.669 1.000 17.76 
ATOM 485 C ASN 60 19.500 23.027 12.114 1.000 22.97 
ATOM 486 0 ASN 60 18.663 23.874 11.790 1.000 32.64 
ATOM 487 CB ASN 60 17.685 21.738 13.239 1.000 20.06 
ATOM 488 CG ASN 60 16.584 21.708 12.205 1.000 36.79 
ATOM 489 OD1 ASN 60 16.728 21.133 11.120 1.000 36.41 
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ATOM 490 ND2 ASN 60 15.456 22.334 12.535 1.000 40.74 
ATOM 491 N ILE 61 20.798 23.284 11.980 1.000 16.07 
ATOM 492 CA ILE 61 21.272 24.509 11.344 1.000 18.72 
ATOM 493 C ILE 61 21.310 24.305 9.831 1.000 16.80 
ATOM 494 0 ILE 61 22.057 23.445 9.352 1.000 16.98 
ATOM 495 CB ILE 61 22.658 24.851 11.919 1.000 17.20 
ATOM 496 CG1 ILE 61 22.554 25.221 13.402 1.000 15.75 
ATOM 497 CG2 ILE 61 23.367 25.925 11.120 1.000 19.27 
ATOM 498 CD1 ILE 61 23.803 25.013 14.238 1.000 15.42 
ATOM 499 N GLN 62 20.462 25.044 9.128 1.000 16.79 
ATOM 500 CA GLN 62 20.261 24.980 7.683 1.000 15.03 
ATOM 501 C GLN 62 21.035 26.067 6.945 1.000 19.17 
ATOM 502 0 GLN 62 21.590 26.983 7.569 1.000 17.27 
ATOM 503 CB GLN 62 18.776 25.119 7.376 1.000 20.99 
ATOM 504 CG GLN 62 17.807 24.131 7.975 1.000 27.33 
ATOM 505 CD GLN 62 18.049 22.689 7.602 1.000 31.25 
ATOM 506 OE1 GLN 62 18.364 22.396 6.448 1.000 38.63 
ATOM 507 NE2 GLN 62 17.901 21.777 8.561 1.000 30.24 
ATOM 508 N LYS 63 21.092 26.020 5.601 1.000 16.09 
ATOM 509 CA LYS 63 21.822 27.035 4.849 1.000 15.73 
ATOM 510 C LYS 63 21.303 28.431 5.197 1.000 14.37 
ATOM 511 0 LYS 63 20.109 28.639 5.428 1.000 15.34 
ATOM 512 CB LYS 63 21.729 26.818 3.332 1.000 19.46 
ATOM 513 CG LYS 63 20.382 27.207 2.742 1.000 23.39 
ATOM 514 CD LYS 63 20.369 27.001 1.233 1.000 35.11 
ATOM 515 CE LYS 63 19.465 25.829 0.871 1.000 37.75 
ATOM 516 NZ LYS 63 18.028 26.214 0.879 1.000 34.91 
ATOM 517 N GLtJ 64 22.254 29.364 5.218 1.000 15.31 
ATOM 518 CA GLIJ 64 22.056 30.796 5.396 1.000 16.92 
ATOM 519 C GLU 64 21.591 31.136 6.813 1.000 14.75 
ATOM 520 0 GLU 64 21.146 32.260 7.104 1.000 19.01 
ATOM 521 CE GLU 64 21.095 31.371 4.354 1.000 21.15 
ATOM 522 CG GLU 64 21.321 30.975 2.919 1.000 19.69 
ATOM 523 CD GLU 64 22.630 31.256 2.247 1.000 22.36 
ATOM 524 OE1 GLU 64 23.424 32.118 2.670 1.000 24.73 
ATOM 525 OE2 GLU 64 22.910 30.587 1.227 1.000 29.68 
ATOM 526 N SER 65 21.732 30.203 7.751 1.000 15.13 
ATOM 527 CA SER 65 21.517 30.418 9.169 1.000 15.94 
ATOM 528 C SER 65 22.564 31.377 9.740 1.000 12.66 
ATOM 529 0 SER 65 23.663 31.468 9.185 1.000 12.74 
ATOM 530 CB SER 65 21.642 29.113 9.987 1.000 16.55 
ATOM 531 OG SER 65 20.568 28.235 9.702 1.000 23.96 
ATOM 532 N THR 66 22.211 32.033 10.852 1.000 13.50 
ATOM 533 CA THR 66 23.162 32.854 11.593 1.000 11.70 
ATOM 534 C THR 66 23.462 32.298 12.990 1.000 12.50 
ATOM 535 0 THR 66 22.550 32.011 13.760 1.000 16.05 
ATOM 536 CB THR 66 22.649 34.311 11.711 1.000 11.83 
ATOM 537 0G1 THR 66 22.458 34.811 10.371 1.000 14.63 
ATOM •538 CG2 TFIR 66 23.655 35.227 12.382 1.000 15.66 
HETATM 539 N LEF 67 24.741 32.099 13.287 1.000 12.59 
HETATM 540 CA LEF 67 25.172 31.771 14.650 1.000 11.19 
HETATM 541 C LEF 67 25.640 33.029 15.358 1.000 10.33 
HETATM 542 0 LEF 67 26.146 33.922 14.678 1.000 13.12 
HETATM 543 CB LEF 67 26.327 30.753 14.620 1.000 12.90 
HETATM 544 CG LEF 67 26.202 29.569 13.662 1.000 13.02 
J-IETATM 545 CD1 LEF 67 27.342 28.566 13.848 1.000 14.58 
HETATM 546 CD2 LEF 67 24.855 28.874 13.807 1.000 17.26 
HETATM 547 Fl LEF 67 28.464 29.131 13.511 1.000 21.05 
ATOM 548 N HIS 68 25.523 33.090 16.675 1.000 11.13 
ATOM 549 CA HIS 68 26.050 34.226 17.421 1.000 10.29 
ATOM 550 C HIS 68 27.334 33.827 18.122 1.000 13.35 
ATOM 551 0 HIS 68 27.371 32.797 18.828 1.000 15.91 
ATOM 552 CB HIS 68 25.009 34.721 18.440 1.000 12.28 
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ATOM 553 CG HIS 68 23.728 35.105 17.767 1.000 20.34 
ATOM 554 ND1 HIS 68 23.542 36.328 17.193 1.000 20.71 
ATOM 555 CD2 HIS 68 22.567 34.421 17.587 1.000 25.29 
ATOM 556 CE1 HIS 68 22.322 36.391 16.678 1.000 22.88 
ATOM 557 NE2 HIS 68 21.708 35.246 16.911 1.000 26.16 
ATOM 558 N LEO 69 28.375 34.635 17.975 1.000 13.06 
ATOM 559 CA LEO 69 29.691 34.357 18.564 1.000 11.96 
ATOM 560 C LEO 69 29.939 35.352 19.680 1.000 14.46 
ATOM 561 0 LEO 69 30.005 36.570 19.443 1.000 15.90 
ATOM 562 CB LEU 69 30.786 34.445 17.499 1.000 12.78 
ATOM 563 CC LEO 69 32.226 34.297 18.002 1.000 15.65 
ATOM 564 CD1 LEO 69 32.444 32.888 18.540 1.000 18.76 
ATOM 565 CD2 LEO 69 33.235 34.584 16.898 1.000 20.95 
ATOM 566 N VAL 70 30.070 34.849 20.899 1.000 13.78 
ATOM 567 CA VAL 70 30.436 35.608 22.091 1.000 15.39 
ATOM 568 C VAL 70 31.802 35.127 22.561 1.000 17.22 
ATOM 569 0 VAL 70 32.062 33.923 22.591 1.000 17.50 
ATOM 570 CB VAL 70 29.418 35.415 23.229 1.000 16.00 
ATOM 571 CG1 VAL 70 29.864 36.137 24.494 1.000 19.96 
ATOM 572 CG2 VAL 70 28.041 35.895 22.775 1.000 18.53 
ATOM 573 N LEO 71 32.697 36.036 22.928 1.000 19.62 
ATOM 574 CA LEO 71 34.039 35.591 23.321 1.000 23.38 
ATOM 575 C LEO 71 34.138 35.566 24.835 1.000 24.10 
ATOM 576 0 LEO 71 33.735 36.520 25.500 1.000 26.05 
ATOM 577 CB LEO 71 35.117 36.481 22.697 1.000 27.88 
ATOM 578 CG LEO 71 35.143 36.572 21.169 1.000 27.53 
ATOM 579 CD1 LEO 71 36.362 37.354 20.691 1.000 26.85 
ATOM 580 CD2 LEO 71 35.138 35.190 20.535 1.000 20.31 
ATOM 581 N ARG 72 34.632 34.471 25.390 1.000 20.67 
ATOM 582 CA ARC 72 34.760 34.325 26.830 1.000 26.94 
ATOM 583 C ARG 72 36.180 34.537 27.328 1.000 39.22 
ATOM 584 0 ARC 72 37.143 34.464 26.570 1.000 34.91 
ATOM 585 CE ARG 72 34.310 32.909 27.226 1.000 42.71 
ATOM 586 CG ARC 72 35.182 31.841 26.567 1.000 38.70 
ATOM 587 CD ARG 72 35.082 30.522 27.310 1.000 38.64 
ATOM 588 NE ARC 72 33.727 29.985 27.311 1.000 33.89 
ATOM 589 CZ ARG 72 33.266 29.122 26.415 1.000 37.75 
ATOM 590 NH1 ARG 72 34.049 28.690 25.434 1.000 32.98 
ATOM 591 NH2 ARG 72 32.018 28.681 26.488 1.000 40.31 
ATOM 592 N LEO 73 36.332 34.780 28.633 1.000 49.22 
ATOM 593 CA LEO 73 37.702 34.953 29.150 1.000 65.30 
ATOM 594 C LEO 73 38.266 36.209 28.488 1.000 68.27 
ATOM 595 0 LEO 73 37.592 37.239 28.486 1.000 46.85 
ATOM 596 CB LEO 73 38.516 33.704 28.887 1.000 66.81 
ATOM 597 CC LEO 73 39.951 33.489 29.336 1.000 63.41 
ATOM 598 CD1 LEO 73 40.407 34.529 30.348 1.000 65.28 
ATOM 599 CD2 LEO 73 40.133 32.087 29.919 1.000 54.06 
ATOM 600 N ARC 74 39.456 36.091 27.938 1.000 70.16 
ATOM 601 CA ARG 74 40.174 37.112 27.200 1.000 67.62 
ATOM 602 C ARC 74 39.252 37.907 26.291 1.000 72.74 
ATOM 603 0 ARC 74 39.218 39.138 26.333 1.000 66.47 
ATOM 604 CE ARC 74 41.289 36.430 26.395 1.000 63.90 
ATOM 605 CC ARC 74 42.029 35.371 27.204 1.000 56.83 
ATOM 606 CD ARC 74 43.361 35.005 26.574 1.000 60.43 
ATOM 607 NE ARC 74 43.227 34.021 25.501 1.000 63.60 
ATOM 608 CZ ARG 74 43.363 32.711 25.679 1.000 57.08 
ATOM 609 NH1 ARC 74 43.636 32.262 26.901 1.000 29.50 
ATOM 610 NH2 ARC 74 43.225 31.887 24.645 1.000 37.23 
ATOM 611 N CLY 75 38.475 37.216 25.458 1.000 77.66 
ATOM 612 CA GLY 75 37.569 37.900 24.552 1.000 80.19 
ATOM 613 C GLY 75 36.317 38.422 25.222 1.000 81.61 
ATOM 614 0 CLY 75 35.272 38.549 24.579 1.000 92.41 
ATOM 615 N CLI 76 36.380 38.736 26.513 1.000 83.01 
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ATOM 616 CA GLY 76 35.213 39.203 27.239 1.000 82.77 
ATOM 617 C GLY 76 35.343 40.633 27.720 1.000 81.20 
ATOM 618 OT1 GLY 76 36.403 40.978 28.284 1.000 80.94 
ATOM 619 OT2 GLY 76 34.383 41.411 27.533 1.000 70.40 
HETATM 620 0 HOH 101 18.907 31.902 16.633 1.000 17.54 
HETATM 621 0 HOH 102 20.016 32.940 14.277 1.000 15.09 
HETATM 622 0 HOH 103 30.141 27.011 22.031 1.000 17.69 
HETATM 623 0 HOH 104 44.727 32.362 16.632 1.000 14.43 
HETATM 624 0 HOH 105 35.265 26.745 22.848 1.000 25.91 
HETATM 625 0 HOH 106 32.044 38.420 19.440 1.000 17.73 
HETATM 626 0 HOH 107 22.581 14.855 12.905 1.000 21.15 
HETATM 627 0 HOH 108 22.288 26.076 26.042 1.000 22.46 
HETATM 628 0 HOH 109 45.639 30.332 19.245 1.000 19.16 
HETATM 629 0 HOH 110 19.828 32.504 19.412 1.000 25.51 
HETATM 630 0 HOH 111 39.061 27.859 7.311 1.000 30.68 
HETATM 631 0 HOH 112 26.474 43.172 19.453 1.000 40.27 
HETATM 632 0 HOH 113 36.777 46.858 30.448 1.000 51.45 
HETATM 633 0 HOH 114 32.061 41.166 24.026 1.000 33.83 
HETATM 634 0 HOH 115 42.134 32.152 5.974 1.000 37.11 
HETATM 635 0 HOH 116 44.941 24.993 8.797 1.000 33.01 
HETATM 636 0 HOH 117 34.812 39.173 6.620 1.000 31.05 
HETATM 637 0 HOH 118 32.895 22.953 3.593 1.000 31.81 
HETATM 638 0 HOH 119 39.732 47.060 27.753 1.000 44.86 
HETATM 639 0 HOH 120 37.799 24.017 17.920 1.000 25.30 
HETATM 640 0 HOH 121 15.366 27.222 9.149 1.000 40.07 
HETATM 641 0 HOH 122 18.196 27.013 10.272 1.000 23.77 
HETATM 642 0 HOH 123 13.644 24.334 21.292 1.000 48.00 
HETATM 643 0 HOH 124 40.107 39.093 9.301 1.000 34.47 
HETATM 644 0 HOH 125 14.573 29.305 21.940 1.000 51.11 
HETATM 645 0 HOH 126 41.923 38.392 16.193 1.000 33.71 
HETATM 646 0 HOH 127 30.627 27.321 24.639 1.000 30.86 
HETATM 647 0 HOH 128 17.993 27.025 4.697 1.000 37.98 
HETATM 648 0 HOH 129 45.559 40.757 23.906 1.000 19.82 
HETATM 649 0 HOH 130 14.607 31.195 23.250 1.000 66.02 
HETATM 650 0 HOH 131 37.518 18.523 7.966 1.000 38.69 
HETATM 651 0 HOH 132 24.951 35.462 0.322 1.000 24.65 
HETATM 652 0 HOH 133 31.742 22.373 24.168 1.000 28.13 
HETATM 653 0 HOH 134 42.750 26.903 12.592 1.000 41.28 
HETATM 654 0 HOH 135 40.409 26.375 5.778 1.000 48.22 
HETATM 655 0 HOH 136 43.973 29.779 29.092 1.0.00 38.93 
HETATM 656 0 HOH 137 30.671 15.907 3.327 1.000 31.41 
HETATM 657 0 HOH 138 33.472 21.528 5.489 1.000 31.03 
HETATM 658 0 HOH 139 20.646 36.834 14.152 1.000 35.34 
HETATM 659 0 HOH 140 38.750 20.631 13.756 1.000 40.29 
HETP.TM 660 0 HOH 141 39.461 37.227 7.245 1.000 43.97 
HETATM 661 0 HOH 142 37.242 42.042 6.598 1.000 45.10 
HETATM 662 0 HOH 143 38.345 29.384 27.672 1.000 34.71 
HETP.TM 663 0 HOH 144 24.084 35.853 25.059 1.000 40.63 
F-!ETATM 664 0 HOH 145 35.909 39.982 22.300 1.000 48.01 
HETATM 665 0 HOH 146 33.208 24.746 24.249 1.000 32.97 
HETP.TM 666 0 HOH 147 18.423 23.638 17.255 1.000 30.81 
HETATM 667 0 HOH 148 35.515 17.507 15.520 1.000 34.60 
HETATM 668 0 HOH 149 28.187 45.440 17.918 1.000 28.13 
HETATM 669 0 HOH 150 35.971 38.252 29.760 1.000 64.63 
HETATM 670 0 HON 151 23.978 25.640 28.001 1.000 27.12 
HETATM 671 0 HON 152 44.465 28.427 21.001 1.000 23.11 
HETATM 672 0 HOH 153 20.690 31.965 27.614 1.000 50.98 
HETATM 673 0 HOH 154 38.758 20.936 11.478 1.000 47.16 
HETATM 674 0 HOH 155 20.750 21.072 5.535 1.000 22.60 
HETATM 675 0 HOH 156 33.185 37.067 5.901 1.000 32.18 
HETATM 676 0 HOH 157 25.386 32.396 26.497 1.000 56.76 
HETATM 677 0 HOH 158 29.416 17.983 25.970 1.000 38.74 
HETATM 678 0 HOH 159 44.661 29.244 12.963 1.000 34.89 
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HETATM 679 0 HOH 160 47.961 24.999 9.657 1.000 38.80 
HETATM 680 0 FIOH 161 21.380 33.181 24.230 1.000 37.62 
HETATM 681 0 HOH 162 16.780 27.006 -3.933 1.000 38.87 
HETATM 682 0 HOH 163 21.339 21.048 8.316 1.000 30.67 
HETATM 683 0 HOH 164 34.462 31.028 3.273 1.000 36.62 
HETATM 684 0 HOH 165 25.621 23.894 27.453 1.000 48.35 
HETATM 685 0 HOH 166 24.921 28.180 0.083 1.000 32.35 
HETATM 686 0 HOH 167 35.978 21.385 1.082 1.000 51.40 
HETATM 687 0 HOH 168 28.114 15.991 4.334 1.000 18.89 
HETATM 688 0 HOH 169 26.240 22.002 1.831 1.000 24.24 
HETATM 689 0 HOH 170 27.115 42.389 11.655 1.000 27.49 
HETATM 690 0 HOH 171 37.085 29.815 7.398 1.000 25.66 
HETATM 691 0 HOH 172 34.132 18.179 11.043 1.000 24.83 
HETATM 692 0 HOH 173 29.251 39.538 5.953 1.000 26.32 
HETATM 693 0 HOH 174 34.785 29.402 5.538 1.000 33.42 
HETATM 694 0 HOH 175 39.297 19.005 6.592 1.000 36.05 
HETATM 695 0 HOH 176 29.717 13.870 10.962 1.000 22.50 
HETATM 696 0 HOH 177 45.021 30.046 23.026 1.000 24.88 
HETATM 697 0 HOH 178 32.787 39.080 22.028 1.000 24.76 
HETATM 698 0 HOH 179 27.140 23.578 25.758 1.000 46.82 
HETATM 699 0 HOH 180 25.141 16.377 24.502 1.000 27.47 
END 
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Organic Section Seminars (1996-1999): various speakers. 
Departmental Colloquia (1996-1999): various speakers. 
Advanced Organic Synthesis (1998): Dr.A.N.Hulme, Mchem course. 
Protein Technology Centre Seminars (1997-1999): various speakers. 
Medicinal Chemistry (1997-1999): Dr. Graeme Stevenson & colleagues, Merck, 
Sharpe & Dobme (Terlings Park, UK). 
Current Awareness in Organic Chemistry (1997-1999), sponsored by Zeneca 
Grangemouth. 
Walker Memorial Lectures (1997-1999): Prof. B.F.G.Johnson (Cambridge), 
Prof.J . M.Lehn (Strasbourg), Dr.T.McKillop (AstraZeneca Ltd). 
Synthons in Organic Chemistry (1998): Prof Dr. E.Villsmaier (Kaiserslautern) 
Amino Acids in Organic Chemistry (1999): Dr.J.Podlech (Stuttgart). 
Romanes Symposium (1998): Prof K.C.Nicolaou (Scripps Research Institute), 
Prof.K.J.Hale (University College, London), Prof P.J.Kocienski (Glasgow). 
RSC Scottish Perkin Division Meetings: Edinburgh (1996), Strathclyde (1997), 
St Andrews (1998). 
SCI Graduate Symposium in Novel Organic Chemistry: Aberdeen (1997), Edinburgh 
(1998), Glasgow (1999). 
5th Solid Phase Synthesis Symposium (1997), London. 
25th European Peptide Symposium (1998), Budapest. 
15 'h International Conference in Medicinal Chemistry (1998), Edinburgh. 
Biological Challenges for Organic Chemistry 11(1999), St Andrews. 
10th Pfizer Organic Chemistry Poster Symposium (1998), London. 
AstraZeneca Medicinal Chemistry Workshop (1999), Alderley Park. 
Zeneca Agrochemicals Pre-postdoc Workshop (1999), Jealotts Hill. 
Presentations & Awards 
Organic Section Seminars (1997, 1999). 
Ubiquitination and Proteolysis, Protein Technology Centre Seminar (1998). 
New Aromatic Substitution Reactions, Zeneca Grangemouth (1998). 
Poster Presentations at 25th  EPS (1998), Pfizer Symposium (1998, Prize winner), 
Biological Challenges for Organic Chemistry 11(1999). 
Total Synthesis of Protein Analogues, SCI Graduate Symposium, Glasgow (1999). 
